Blockchain and nucleic acid storage of non-fungible tokens
By integrating DNA storage and computation with blockchain technology, the patent addresses the challenges of secure and long-term storage of blockchain keys and NFTs, and creates durable links between digital and physical assets, enhancing security and durability.
Patent Information
- Application Number
- JP2024529480
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-19
- Filing Date
- 2022-11-18
- Publication Date
- 2024-11-13
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current blockchain systems lack secure and long-term storage solutions for blockchain keys and NFTs, as well as durable links between digital and physical assets, with existing technologies being susceptible to hacking and having limited longevity.
Integrating DNA storage and computation with blockchain technology to encode blockchain keys and NFT information in nucleic acid molecules, providing an air gap and additional security layers, and creating durable links between digital and physical assets using DNA identifiers.
Ensures secure, long-term storage of blockchain keys and NFTs, with enhanced security against hacking and tampering, and establishes robust, durable connections between digital and physical assets.
Smart Images

Figure 2024542197000001_ABST
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to and the benefit of U.S. Provisional Patent Application No. 63 / 281,395, entitled "NUCLEIC ACID STORAGE FOR BLOCKCHAIN AND NON-FUNGIBLE TOKENS," filed November 19, 2021. The entire contents of the above-cited application are incorporated herein by reference. [Background technology]
[0002] background
[0002] A blockchain provides a list of records ("blocks") in a distributed database that is shared among nodes of a network (e.g., a computer network) and linked using cryptographic methods. Blockchains can be used to store information, for example, in digital form. Blockchains are commonly used in cryptocurrency systems, such as Bitcoin, to maintain secure, decentralized records of transactions. Blockchains are typically managed by a peer-to-peer network for use as a public distributed ledger. So-called nodes collectively conform to a protocol to communicate and verify new blocks. Because each (new) block contains information about the blocks that preceded it, the blocks form a chain, with each additional block reinforcing the blocks that preceded it. Thus, blockchains are resistant to data changes because, once recorded, the data in any given block cannot be retroactively altered without altering all subsequent blocks. Thus, in effect, blockchains provide a secure record of data while eliminating the need for a trusted third party.
[0003]
[0003] A particular type of data commonly stored on a blockchain is a non-fungible token (NFT). NFTs can be stored, sold, and / or traded. NFTs can serve as a unique signature and proof of ownership and can be associated with a particular asset. Such assets can be virtual / digital or physical (e.g., a file or physical object). For example, a license to use or copy an asset can be associated with an NFT, and the NFT (and the associated license) can be transferred (e.g., traded or sold) in a digital marketplace. Summary of the Invention [Means for solving the problem]
[0004] overview
[0004] Described herein are techniques for integrating DNA storage and DNA computation with blockchain technology, particularly decentralized ledgers and non-fungible tokens (NFTs). Some embodiments of these techniques are systems and methods for storing blockchain keys in DNA molecules. Storing private keys in DNA provides an additional layer of security, for example, by creating an air gap between the blockchain and the key and / or by requiring a private decryption method to read the DNA and translate the information into digital data. Some embodiments of these techniques are systems and methods for storing NFT information, for example, for asset tokenization. Digital tokens can be encoded in DNA, thus providing a permanent and secure link between digital assets (e.g., NFTs) and physical or virtual objects (e.g., sneakers or digital graphics). The techniques disclosed herein can also be deployed to implement biological blockchains. Blockchains can be enhanced using DNA storage and DNA computation as the basis of consensus, providing permanent archiving and improved security.
[0005] In one aspect, provided herein is a method of preparing a library of nucleic acid molecules for use in a blockchain. The method includes storing digital information representing a key for a blockchain transaction in a key for the nucleic acid molecule, thereby obtaining or storing a library of nucleic acid molecules. The method includes sequencing at least a portion of the library of nucleic acid molecules, thereby obtaining or sequencing a sequencing read, and converting the sequencing read into a symbol string representing the key. The method includes applying the symbol string, thereby accessing or applying an electronic data file that is part of the blockchain transaction.
[0006] In one aspect, provided herein is a method of preparing a library of nucleic acid molecules for use in a blockchain. The method includes, by a first processor of a computer network, requesting a transaction for an item in the blockchain. The method includes, by a second processor of the computer network, generating a transaction data block. The transaction data block includes at least one data item selected from sender information, recipient information, transaction amount, and request date. The method includes broadcasting the transaction data block to multiple processors of the computer network associated with multiple nodes. The method includes, by the processors associated with the multiple nodes, verifying the transaction; and, by one or more processors of the computer network, adding the transaction data block to the blockchain, thereby obtaining an updated blockchain. The method includes storing digital information representing the digital information of the updated blockchain in nucleic acid molecules, thereby obtaining and storing a library of nucleic acid molecules representing the digital information of the updated blockchain, and completing the transaction.
[0007] In one aspect, provided herein is a method of preparing a library of nucleic acid molecules for use in a blockchain. The method includes requesting, by a first processor of a computer network, a transaction of blockchain items encoded in a plurality of nucleic acid molecules. The method includes generating, by a second processor of the computer network, a transaction data block, the transaction data block including at least one data item selected from sender information, recipient information, transaction amount, and request date. The method also includes storing, in the nucleic acid molecules, digital information representing the digital information of the transaction data block, thereby obtaining and storing a library of nucleic acid molecules representing the digital information of the transaction data block.
[0008] BRIEF DESCRIPTION OF THE DRAWINGS The novel features of the technology described herein are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings (also referred to herein as "Figure" and "FIG."). [Brief explanation of the drawings]
[0009] [Figure 1]
[0009] FIG. 1 is a block diagram of an example blockchain transaction. [Figure 2]
[0010] FIG. 1 is a block diagram of an example blockchain transaction using DNA-encoded private keys. [Figure 3]
[0011] FIG. 1 is a block diagram of an example blockchain transaction using DNA-encoded public keys. [Figure 4]
[0012] FIG. 1 is a block diagram illustrating an example process for linking physical or virtual objects to NFTs using a library of DNA identifiers. [Figure 5]
[0013] FIG. 1 is a block diagram of an example blockchain transaction in which transactions are conducted electronically online and managed through a decentralized network, and records of transactions are coded using DNA identifiers distributed across the network. [Figure 6]
[0014] A block diagram of an example blockchain transaction in which transactions are conducted electronically online and managed through a decentralized network, records of transactions are coded using DNA identifiers, and sequence information is distributed across the network. [Figure 7]
[0015] FIG. 1 is a block diagram of an example blockchain transaction in which the transaction is conducted using DNA identifiers and managed through a central trusted authority. [Figure 8]
[0016] FIG. 1 is a block diagram of an example blockchain transaction in which transactions are conducted using DNA identifiers and managed through a decentralized network. [Figure 9]
[0017] FIG. 1 is a block diagram of an example blockchain transaction in which the transaction is conducted using sequence information from a DNA identifier and managed through a decentralized network. [Figure 10]
[0018] 1 shows a schematic overview of the process of encoding, writing, accessing, querying, reading, and decoding digital information stored in nucleic acid sequences. [Figure 11A]
[0019] 1 illustrates a schematic diagram of an example method for encoding digital data, referred to as "data at an address," using objects or identifiers (e.g., nucleic acid molecules), and shows combining a rank object (or address object) with a byte value object (or data object) to create an identifier. [Figure 11B]
[0019] An example method for encoding digital data, referred to as "data-at-address," using objects or identifiers (e.g., nucleic acid molecules) is shown schematically, and an embodiment of the data-at-address method is shown in which rank objects and byte value objects are themselves combinatorial concatenations of other objects. [Figure 12A]
[0020] 1A-1C are schematic diagrams illustrating an example method for encoding digital information using objects or identifiers (e.g., nucleic acid sequences), illustrating the encoding of digital information using rank objects as identifiers. [Figure 12B]
[0020] An example method for encoding digital information using objects or identifiers (eg, nucleic acid sequences) is illustrated schematically, showing an embodiment of the encoding method in which the address object is itself a combinatorial concatenation of other objects. [Figure 13]
[0021] Shows a contour plot in logarithmic space of the combinatorial space of possible identifiers (C, x-axis) versus the average number of identifiers (k, y-axis) that can be constructed to store information of a given size (contour). [Figure 14]
[0022] 1 shows a schematic overview of how information can be written into a nucleic acid sequence (e.g., deoxyribonucleic acid). [Figure 15A]
[0023] An example method, termed the "product approach," for constructing an identifier (e.g., a nucleic acid molecule) by combinatorially assembling distinguishable components (e.g., nucleic acid sequences) is shown, and the architecture of an identifier constructed using the product approach is shown. [Figure 15B]
[0023] An example method, called the "product method," for constructing an identifier (e.g., a nucleic acid molecule) by combinatorially assembling distinguishable components (e.g., nucleic acid sequences) is presented, along with an example of a combinatorial space of identifiers that can be constructed using the product method. [Figure 16]
[0024] 1 illustrates a schematic representation of the use of overlap extension polymerase chain reaction to construct an identifier (e.g., a nucleic acid molecule) from components (e.g., nucleic acid sequences). [Figure 17]
[0025] 1 illustrates a schematic representation of the use of sticky end ligation to construct an identifier (e.g., a nucleic acid molecule) from components (e.g., nucleic acid sequences). [Figure 18]
[0026] 1A-1C illustrate a schematic representation of the use of recombinase assembly to construct an identifier (e.g., a nucleic acid molecule) from components (e.g., nucleic acid sequences). [Figure 19A]
[0027] 1 shows template-directed ligation and schematically illustrates the use of template-directed ligation to construct an identifier (e.g., a nucleic acid molecule) from components (e.g., nucleic acid sequences). [Figure 19B]
[0027] Figure 1 shows template-directed ligation, showing a histogram of copy numbers (abundances) of 256 distinct nucleic acid sequences each assembled combinatorially from six nucleic acid sequences (e.g., components) in one pooled template-directed ligation reaction. [Figure 20A]
[0028] 1 shows a schematic diagram of an example of a method, termed the "permutation method," for constructing identifiers (e.g., nucleic acid molecules) with permuted components (e.g., nucleic acid sequences), illustrating the architecture of an identifier constructed using the permutation method. [Figure 20B]
[0028] An example of a method called "permutation" for constructing identifiers (e.g., nucleic acid molecules) with permuted components (e.g., nucleic acid sequences) is shown schematically, along with an example of a combinatorial space of identifiers that can be constructed using permutation. [Figure 20C]
[0028] An example of a method called "permutation-based" for constructing an identifier (e.g., a nucleic acid molecule) having permuted components (e.g., a nucleic acid sequence) is shown schematically, and an example of an implementation of the permutation-based method is shown using template-directed ligation. [Figure 20D]
[0028] An example of a method called the "permutation method" for constructing an identifier (e.g., a nucleic acid molecule) having permuted components (e.g., a nucleic acid sequence) is shown schematically, and an example of how the embodiment from Figure 20C can be modified to construct an identifier having permuted and repeated components is shown. [Figure 20E]
[0028] An example of a method called the "permutation method" for constructing an identifier (e.g., a nucleic acid molecule) having permuted components (e.g., a nucleic acid sequence) is shown schematically, and the example embodiment from Figure 20D shows how undesirable by-products can be derived that can be removed using nucleic acid size selection. [Figure 20F]
[0028] An example of a method called "permutation" for constructing identifiers (e.g., nucleic acid molecules) with permuted components (e.g., nucleic acid sequences) is shown schematically, and another example shows how template-directed ligation and size selection can be used to construct identifiers with permuted and repeated components. [Figure 20G]
[0028] A schematic diagram of an example of a method called "permutation" for constructing an identifier (e.g., a nucleic acid molecule) with permuted components (e.g., a nucleic acid sequence) is shown, illustrating an example of when size selection may fail to separate a particular identifier from undesired by-products. [Figure 21A]
[0029] 1 shows a schematic diagram of an example of a method, referred to as the "MchooseK" method, for constructing an identifier (e.g., a nucleic acid molecule) using any number, K, of assembled components (e.g., nucleic acid sequences) out of a larger number, M, of possible components, and illustrates the architecture of an identifier constructed using the MchooseK method. [Figure 21B]
[0029] A schematic diagram of an example of a method, referred to as the "MchooseK" method, for constructing an identifier (e.g., a nucleic acid molecule) using any number, K, of assembled components (e.g., nucleic acid sequences) out of a larger number, M, of possible components is shown, along with an example of the combinatorial space of identifiers that can be constructed using the MchooseK method. [Figure 21C]
[0029] Schematic diagram of an example of a method, referred to as the "MchooseK" method, for constructing an identifier (e.g., a nucleic acid molecule) using any number, K, of assembled components (e.g., nucleic acid sequences) out of a larger number, M, of possible components, and an example implementation of the MchooseK method using template-directed ligation is shown. [Figure 21D]
[0029] An example of a method, referred to as the "MchooseK" method, for constructing an identifier (e.g., a nucleic acid molecule) using any number, K, of assembled components (e.g., nucleic acid sequences) out of a larger number, M, of possible components is shown schematically, and the example embodiment from Figure 21C shows how undesirable by-products can be removed using nucleic acid size selection. [Figure 22A]
[0030] 1 illustrates a schematic diagram of an example of a method, referred to as a "compartmentalization scheme," for constructing identifiers with compartmentalized components, and shows an example of the combinatorial space of identifiers that can be constructed using the compartmentalization scheme. [Figure 22B]
[0030] A schematic diagram of an example of a method called the "compartmentalization method" for constructing an identifier having compartmentalized components is shown, along with an example of an implementation of the compartmentalization method using template-directed ligation. [Figure 23A]
[0031] 1 shows a schematic diagram of an example of a method called the "unconstrained string" (or USS) method for constructing an identifier composed of a string of any component derived from several possible components, and an example of the combinatorial space of identifiers that can be constructed using the USS method. [Figure 23B]
[0031] A schematic diagram of an example of a method called the "unconstrained string" (or USS) approach for constructing an identifier composed of a string of any component derived from several possible components is shown, along with an example implementation of the USS approach using template-guided ligation. [Figure 24A]
[0032] 1 illustrates a schematic example of a method called "component elimination" for constructing an identifier by removing components from a parent identifier, and shows an example of a combinatorial space of identifiers that can be constructed using the component elimination scheme. [Figure 24B]
[0032] A schematic illustration of an example of a method called "component deletion" for constructing an identifier by removing components from a parent identifier is shown, and an example of an implementation of the component deletion method using double-stranded targeted cleavage and repair is shown. [Figure 25]
[0033] 1 shows a schematic representation of a parent identifier with a recombinase recognition site from which further identifiers can be constructed by applying a recombinase to the parent identifier. [Figure 26A]
[0034] 10A-10C are schematic diagrams outlining examples of methods for accessing portions of information stored in nucleic acid sequences by accessing a few specific identifiers from a larger number of identifiers, and show examples of methods for accessing identifiers containing specified components using polymerase chain reaction, affinity tagged probes, and degradation targeted probes. [Figure 26B]
[0034] A schematic overview of an example method for accessing some of the information stored in a nucleic acid sequence by accessing several specific identifiers from a larger number of identifiers is shown, and an example of a method for using the polymerase chain reaction to perform an "OR" or "AND" operation to access identifiers containing multiple specified components is shown. [Figure 26C]
[0034] A schematic overview of an example method for accessing some of the information stored in a nucleic acid sequence by accessing several specific identifiers from a larger number of identifiers is shown, and an example of a method for using affinity tags to perform an "OR" or "AND" operation to access identifiers containing multiple specified components is shown. [Figure 27A]
[0035] 1 shows an example of encoding, writing, and reading data encoded in a nucleic acid molecule, and an example of encoding, writing, and reading 5,856 bits of data. [Figure 27B]
[0035] An example of encoding, writing, and reading data encoded in a nucleic acid molecule is shown, and an example of encoding, writing, and reading 62,824 bits of data is shown. [Figure 28]
[0036] 1 illustrates a computer system programmed or otherwise configured to implement the methods presented herein. [Figure 29]
[0037] 1 shows an example of a scheme for the assembly of any two selected double-stranded components from a single parental set of double-stranded components. [Figure 30]
[0038] A possible sticky end component structure composed of two oligos, X and Y, is shown. [Figure 31]
[0039] 1 shows an example of constructing an identifier from components with multiple functionalities. [Figure 32A]
[0040] An example of the effect of identifier rank on PCR-based random access is shown. [Figure 32B]
[0040] An example of the effect of identifier rank on PCR-based random access is shown. [Figure 33A]
[0041] 1 shows an example of the effect of an identifier architecture with a non-uniform component distribution on PCR-based random access. [Figure 33B]
[0041] An example of the effect of an identifier architecture with non-uniform component distribution on PCR-based random access is shown. [Figure 34]
[0042] 1 shows an example of the effect of increasing layers in an identifier architecture on PCR-based random access. [Figure 35]
[0043] An example of a multi-bin positional coding scheme across an alphabet of nine symbols is shown. [Figure 36]
[0044] An example of a multi-bin identifier distribution coding scheme is shown, with an identifier library of two identifiers and a bin set of three bins, that allows encoding any of nine possible messages in a four-bit string. [Figure 37]
[0045] We present an example of a multi-bin identifier distribution coding scheme with identifier reuse having a library of two identifiers and a bin set of three bins that allows encoding any of 64 possible messages in a 6-bit string. [Figure 38]
[0046] Here is an example of encoding information into DNA using integer division. [Figure 39]
[0047] 1 illustrates an example of an encoding pipeline that includes algorithmic modules that prepare and convert a source bitstream into a building program specification that is interpreted by a writer. [Figure 40]
[0048] 1 illustrates an example of one embodiment of a data structure for representing an identifier library in serialized form. [Figure 41]
[0049] 1 shows an example of two source bitstreams and a generic identifier library prepared for computation using operations defined in the identifier pool. [Figure 42]
[0050] 1 shows the inputs and results of three example logical operations performed on the identifier pool, illustrating how the identifier library can be used as a platform for in vitro computation. [Figure 43A]
[0051] An example of storing an image file and reading the image file at multiple resolutions is shown. [Figure 43B]
[0051] An example of storing an image file and reading the image file at multiple resolutions is shown. [Figure 43C]
[0051] An example of storing an image file and reading the image file at multiple resolutions is shown. [Figure 43D]
[0051] An example of storing an image file and reading the image file at multiple resolutions is shown. [Figure 43E]
[0051] An example of storing an image file and reading the image file at multiple resolutions is shown. [Figure 43F]
[0051] An example of storing an image file and reading the image file at multiple resolutions is shown. [Figure 43G]
[0051] An example of storing an image file and reading the image file at multiple resolutions is shown. [Figure 44]
[0052] An example method for generating entropy that can be used to create a random bit string is shown. [Figure 45A]
[0053] An example method for generating and storing entropy (random bit strings) is shown. [Figure 45B]
[0053] An example method for generating and storing entropy (random bit strings) is shown. [Figure 45C]
[0053] An example method for generating and storing entropy (random bit strings) is shown. [Figure 46A]
[0054] 1 illustrates an example method for organizing and accessing random bit strings using an input. [Figure 46B]
[0054] An example method for organizing and accessing random bit strings using input is shown. [Figure 47]
[0055] An example method for securing and authenticating access to artifacts using physical DNA keys is presented. DETAILED DESCRIPTION OF THE INVENTION
[0010] explanation
[0056] Described herein are techniques for integrating chemical storage, e.g., DNA storage, and chemical computing, e.g., DNA computing, with blockchain technology, particularly decentralized ledgers and non-fungible tokens (NFTs). The techniques include systems and methods related to (I) enhancing existing blockchain technology, (II) linking digital assets with biological identifiers, and / or (III) biological blockchain and metaverse technology.
[0011]
[0057] Data storage in DNA molecules can provide an air gap between all internet networks and blockchain keys. Additionally, the technology described herein can be used to provide read-only nodes of an existing blockchain that automatically persist data from that blockchain to DNA molecules over the long term of the blockchain's history (persistence means that the data continues to exist even after the process that created it has stopped or the machine it is running on has lost power).
[0012]
[0058] Described herein are techniques for integrating chemical storage, e.g., DNA storage, and chemical computing, e.g., DNA computing, with blockchain technology. Some embodiments of these techniques are systems and methods for storing blockchain keys in chemical entities, e.g., RNA, proteins, aptamers, etc. Thus, the techniques described herein with respect to DNA can also be implemented with other types of molecules, e.g., biomolecules, e.g., RNA, proteins, aptamers, etc.
[0013]
[0059] Currently, there is no standard way to represent or transfer molecule-to-data mapping. As described herein, there is no current standard for going from DNA molecules to data with much fewer additional layers of encryption on that mapping. The techniques described herein can be used, for example, for molecule-to-data mapping, e.g., from DNA molecules to data, that includes an encryption layer in addition to the mapping.
[0014] (I) Improvements to existing blockchain and NFT systems
[0060] Described herein are techniques for integrating chemical storage, such as DNA storage and DNA computing, with blockchain technology. Some embodiments of these techniques are systems and methods for storing blockchain keys in DNA molecules. A blockchain key is a string of data that includes a public key (a long string of numbers) that serves as an address in the blockchain. A private key functions similar to a password, giving the owner access to digital assets or a means to otherwise interact with the blockchain. Figure 1 shows an example blockchain transaction. The sender sends plaintext, which is encrypted using a public key (the public key of the intended recipient). The public key is mathematically linked to the recipient's private key, but is different from the recipient's private key. The private key is used by the recipient to decrypt the encrypted text.
[0015]
[0061] Described herein are techniques for encoding digital information (e.g., information representing a blockchain transaction or a blockchain key) into a nucleic acid sequence. A method for encoding such digital information into a nucleic acid sequence includes (a) translating the digital information into a symbol string, (b) mapping the symbol string to a plurality of identifiers, and (c) constructing an identifier library that includes at least a subset of the plurality of identifiers. The identifiers are read (sequenced) to retrieve (decode) the digital information stored therein. Any of the encoding / decoding techniques described herein can be used to encode and / or decode blockchain keys as described herein.
[0016]
[0062] The technology described herein can provide a link between the digital realm and the physical world, thereby, for example, providing an additional backup of information independent of electronic systems and / or providing an additional layer of security. The identifier library described above can be physically generated by physically constructing an identifier corresponding to each symbol of digital information, as described herein. For example, identifiers can be constructed according to a product method using overlap extension polymerase chain reaction (OEPCR) or assembled according to a product method using sticky end ligation. The identifier library can be stored separately from any digital system and can be copied and distributed to multiple nodes, for example, in a blockchain. Information can be retrieved (read) using molecular biology techniques, including, for example, sequencing using next-generation sequencing (NGS) techniques or nanopore sequencing.
[0017]
[0063] The technology described herein can be used to store (blockchain) keys in DNA, for example, to provide one or more additional layers of storage security using DNA. Generally, blockchain keys can be stored in a "hot wallet" (keys on a device connected to the internet) or a "cold wallet" (keys on a device not connected to the internet or in an analog form such as a piece of paper with a handwritten marking of the key). Cold wallets can also use DNA. A DNA cold wallet can contain keys that are encrypted and stored in DNA, e.g., in solution or solid solution, and require sequencing and decryption before the key can be used in the blockchain.
[0018]
[0064] DNA cold wallets can address the challenge of how to store blockchain keys in a way that is long-lasting, secure, and resistant to online attacks. Storage technologies all have varying degrees of security, ease of use, and latency associated with them. Hot wallet-level technologies for storing blockchain keys have low latency and low security. Cold wallet-level technologies for storing blockchain keys have very high latency but very high security. There are several ways for users to store blockchain keys, for example, using DNA.
[0019]
[0065] Several consumer cold storage solutions exist, as well as technology for users to create the cold wallet themselves, with most blockchains. The technology described herein can provide an additional level of security that comes from encoding the cold wallet into a DNA sample, which requires a DNA sequencer, DNA-to-data mapping, and user decryption to extract the key from the sample.
[0020]
[0066] Figure 2 shows an example of a blockchain transaction using a DNA-encoded private key. The sender sends plaintext, which is encrypted using a public key (the public key of the intended recipient). The public key is mathematically linked to, but distinct from, the recipient's private key. The private key used by the recipient to decrypt the encrypted text is encoded into a DNA molecule, e.g., an identifier library, as described herein. To decrypt the text, the digital information that constitutes the private key is obtained by reading the DNA sequence (e.g., using a DNA sequencer, e.g., an NGS device) and decoding the sequence (e.g., mapping the sequence to a string of symbols, e.g., a string of binary data), as described below.
[0021]
[0067] As described herein, one or more (chemical) computational steps can be performed on or by a DNA strand that encodes a private (or public) key. In some embodiments, the identifier used to encode the private (or public) key can include one or more logic gate elements as described herein. The computation can be performed without having to read or decode the actual digital information from a pool of molecules. The computation can include any combination of Boolean logic gates, such as AND, OR, NOT, or NAND operations.
[0022]
[0068] Existing techniques for key duplication are limited to either manual duplication or some computer-enabled duplication method, both of which are prone to either attacks or errors. In contrast, the technique described herein provides DNA sample keys that can be easily duplicated without decoding or sequencing and without storage in a physical location, and that maintain data integrity for thousands of years. Conventional computer storage media cannot maintain integrity over this period.
[0023]
[0069] The techniques described herein can be used to create DNA samples of public keys that are distributed or applied to objects, for example, as shown in FIG. 3. In an example embodiment, the techniques described herein can be used to apply identifiers to objects that link to public keys on a blockchain, for example, as described below. For example, these identifiers can be attached to the object, e.g., sprayed on the object, or provided in a vial or pouch. These identifiers can be highly complex and long-lasting. Existing techniques are limited to long strings of text, barcodes, QR codes, or short-range (near-field) identifiers. Existing techniques are limited by the lifespan of the ink printed on them or by the lifespan of the plastic or electronic tag.
[0024]
[0070] The technology described herein can provide additional security by storing wallet keys in DNA for long periods of time. Storing wallet keys in DNA provides an additional layer of security because it requires additional equipment (e.g., a DNA sequencer and / or a lab) and a DNA-to-data mapping key to extract the private key stored within the DNA sample. This technology provides decryption ease and / or isolation of wallet keys from hackers, leading to high security with both air gaps and technology gaps for decrypting DNA molecules back to their original binary data. For example, as discussed below, DNA copies of public keys for distribution have significant advantages because DNA can be easily replicated and mass-produced for attachment to physical objects.
[0025]
[0071] The technology described herein can be used for DNA coding schemes as NFTs. As described later in this specification, a coding scheme is a unique mapping between DNA molecules and bytes of data. While DNA samples can be easily replicated and transferred, decoding the data and utilizing the DNA samples also requires mapping information of those DNA molecules to digital information (e.g., data bytes). This mapping information is unique to a dataset and can be used as an NFT. That is, the information needed to decode the information stored in the DNA (the DNA mapping) can itself be an NFT (e.g., a "decode NFT"). Thus, storing a DNA-data encryption mapping, described herein as an NFT, can enable ownership of the decryption potential of a given DNA library. This allows any entity to own a DNA library (e.g., a DNA sample encoding an NFT or blockchain key), but only the owner of the decode NFT has the ability to decrypt the DNA library.
[0026]
[0072] The techniques described herein can be used with representations of public keys that can be created graphically and are not made of DNA molecules. The representation is in "molecular space," which is the representation of the DNA molecules that represent that data. The graphical representation is any standardized visualization that can be scanned or automatically interpreted using a machine or by eye.
[0027]
[0073] The above-described technique for storing public or private keys in DNA can also be applied to other components of blockchain technology. For example, the technique described herein can be used in DNA cold storage nodes of existing blockchains. For example, this technique can be used for long-term storage of all past blocks from a blockchain, including records of all past transactions on that blockchain. Existing technology for backing up blockchains is the nodes in the blockchain. These nodes and their storage disks do not last as long as DNA storage, and therefore existing technologies do not provide as long a lifespan for data as DNA, since they are limited by the lifespan of the disks used for storage. The technique described herein can ensure the ultra-long lifespan of a blockchain by establishing non-voting / mining nodes that continuously write confirmed blocks in the chain to an ever-growing DNA library. Records stored in DNA can be replicated and distributed to one or more (physical) nodes of the blockchain.
[0028] (II) Linking Digital Assets to the Physical World (Authentication)
[0074] Described herein are techniques for integrating chemical storage, e.g., DNA storage, and computation, with blockchain technology, e.g., linking non-fungible tokens (NFTs) to real-world objects (e.g., physical or digital objects). Some embodiments of these techniques are systems and methods for storing NFT information, e.g., for asset tokenization. Asset tokenization is a process in which an issuer creates digital tokens representing either digital or physical assets in a distributed ledger or blockchain (e.g., an electronic or chemical blockchain). The digital tokens can be encoded in DNA, thus providing a link between a digital asset (e.g., an NFT) and a physical or virtual object (e.g., sneakers or digital graphics), for example, as shown in FIG. 4.
[0029]
[0075] Described herein are techniques for encoding digital information (e.g., information representing an NFT) into a nucleic acid sequence. A method for encoding such digital information into a nucleic acid sequence includes (a) translating the digital information into a symbol string, (b) mapping the symbol string to a plurality of identifiers, and (c) constructing an identifier library that includes at least a subset of the plurality of identifiers. The identifiers can be applied (e.g., attached) to a physical object. The identifiers can be retrieved and read (e.g., sequenced) from the object to retrieve (decode) the digital information stored therein. Any of the encoding / decoding techniques described herein can be used to encode and / or decode NFTs as described herein.
[0030]
[0076] The identifier library can be physically generated by physically constructing identifiers corresponding to each symbol of digital information, as described herein. For example, the identifiers can be constructed in a multi-step manner using overlap extension polymerase chain reaction (OEPCR) or assembled in a multi-step manner using sticky end ligation. The library construction process can be implemented as a biological token generator. This generator includes a process for continuously generating identifier molecules that can be sampled periodically or as needed to extract a new set encoding a new NFT. The random biological process described herein can be used, for example, to ensure the uniqueness of each NFT.
[0031]
[0077] In some embodiments, information representing an NFT can be encoded into the copy number of a DNA strand used as an identifier. In some embodiments, information representing an NFT can be encoded into the length and / or weight of a DNA strand used as an identifier. Such encoding schemes can be more robust than translation / mapping encoding schemes and can be read more quickly because they do not require encoding (and reading) digital information. In one example embodiment, the amount of one type of DNA strand can be sufficient to identify an NFT. In one example embodiment, the relative amounts of two or more types of DNA strands can be sufficient to identify an NFT.
[0032]
[0078] One or more (chemical) computational steps can be performed on or by the DNA strand encoding the NFT, as described herein. In some embodiments, the identifier used to encode the NFT can include one or more logic gate elements, as described herein. The computation can be performed without the need to read or decode actual digital information from a pool of molecules. The computation can include any combination of Boolean logic gates, such as AND, OR, NOT, or NAND operations.
[0033]
[0079] The technologies described herein can connect (e.g., attach) DNA identifiers to physical objects, where the DNA identifiers represent ownership of NFTs on a blockchain, e.g., a biological blockchain or a virtual / digital blockchain as described herein. These technologies include, for example, sequentially tagging objects to transform fungible items into non-fungible items (e.g., a baseball vs. a World Series winning ball). In some applications, the technologies disclosed herein can include, but are not limited to, encapsulation of DNA identifiers in droplets and stable production of DNA identifiers that can be applied to surfaces, biological spores, or applied using microinjection printing. In some embodiments, the DNA identifiers can be applied to objects in liquid form (e.g., ink containing DNA molecules). To extract the information encoded in the DNA identifiers, areas of the object containing the (dried) ink can be wiped, and the DNA can be sequenced. The DNA identifiers can also be stored in liquid or dry form in vials or sealed pouches that can be associated with (e.g., physically attached to) the physical object. Additionally or alternatively, the DNA can include magnetic or optical tags that can be analyzed, for example, using a microscope or other optical device.
[0034]
[0080] Ownership of physical assets can be strengthened with a digital record of ownership and provenance. The value of a physical good can increase if its provenance or authenticity can be traced and verified. The link between the digital asset and the physical asset should be secure, durable, and difficult to counterfeit or tamper with. In some embodiments, the link is invisible (e.g., on a diamond), does not affect the performance of the physical good (e.g., in textiles), and can even be safe for consumption (e.g., in agriculture, e.g., seafood). DNA tags in the form of identifiers as described herein provide these characteristics.
[0035]
[0081] Some existing technologies link physical objects (e.g., sneakers, artwork, event tickets) to digital tokens via QR codes, NFC tags, or RFID tags printed somewhere on the shoe. Similarly, physical collectible toys can also be linked to NFTs to ensure authenticity and provenance. Each such toy has a physical tag on the figurine's foot that can be scanned. In each of these cases, the linking technology is not durable. In the case of toys, the tag is intentionally constructed to be tamper-resistant; therefore, if the tag is removed or cut, it becomes non-scannable, hindering consumers' ability to prove the origin and authenticity of their collectible toy. The technology described herein goes beyond DNA tagging for supply chain authentication, where authentication is not linked to a blockchain. The technology described herein goes beyond DNA tags, which encode data but simply function as barcodes that identify products.
[0036]
[0082] In some implementations of the technology described herein, a physical item can be linked to a digital asset through a tag containing a library of DNA identifiers (identifier tag sequences). The identifier tag sequence can be coded to represent an NFT representing the object and linked to a blockchain as a public key to access the NFT and object. The owner of the physical item can also be given a private key (e.g., a private key encoded in DNA as described above) that allows the owner to trade or publicly claim ownership of the NFT.
[0037]
[0083] In some embodiments, identifier tags may be sprayed, coated, manufactured as freeze-dried pellets, encapsulated in liquids, gels, droplets, cloned into biological organisms, or any combination thereof. Blockchain-linked identifier tags can provide greater security than QR codes or similar tags, which can be easily counterfeited or damaged. The technology described herein is more difficult to tamper with and provides a longer-lasting link between physical and digital assets. Furthermore, identifier tags described herein can be invisible, unlike QR codes or other tags, providing a more covert method of authentication. This invisibility can also be useful in situations where the performance or aesthetics of a physical item would be adversely affected by a visible tag.
[0038]
[0084] In some embodiments, the identifier tags described herein can be manufactured and packaged to instantly tag objects, enabling them to go from fungible to non-fungible. For example, a baseball caught by a fan during a game—the value of that ball can instantly increase, and an instant tagging strategy allows for future authentication of that moment. In this case, the fan can, for example, apply a spray containing a DNA identifier library that encodes the NFT. The identifier tags described herein can encode data, such as a description of a physical or digital asset, into the tag itself. In some embodiments, a computational function can be performed on the data encoded in the identifier tag to verify authenticity.
[0039]
[0085] In some embodiments, rather than providing a link between the physical item and the virtual item, the physical item can be the identifier tag itself, for example, DNA in a liquid, solid, gel, or other form (e.g., embedded in a piece of jewelry).
[0040]
[0086] In some embodiments, the DNA of an organism, e.g., a human, can be integrated into a DNA identifier or DNA tag. For example, a DNA tag (e.g., a vial, droplet, or other DNA carrier) can include the organism's DNA or a fragment thereof in addition to a DNA identifier encoding digital information as described herein. In some embodiments, the organism's DNA can be the DNA of the owner of the physical asset associated with the NFT. In some embodiments, the organism's DNA can function as a private key.
[0041]
[0087] In one example embodiment, the technology described herein can be used to link physical technical works to digital assets through tags that include a library of DNA identifiers (identifier tag sequences). In some embodiments, an artist's own DNA (or fragments thereof) can be integrated into the DNA identifiers or DNA tags associated with the technical works.
[0042]
[0088] In some embodiments, the physical object tagged using a DNA tag as described herein can be an organism, e.g., a living organism. The organism can be a cell or a multicellular organism. The DNA identifier can be associated with the organism as described above for the physical object, or the DNA identifier can be present in one or more cells of the organism. In some embodiments, the DNA identifier can be present in the extracellular space, e.g., in blood or other bodily fluids. Tagging of the organism can be achieved by injecting the DNA identifier suspended in a fluid into the organism. In some embodiments, the DNA identifier is delivered to one or more cells using, for example, transfection techniques.
[0043]
[0089] In some implementations, the above techniques for linking digital assets or tokens to physical goods can also be used in conjunction with virtual or digital goods. A virtual / digital good can be a data file, such as a digitized image (e.g., a .jpeg, .gif, .tiff, or .bmp file), a digital video clip (e.g., an .avi or .mpg file), an audio clip (e.g., an .mp3 or .wav file), or any other digital file (e.g., a text document, spreadsheet, or other such file). In one example embodiment, a concert can be digitally recorded and stored as a video data file, an audio data file, or both. An identifier tag sequence can be coded to represent an NFT representing the data file and linked to a blockchain as a public key for accessing the NFT and digital object.
[0044]
[0090] In some embodiments, digital goods such as digital documents, images, or video files can be encoded into DNA libraries for archival purposes. Digital goods can be highly valuable and may be desired to be preserved for long periods of time, such as decades or centuries. The DNA sample or DNA molecule encoding the digital goods can be engineered to verify the authenticity of the digital goods encoded in the DNA library. In one such approach, the DNA molecules can contain modified bases, e.g., isotopes, at a rate known only to the authenticating institution. In some embodiments, the approach can be public. In one approach, the composition of the DNA sample or the contents of the container containing the DNA can be known only to the authenticating institution. In another approach, in addition to the DNA encoding the digital goods, one or more other decoy libraries containing decoy DNA molecules can be present in the DNA sample encoding the digital goods. The details of separating the decoy library from the target library can be known only to the authenticating institution. Using these approaches, digital goods encoded in DNA, e.g., DNA identifier libraries, as described herein can be authenticated as the exact original sample encoding the digital goods. In some embodiments, the DNA can be designed or modified to thwart traditional methods of copying DNA, such as PCR. For example, double-stranded DNA strands can be artificially linked at their ends to prevent complete strand assembly, reducing the efficiency of primer binding, for example, using phosphorothioate linkages across the DNA strand. In some embodiments, some or all bases can have additional synthetic chemical groups, such as azides, attached, for example, using click chemistry. In this way, digital goods encoded in DNA libraries can be prevented from being easily copied, ensuring the preservation of only a single, original copy.
[0045]
[0091] In some embodiments, the identifier tags described herein can be tamper-resistant. Identifier tags can be synthesized to make the tags impossible to copy by others. Identifier tags can be encapsulated in a device that, if tampered with, destroys the DNA (e.g., tampering causes a chemical reaction between a reagent and the DNA) and loses the link between the physical and digital goods. While DNA stability is a positive attribute for long-term use of identifier tags, in some cases, the ability to destroy DNA can be a desirable feature.
[0046] (III) Biological Blockchain and Metaverse
[0092] The technology described herein can also be used to implement a blockchain based on a constantly evolving library of DNA identifiers. Transactions on the blockchain and the creation of new blocks along with transactions may require the creation of DNA identifiers representing blocks of data and adding those identifiers to the set of already existing identifiers from previous blocks. Sequencing of the DNA library at any point in time can be used to establish consensus (a fault-tolerant mechanism for achieving agreement on a single data value or a single state of the network among distributed processes or multi-agent systems) and data validation. The technology can also provide fungible or non-fungible tokens as assets for sequencing.
[0047]
[0093] The technology described herein can be deployed to implement a biological blockchain. Blockchains can provide decentralized consensus for a wide range of contracts, coins, and other use cases. Blockchains can generally be enhanced using DNA storage and computation as the basis for consensus. In some embodiments, the decentralized feature can be achieved by linking multiple DNA synthesis facilities. Sequencing a sample can be used to verify previous blocks in a DNA library.
[0048]
[0094] Existing blockchain technology is based on the original Bitcoin paper, which described a public codebase originally written by the anonymous author Satoshi Nakamoto. Blockchains can vary in speed, throughput, consensus type, and community of developers and users. The biological blockchain described herein differs from other existing blockchains in that the chain is an ever-growing library of DNA molecules whose presence or absence can be decoded into binary (or text) data. The blockchain can reside in one or more bioreactors that can be sampled periodically.
[0049]
[0095] Existing blockchains cannot achieve the longevity of their inherent hard drive disks. A given node of a given blockchain is not decryptable for more than 20 years on average. DNA libraries can be stored for much longer periods. The technology described herein provides an extension to blockchain technology that uses an immutable but writable library of DNA molecules as the blockchain, a given write job adding to the library as a block addition, and sequencing of the DNA library as verification (mining).
[0050]
[0096] Most consensus algorithms in blockchains are either proof-of-work (a type of consensus mechanism in which one party proves to other parties that a certain amount of specific computational effort has been expended, e.g., used to verify cryptocurrency transactions) or proof-of-stake (a type of consensus mechanism in which cryptocurrency holders can contribute coins, thereby granting them the right to check new blocks of transactions and add them to the blockchain). The technology described herein includes consensus systems and methods based on DNA sequencing proofs. This proof can verify past transactions as well as newly written transactions. Tokens, either native or synthetic, can be awarded to incentivize sequencing and mining on the blockchain network.
[0051]
[0097] Figure 5 is a flow diagram of an example blockchain transaction in which transactions are conducted electronically online and managed through a decentralized network, and records of the transactions are encoded using DNA identifiers distributed across the network. The transaction is requested electronically, and the transaction data is represented electronically online as a block. The transaction is verified electronically by the network, and a new block is added to the blockchain. This transaction and / or the entire blockchain record is encoded into DNA using techniques for encoding digital information into DNA as described herein. The DNA record can then be copied and sent to each node in the blockchain. The transaction is then complete.
[0052]
[0098] Figure 6 is a flow diagram of an example blockchain transaction in which a transaction is conducted electronically online and managed through a decentralized network, a record of the transaction is encoded using a DNA identifier, and sequence information is distributed to the network. The transaction is requested electronically, and the transaction data is electronically represented online as a block. The transaction is electronically verified by the network, and a new block is added to the blockchain. This transaction and / or the entire blockchain record is encoded into DNA using techniques for encoding digital information into DNA as described herein. The DNA is then sequenced, and the sequence information (e.g., digital information) is then sent to each node in the blockchain. The transaction is now complete.
[0053]
[0099] Figure 7 is a flow diagram of an example blockchain transaction in which the transaction is conducted using DNA identifiers and managed through a central trusted authority. The transaction is requested (e.g., electronically), and the transaction data is encoded into DNA using techniques for encoding digital information into DNA as described herein. The DNA is then stored, for example, in a vial (or other storage embodiment), and the vial is then transferred to a central repository or notary registry. The notary verifies the transaction. One or more DNA blocks from an existing blockchain are transparently and immutably added to the vial. The transaction is then complete.
[0054]
[0100] Figure 8 is a flow diagram of an example blockchain transaction in which the transaction is conducted using DNA identifiers and managed through a decentralized network. The transaction is requested (e.g., electronically), and the transaction data is encoded into DNA using techniques for encoding digital information into DNA as described herein. The DNA is then copied and stored, for example, in vials (or other storage embodiments), and the vials are then distributed to the network, e.g., each node in the blockchain transaction. The network (or a portion thereof) verifies the transaction. One or more DNA blocks from an existing blockchain are transparently and immutably added to the vial. The transaction is then complete.
[0055]
[0101] Figure 9 is a flow diagram of an example blockchain transaction in which the transaction is conducted using sequence information from a DNA identifier and managed through a decentralized network. The transaction is requested (e.g., electronically), and the transaction data is encoded into DNA using techniques for encoding digital information into DNA as described herein. The DNA is then sequenced, and the sequence information is copied and distributed to each node in the network, e.g., the blockchain transaction. The network (or a portion thereof) verifies the transaction. One or more DNA block sequences from an existing blockchain are transparently and immutably added to the sequence. The transaction is then completed.
[0056]
[0102] The NFT and blockchain technologies described herein are also adaptable for use in various applications in the Metaverse. DNA identifiers encoding digital information can be used alone or in combination with Metaverse terminals, such as virtual reality (VR) and / or augmented reality (AR) devices, to verify a user's identity, for example. In some embodiments, the DNA identifier can function as a "digital fingerprint" to unlock an AR or VR device or its programmed features, for example. The DNA identifier can be stored in a wallet or attached (sprayed) to the user as described above and read by the terminal.
[0057]
[0103] The following describes configurations and methods for storing digital data that can be used in conjunction with the above-mentioned blockchain and NFT technologies.
[0058]
[0104] The term "symbol," as used herein, generally refers to the representation of a unit of digital information. Digital information can be divided or translated into a string of symbols. In one example, a symbol can be a bit, and can have a value of "0" or "1."
[0059]
[0105] The terms "distinguishable" or "unique," as used herein, generally refer to an object that can be distinguished from other objects in a group. For example, a distinguishable or unique nucleic acid sequence can be a nucleic acid sequence that does not have the same sequence as any other nucleic acid sequence. A distinguishable or unique nucleic acid molecule may not have the same sequence as any other nucleic acid molecule. A distinguishable or unique nucleic acid sequence or molecule may also share regions of similarity with another nucleic acid sequence or molecule.
[0060]
[0106] The term "component," as used herein, generally refers to a nucleic acid sequence. A component can be a distinct nucleic acid sequence. A component can be linked or assembled with one or more other components to generate other nucleic acid sequences or molecules.
[0061]
[0107] The term "stratum," as used herein, generally refers to a group or pool of components. Each stratum may contain a set of distinguishable components such that the components in one stratum differ from the components in another stratum. Components from one or more stratums may be assembled to generate one or more identifiers.
[0062]
[0108] The term "identifier," as used herein, generally refers to a nucleic acid molecule or sequence that represents the position and value of a bit string within a larger bit string. More generally, an identifier may refer to any object that represents or corresponds to a symbol in a symbol string. In some embodiments, an identifier may include one or more concatenated components.
[0063]
[0109] The term "combinatorial space," as used herein, generally refers to the set of all possible distinct identifiers that can be generated from a starting set of objects, such as components, and an allowable set of rules for how to modify those objects to form identifiers. The size of the combinatorial space of identifiers created by assembling or linking components can depend on the number of layers of components, the number of components in each layer, and the particular assembly method used to generate the identifiers.
[0064]
[0110] The term "identifier rank," as used herein, generally refers to a relationship that defines the ordering of identifiers in a set.
[0065]
[0111] The term "identifier library," as used herein, generally refers to a collection of identifiers that correspond to symbols in a string representing digital information. In some embodiments, the absence of a given identifier in an identifier library can indicate a symbol value at a particular location. One or more identifier libraries can be combined into a pool, group, or set of identifiers. Each identifier library can include a unique barcode that identifies the identifier library.
[0066]
[0112] The term "nucleic acid," as used herein, generally refers to deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or variants thereof. Nucleic acids can include one or more subunits selected from adenosine (A), cytosine (C), guanine (G), thymine (T), and uracil (U), or variants thereof. Nucleotides can include A, C, G, T, or U, or variants thereof. Nucleotides can include any subunit that can be incorporated into a growing nucleic acid chain. Such subunits can be A, C, G, T, or U, or any other subunit that can be specific to one of more complementary A, C, G, T, or U, or that can be complementary to a purine (i.e., A or G, or variants thereof) or a pyrimidine (i.e., C, T, or U, or variants thereof). In some instances, nucleic acids can be single-stranded or double-stranded, and in some cases, nucleic acid molecules are circular.
[0067]
[0113] The terms "nucleic acid molecule" or "nucleic acid sequence," as used herein, generally refer to a polymeric form of nucleotides or polynucleotides, which may be of various lengths, either deoxyribonucleotides (DNA) or ribonucleotides (RNA), or analogs thereof. The term "nucleic acid sequence" can refer to the alphabetical representation of a polynucleotide; alternatively, the term can apply to the physical polynucleotide itself. This alphabetical representation can be entered into a database in a computer having a central processing unit and used to encode digital information, for mapping nucleic acid sequences or nucleic acid molecules to symbols or bits. A nucleic acid sequence or oligonucleotide may contain one or more non-standard nucleotides, nucleotide analogs, and / or modified nucleotides.
[0068]
[0114] "Oligonucleotide," as used herein, generally refers to a single-stranded nucleic acid sequence, typically composed of a specific sequence of the four nucleotide bases adenine (A), cytosine (C), guanine (G), and thymine (T), or, if the polynucleotide is RNA, adenine (A), cytosine (C), guanine (G), and uracil (U).
[0069]
[0115] Examples of modified nucleotides include, but are not limited to, diaminopurine, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl)uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylguanine, 5-methylaminomethyl-2-thiouridine ... methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueuosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-D46-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxocine, pseudouracil, queuosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methyl ester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl)uracil, (acp3)w, 2,6-diaminopurine, and the like. Nucleic acid molecules may have modified base moieties (e.g., at one or more atoms normally available to form hydrogen bonds with a complementary nucleotide and / or at one or more atoms normally unavailable to form hydrogen bonds with a complementary nucleotide), modified sugar moieties, or modified phosphate backbones. Nucleic acid molecules may also contain amine-modifying groups such as aminoallyl-dUTP (aa-dUTP) and aminohexhylacrylamide-dCTP (aha-dCTP) to allow covalent attachment of amine-reactive moieties such as N-hydroxysuccinimide ester (NHS).
[0070]
[0116] The term "primer," as used herein, generally refers to a nucleic acid strand that serves as the starting point for nucleic acid synthesis, such as in polymerase chain reaction (PCR). In one example, during replication of a DNA sample, an enzyme that catalyzes replication initiates replication at the 3' end of a primer bound to the DNA sample and copies the opposite strand. For more information regarding PCR, including details about primer design, see Chemical Methods Section D.
[0071]
[0117] The terms "polymerase" or "polymerase enzyme," as used herein, generally refer to any enzyme capable of catalyzing a polymerase reaction. Examples of polymerases include, but are not limited to, nucleic acid polymerases. Polymerases can be naturally occurring or synthetic. An example of a polymerase is Φ29 polymerase or a derivative thereof. In some cases, a transcriptase or a ligase (i.e., an enzyme that catalyzes the formation of a bond) is used in conjunction with or as a substitute for a polymerase to construct new nucleic acid sequences. Examples of polymerases include DNA polymerases, RNA polymerases, thermostable polymerases, wild-type polymerases, modified polymerases, E. coli DNA polymerase I, T7 DNA polymerase, bacteriophage T4 DNA polymerase Φ29 (phi29) DNA polymerase, Taq polymerase, Tth polymerase, Tli polymerase, Pfu polymerase, Pwo polymerase, VENT polymerase, DEEPVENT polymerase, Ex-Taq polymerase, LA-Taw polymerase, Sso polymerase, Poc polymerase, Pab polymerase, Mth polymerase, ES4 polymerase, Tru polymerase, Tac polymerase, Tne polymerase, Tma polymerase, Tca polymerase, Tih polymerase, Tfi polymerase, and Platinum Examples include Taq polymerase, Tbr polymerase, Tfl polymerase, Pfutubo polymerase, Pyrobest polymerase, KOD polymerase, Bst polymerase, Sac polymerase, Klenow fragment polymerase with 3' to 5' exonuclease activity, and variants, modifications, and derivatives thereof. For additional polymerases that can be used with PCR, and for more information on how polymerase properties can affect PCR, see Chemical Methods section D.
[0072]
[0118] The term "species," as used herein, generally refers to one or more DNA molecules of the same sequence. When "species" is used in the plural sense, it can be assumed that every species within the plural has a distinguishable sequence, which is sometimes clarified by writing "distinguishable species" instead of "species."
[0073]
[0119] Digital information, such as computer data, in the form of binary code may include a sequence or string of symbols. Binary code may, for example, encode or represent text or computer processor instructions using a binary system with two binary symbols called bits, typically 0 and 1. Digital information may be represented in the form of a non-binary code, which may include a sequence of non-binary symbols. Each encoded symbol may be reassigned to a unique bit string (or "byte"), and the unique bit strings or bytes may be arranged into a byte string or byte stream. The bit value for a given bit may be one of two symbols (e.g., 0 or 1). A byte may contain a string of N bits, for a total of 2 N For example, a byte containing 8 bits can have a total of 2 8 Or 256 possible unique byte values can be produced, where each of the 256 bytes can correspond to one of the 256 possible distinct symbols, characters, or instructions that can be encoded in the byte. Raw data (e.g., text files and computer instructions) can be represented as a sequence of bytes or a byte stream. Zip files, or compressed data files that contain raw data, can also be stored as a byte stream; these files can be stored in compressed form as a byte stream and then restored to raw data before being read by a computer.
[0074]
[0120] The disclosed methods and systems can be used to encode computer data or information with multiple identifiers, each of which can represent one or more bits of primary information. In some examples, the disclosed methods and systems encode data or information using identifiers, each of which can represent two bits of primary information.
[0075]
[0121] Previous methods for encoding digital information into nucleic acids have relied on the base-by-base synthesis of nucleic acids, which can be expensive and time-consuming. Alternative methods can improve the efficiency and commercial viability of digital information storage by reducing the reliance on base-by-base nucleic acid synthesis to encode digital information, and can eliminate the need for de novo synthesis of distinct nucleic acid sequences for every new information storage requirement.
[0076]
[0122] Rather than relying on base-by-base or de novo nucleic acid synthesis (e.g., phosphoramidite synthesis), the new methods can encode digital information (e.g., binary code) into multiple identifiers or nucleic acid sequences comprising combinatorial sequences of components. In this way, the new strategies can generate a first set of distinct nucleic acid sequences (or components) for a first request for information storage, and then reuse the same nucleic acid sequences (or components) for subsequent information storage requests. These approaches can significantly reduce the cost of DNA-based information storage by reducing the role of de novo synthesis of nucleic acid sequences in the process of encoding and writing information to DNA. Furthermore, unlike embodiments of base-by-base synthesis (e.g., phosphoramidite chemistry-based or template-free polymerase-based nucleic acid extension), which may use cyclic delivery of each base to each extended nucleic acid, the new methods of writing information to DNA using identifier construction from components are highly parallelizable processes that do not necessarily use cyclic nucleic acid extension. Thus, the new methods can increase the speed at which digital information can be written to DNA compared to traditional methods.
[0077] Methods for encoding and writing information into nucleic acid sequences
[0123] In one aspect, the present disclosure provides a method for encoding information into a nucleic acid sequence. The method for encoding information into a nucleic acid sequence may include (a) converting the information into a symbol string, (b) mapping the symbol string to a plurality of identifiers, and (c) constructing an identifier library including at least a subset of the plurality of identifiers. Each identifier of the plurality of identifiers may include one or more components. Each component of the one or more components may include a nucleic acid sequence. Each symbol at each position in the symbol string may correspond to a distinct identifier. Each identifier may correspond to each symbol at each position in the symbol string. Furthermore, one symbol at each position in the symbol string may correspond to the absence of an identifier. For example, each occurrence of a "0" in a string of binary symbols (e.g., bits) of "0" and "1" may correspond to the absence of an identifier.
[0078]
[0124] In another aspect, the present disclosure provides a method for nucleic acid-based computer data storage. The method for nucleic acid-based computer data storage may include (a) receiving computer data, (b) synthesizing nucleic acid molecules including a nucleic acid sequence that encodes the computer data, and (c) storing the nucleic acid molecules having the nucleic acid sequence. The computer data may be encoded in at least a subset of the synthesized nucleic acid molecules, rather than the sequence of each of the nucleic acid molecules.
[0079]
[0125] In another aspect, the present disclosure provides a method for writing and storing information in a nucleic acid sequence. The method may include (a) receiving or encoding a virtual identifier library representing the information, (b) physically constructing the identifier library, and (c) storing one or more physical copies of the identifier library in one or more separate locations. Each identifier in the identifier library may include one or more components. Each of the one or more components may include a nucleic acid sequence.
[0080]
[0126] In another aspect, the present disclosure provides a method for nucleic acid-based computer data storage. The method for nucleic acid-based computer data storage may include: (a) receiving computer data; (b) synthesizing a nucleic acid molecule comprising at least one nucleic acid sequence encoding the computer data; and (c) storing the nucleic acid molecule comprising at least one nucleic acid sequence. Synthesizing the nucleic acid molecule may be in the absence of base-by-base nucleic acid synthesis.
[0081]
[0127] In another aspect, the present disclosure provides a method for writing and storing information in a nucleic acid sequence. The method for writing and storing information in a nucleic acid sequence may include (a) receiving or encoding a virtual identifier library representing the information, (b) physically constructing the identifier library, and (c) storing one or more physical copies of the identifier library in one or more separate locations. An individual identifier in the identifier library may include one or more components. An individual component of the one or more components may include a nucleic acid sequence.
[0082]
[0128] In another aspect, the disclosure provides a method for storing digital information in a nucleic acid sequence, the method comprising: (a) receiving the digital information as a symbol string, wherein each symbol in the symbol string has a symbol value and a symbol position within the symbol string; and (b) forming a first identifier nucleic acid sequence, the method comprising: (1) selecting one component nucleic acid sequence from each of M layers from a set of distinguishable component nucleic acid sequences separated into M distinct layers; (2) depositing the M selected component nucleic acid sequences into compartments; and (3) physically assembling the M selected component nucleic acid sequences in (2) such that the component nucleic acid sequences from the first and second layers correspond to first and second end sequences of the identifier nucleic acid sequence, and the component nucleic acid sequence in the third layer corresponds to a third sequence of the identifier nucleic acid sequence, defining a physical order of the M layers in the first identifier nucleic acid sequence, thereby defining the first and second end sequences and (c) forming a plurality of additional identifier nucleic acid sequences, each of which has (1) a first and second end sequence and a third sequence located between the first and second end sequences, and (2) corresponds to each symbol position, wherein at least one of the first end sequence, the second end sequence, and the third sequence of at least one additional identifier nucleic acid sequence is identical to the target sequence of the first identifier nucleic acid sequence in (b), allowing a probe to select at least two identifier nucleic acid sequences corresponding to each symbol having consecutive symbol positions within the symbol string; and (d) collecting the identifier nucleic acid sequences in (b) and (c) into a pool in the form of a powder, liquid, or solid.
[0083]
[0129] In another aspect, the disclosure provides a method for storing digital information in a nucleic acid sequence, the method comprising: (a) receiving the digital information as a symbol string, each symbol in the symbol string having a symbol value and a symbol position within the symbol string, the digital information including image data represented by a collection of vectors; (b) forming a first identifier nucleic acid sequence by depositing M selected component nucleic acid sequences selected from a set of distinguishable component nucleic acid sequences separated into M distinct layers into a compartment; and (c) forming a plurality of identifier nucleic acid sequences, each of the plurality of identifier nucleic acid sequences being positioned between first and second end sequences and between the first and second end sequences. and a third sequence for positioning the at least one additional identifier nucleic acid sequence at each symbol position, wherein at least one of the first end sequence, the second end sequence, and the third sequence of the at least one additional identifier nucleic acid sequence is identical to the target sequence of the first identifier nucleic acid sequence in (b), allowing a single probe to select at least two identifier nucleic acid sequences corresponding to each symbol having an associated symbol position within the symbol string; and (d) collecting the identifier nucleic acid sequences in (b) and (c) in a pool having a powder, liquid, or solid form, wherein storing image data in the nucleic acid sequences allows any nearby pixel to be queried for its color value using a random access method.
[0084]
[0130] In another aspect, the disclosure provides a method for storing digital information in a nucleic acid sequence, the method comprising: (a) receiving the digital information as a symbol string, each symbol in the symbol string having a symbol value and a symbol position within the symbol string; (b) depositing M selected component nucleic acid sequences selected from a set of distinguishable component nucleic acid sequences separated into M distinct layers into a compartment to form a first identifier nucleic acid sequence; and (c) physically assembling a plurality of identifier nucleic acid sequences, each of the plurality of identifier nucleic acid sequences comprising a first and second terminal sequence and and a third sequence located between the first and second terminal sequences, corresponding to each symbol position, wherein at least one of the first terminal sequence, the second terminal sequence, and the third sequence of the at least one additional identifier nucleic acid sequence is identical to the target sequence of the first identifier nucleic acid sequence in (b), such that a single probe can select at least two identifier nucleic acid sequences corresponding to each symbol having an associated symbol position within the symbol string; and (d) collecting the identifier nucleic acid sequences in (b) and (c) into a pool having a powder, liquid, or solid form.
[0085]
[0131] In another aspect, the disclosure provides a method for storing digital information in a nucleic acid sequence, the method comprising: (a) receiving the digital information as a symbol string, each symbol in the symbol string having a symbol value and a symbol position within the symbol string; (b) dividing the symbol string into one or more blocks of a size equal to or less than a fixed length; (c) depositing M selected component nucleic acid sequences selected from a set of M distinct component nucleic acid sequences separated into different layers into compartments to form a first nucleic acid sequence; and (d) physically assembling a plurality of identifier nucleic acid sequences, wherein the plurality of identifier nucleic acid sequences are (b) and (c) are assembled into a pool having a powder, liquid, or solid form, each of which has a first and second terminal sequence and a third sequence located between the first and second terminal sequences, corresponding to each symbol position, and at least one of the first terminal sequence, the second terminal sequence, and the third sequence of the at least one additional identifier nucleic acid sequence is identical to the target sequence of the first identifier nucleic acid sequence in (b), allowing a single probe to select at least two identifier nucleic acid sequences corresponding to each symbol having an associated symbol position within the symbol string; and (e) collecting the identifier nucleic acid sequences in (b) and (c) into a pool having a powder, liquid, or solid form.
[0086]
[0132] In another aspect, the disclosure provides a method for storing digital information in a nucleic acid sequence, the method comprising: (a) receiving the digital information as a symbol string, each symbol in the symbol string having a symbol value and a symbol position within the symbol string; (b) depositing M selected component nucleic acid sequences selected from a set of distinguishable component nucleic acid sequences separated into M distinct layers into compartments to form a first nucleic acid sequence; and (c) physically assembling a plurality of identifier nucleic acid sequences, each of the plurality of identifier nucleic acid sequences having first and second terminal sequences and a third sequence located between the first and second terminal sequences, corresponding to each symbol position, and (d) assembling the identifier nucleic acid sequences in (b) and (c) into a pool having a powder, liquid, or solid form; and (e) using the identifier nucleic acid sequences in (d) to perform calculations on the symbol string involving Boolean logic operations including AND, OR, NOT, or NAND to generate a new pool of nucleic acid molecules.
[0087]
[0133] In another aspect, the disclosure provides a method for storing digital information in a nucleic acid sequence, the method comprising: (a) receiving the digital information as a symbol string, each symbol in the symbol string having a symbol value and a symbol position within the symbol string; (b) forming a first identifier nucleic acid sequence by: (1) selecting one component nucleic acid sequence from a set of distinguishable component nucleic acid sequences separated into M distinct layers, from each of the M layers; and (2) depositing the M selected component nucleic acid sequences into compartments; and (c) physically assembling a plurality of identifier nucleic acid sequences, wherein the plurality of identifier nucleic acid sequences are (b) assembling at least two additional identifier nucleic acid sequences, each having a first and second end sequence and a third sequence located between the first and second end sequences, corresponding to each symbol position, wherein at least one of the first end sequence, the second end sequence, and the third sequence of the at least one additional identifier nucleic acid sequence is identical to the target sequence of the first identifier nucleic acid sequence in (b), such that a single probe can select at least two identifier nucleic acid sequences corresponding to each symbol having an associated symbol position within the symbol string; and (d) collecting the identifier nucleic acid sequences in (b) and (c) into a pool in the form of a powder, liquid, or solid.
[0088]
[0134] In another aspect, the disclosure provides a method for storing digital information in a nucleic acid sequence, the method comprising: (a) receiving the digital information as a symbol string, each symbol in the symbol string having a symbol value and a symbol position within the symbol string; and (b) (1) selecting one component nucleic acid sequence from each of M layers from a set of distinguishable component nucleic acid sequences separated into M distinct layers; (2) depositing the M selected component nucleic acid sequences in (2) into compartments; and (3) physically assembling the M selected component nucleic acid sequences in (2), thereby forming a first identifier nucleic acid sequence comprising designated components, the designated components corresponding to at least one target. (c) physically assembling a plurality of identifier nucleic acid sequences, each having a designated component, the designated component comprising at least one target sequence of the first identifier nucleic acid sequence in (b), allowing a probe to select at least two identifier nucleic acid sequences corresponding to each symbol having consecutive symbol positions within the symbol string; and (d) collecting the identifier nucleic acid sequences in (b) and (c) into a pool having a powder, liquid, or solid form.
[0089]
[0135] FIG. 10 shows the overall process of encoding information into a nucleic acid sequence, writing information into a nucleic acid sequence, reading the information written into a nucleic acid sequence, and decoding the read information. Digital information or data can be translated into one or more symbol strings. In one example, the symbols are bits, and each bit can have a value of either "0" or "1." Each symbol can be mapped or encoded to an object (e.g., an identifier) that represents that symbol. Each symbol can be represented by a distinct identifier. The distinct identifier can be a nucleic acid molecule composed of components. The components can be nucleic acid sequences. Digital information can be written into a nucleic acid sequence by generating an identifier library corresponding to the information. The identifier library can be physically created by physically constructing an identifier corresponding to each symbol in the digital information. All or any portion of the digital information can be accessed at a time. In one example, a subset of identifiers is accessed from the identifier library. The subset of identifiers can be read by sequencing and identifying the identifiers. To decode the digital data, the identified identifiers can be associated with corresponding symbols.
[0090]
[0136] A method for encoding and reading information using the approach of Figure 10 can include, for example, receiving a bitstream and using an identifier rank or nucleic acid index to map each bit (a bit having a bit value of "1") in the bitstream to a distinct nucleic acid identifier. Constructing a nucleic acid sample pool or identifier library that includes copies of identifiers corresponding to bit value 1 (and does not include identifiers with a bit value of 0). Reading the sample can include using molecular biology methods (e.g., sequencing, hybridization, PCR, etc.) to identify which identifiers are represented in the identifier library and assigning a bit value of "1" to the bits corresponding to those identifiers and a bit value of "0" otherwise (again, referencing the identifier rank to identify the bit in the original bitstream to which each identifier corresponds), and thus decoding the information back into the encoded bitstream.
[0091]
[0137] Encoding a string of N distinct bits allows an equal number of unique nucleic acid sequences to be used as possible identifiers. This approach to information encoding may use de novo synthesis of an identifier (e.g., a nucleic acid molecule) for each new item of information (N-bit string) to be stored. In other cases, the cost of synthesizing an identifier (a number equal to or less than N) anew for each new item of information to be stored can be reduced by one-time de novo synthesis and continued maintenance of all possible identifiers, such that encoding a new item of information may involve mechanically selecting and mixing together pre-synthesized (or pre-assembled) identifiers to form an identifier library. In other cases, both (1) the de novo synthesis of up to N identifiers for each new item of information to be stored, or (2) the cost of maintaining and selecting from N possible identifiers for each new item of information to be stored, or any combination thereof, can be reduced by synthesizing and maintaining several (fewer than N, and in some cases much fewer than N) nucleic acid sequences and then modifying these sequences through enzymatic reactions to generate up to N identifiers for each new item of information to be stored.
[0092]
[0138] Identifiers can be rationally designed and selected to facilitate read, write, access, copy, and delete operations. Identifiers can be designed and selected to minimize write errors, mutations, degradation, and read errors. See Chemical Methods Section H for rational design of DNA sequences, including synthetic nucleic acid libraries (e.g., identifier libraries).
[0093]
[0139] 11A and 11B schematically illustrate an example method, referred to as "data-at-address," for encoding digital data into objects or identifiers (e.g., nucleic acid molecules). FIG. 11A illustrates encoding a bitstream into an identifier library, where individual identifiers are constructed by concatenating or assembling a single component that specifies an identifier rank with a single component that specifies a byte value. In general, the data-at-address method uses identifiers that encode information modularly by including two objects: one object is a "byte value object" (or "data object") that identifies a byte value, and one object is a "rank object" (or "address object") that identifies the identifier rank (or the relative position of the byte in the original bitstream). FIG. 11B illustrates an example of a data-at-address method in which each rank object can be combinatorially constructed from a set of components, and each byte value object can be combinatorially constructed from a set of components. The combinatorial construction of rank and byte value objects allows more information to be written into an identifier than if the objects were made of only a single component (see, e.g., FIG. 11A).
[0094]
[0140] 12A and 12B schematically illustrate another example of a method for encoding digital information into an object or identifier (e.g., a nucleic acid sequence). FIG. 12A illustrates encoding a bit stream into an identifier library, where the identifier is constructed from a single component that specifies an identifier rank. The presence of an identifier at a particular rank (or address) specifies a bit value of "1," and the absence of an identifier at a particular rank (or address) specifies a bit value of "0." This type of encoding may use identifiers that encode only the rank (the relative position of the bit in the original bit stream) and use the presence or absence of those identifiers in the identifier library to encode a bit value of "1" or "0," respectively. Reading and decoding the information may involve identifying identifiers present in the identifier library and assigning a bit value of "1" to their corresponding rank, and a bit value of "0" otherwise. FIG. 12B illustrates an example encoding method in which each identifier may be combinatorially constructed from a set of components, with each possible combinatorial structure specifying a rank. Such a combinatorial structure allows more information to be written into an identifier than if the object were made of only a single component (see, e.g., FIG. 12A). For example, a component set may include five distinct components. The five distinct components may be assembled to generate ten distinct identifiers, each containing two of the five components. Each of the ten distinct identifiers may have a rank (or address) corresponding to the position of a bit in the bit stream. The identifier library may include a subset of the ten possible identifiers corresponding to the positions of bit values "1" and may exclude a subset of the ten possible identifiers corresponding to the positions of bit values "0" in a bit stream of length 10.
[0095]
[0141] FIG. 13 shows a contour plot in logarithmic space of the relationship between the combinatorial space of possible identifiers (C, x-axis) and the average number of identifiers (k, y-axis) physically constructed to store information of a given original size in bits (D, contour) using the encoding method shown in FIGS. 12A and 12B. This plot assumes that the original information of size D is re-encoded into a C-bit string (C can be a value greater than D), where some bits k have a bit value of "1." The plot further assumes that encoding of information into nucleic acids is performed on the re-encoded bit string, constructing identifiers for positions with a bit value of "1" and not constructing identifiers for positions with a bit value of "0." According to the assumption, the combinatorial space of possible identifiers has size C to identify every position in the re-encoded bit string, and the number of identifiers used to encode a bit string of size D is such that D=log(Cchoosek), where Cchoosek can be a mathematical expression for some method of choosing k unordered results from C possibilities. Thus, as the combinatorial space of possible identifiers grows beyond the size (in bits) of a given information item, the number of physically constructed identifiers used to store that given information may decrease.
[0096]
[0142] Figure 14 shows an overview of a method for writing information to a nucleic acid sequence. Prior to writing, the information may be translated into a symbol string and encoded into multiple identifiers. Writing information may include setting up reactions to generate possible identifiers. Reactions may be prepared by depositing inputs into compartments. Inputs may include nucleic acids, components, templates, enzymes, or chemical reagents. Compartments may be wells, tubes, locations on a surface, chambers in a microfluidic device, or droplets in an emulsion. Multiple reactions may be set up in multiple compartments. Reactions may proceed to generate identifiers through programmed temperature incubation or cycling. Reactions may be selectively or universally removed (e.g., deleted). Reactions may also be selectively or universally interrupted, combined, and purified to collect identifiers into a single pool. Identifiers from multiple identifier libraries may be collected in the same pool. Individual identifiers may include barcodes or tags to identify which identifier library they belong to. Alternatively or additionally, the barcodes may include metadata about the encoded information. Supplemental nucleic acids or identifiers can also be included in the identifier pool along with the identifier library. The supplemental nucleic acids or identifiers may contain metadata for the encoded information or may function to obscure or hide the encoded information.
[0097]
[0143] The identifier rank (e.g., nucleic acid index) can constitute a method or key for ordering identifiers. The method can include a lookup table with all identifiers and their corresponding ranks. The method can also include a lookup table with the ranks of all components that make up the identifier and a function that determines the order of any identifier containing a combination of those components. Such a method can be referred to as lexicographic ordering and can be similar to the way words are alphabetized in a dictionary. In a data-at-address encoding method, the identifier rank (encoded by the identifier's rank object) can be used to identify the location of a byte (encoded by the identifier's byte value object) in the bitstream. In an alternative method, the identifier rank of the current identifier (encoded by the entire identifier itself) can be used to identify the location of a bit value "1" in the bitstream.
[0098]
[0144] The key may assign distinct bytes to unique subsets of identifiers (e.g., nucleic acid molecules) within a sample. For example, in a simple form, the key may assign each bit in a byte to a unique nucleic acid sequence that specifies the position of that bit, and then the presence or absence of that nucleic acid sequence within the sample may specify a bit value of 1 or 0, respectively. Reading the encoded information from the nucleic acid sample may involve any number of molecular biology techniques, including sequencing, hybridization, or PCR. In some embodiments, reading the encoded dataset may include reconstructing a portion of the dataset or reconstructing the entire encoded dataset from each nucleic acid sample. If the sequence can be read, a nucleic acid index can be used along with the presence or absence of a unique nucleic acid sequence, and the nucleic acid sample can be decoded into a bitstream (e.g., multiple bits, a byte, individual strings of multiple bytes, or strings of multiple bytes).
[0099]
[0145] Identifiers can be constructed by combinatorially assembling component nucleic acid sequences. For example, information can be encoded by taking a set of nucleic acid molecules (e.g., identifiers) from a defined set of molecules (e.g., combinatorial space). Each possible identifier for a defined set of molecules can be an assembly of nucleic acid sequences (e.g., components) from a pre-assembled set of components that can be separated into layers. Each individual identifier can be constructed by linking one component from every layer in a fixed order. For example, if there are M layers, and each layer can have n components, then at most C=n M unique identifiers can be constructed, up to a maximum of 2 C It is possible to decode and store up to C different information items or bits. For example, storing 1 megabit of information requires 1×10 6 Distinguishable identifiers or size C = 1 x 10 6 The identifier in this example can be assembled from a variety of components organized in different ways. The assemblies can each have n=1×10 3 Alternatively, the assembly can be made from M=2 pre-assembled layers each containing n=1×10 components. 2 The assembly can be made from M=3 layers containing components. In some embodiments, the assembly can be made from M=2, M=3, M=4, M=5, or more layers. As this example shows, the total number of components can be reduced by using a larger number of layers to encode the same amount of information. Using a smaller total number of components can be advantageous in terms of writing costs.
[0100]
[0146] In one example, one can start with two sets or layers of unique nucleic acid sequences, X and Y, each having x and y components (e.g., nucleic acid sequences), respectively. Each nucleic acid sequence from X can be assembled into each nucleic acid sequence from Y. While the total number of nucleic acid sequences held in the two sets can be the sum of x and y, the total number of nucleic acids, and therefore possible identifiers, that can be generated can be the product of x and y. If sequences from X can be assembled into sequences of Y in any order, even more nucleic acid sequences (e.g., identifiers) can be generated. For example, the number of nucleic acid sequences (e.g., identifiers) generated can be twice the product of x and y if the order of assembly is programmable. This set of all possible nucleic acid sequences that can be generated can be referred to as XY. The order of the assembled units of the unique nucleic acid sequences in XY can be controlled using nucleic acids with distinct 5' and 3' ends, and restriction enzyme digestion, ligation, polymerase chain reaction (PCR), and sequencing can be performed on the distinct 5' and 3' ends of the sequences. Such techniques can reduce the total number of nucleic acid sequences (e.g., components) used to encode N distinguishable bits by encoding information in the combination and order of the assembly product. For example, to encode 100 bits of information, two layers of 10 distinguishable nucleic acid molecules (e.g., components) may be assembled in a fixed order to generate 10*10 or 100 distinguishable nucleic acid molecules (e.g., identifiers), or one layer of 5 distinguishable nucleic acid molecules (e.g., components) and another layer of 10 distinguishable nucleic acid molecules (components) may be assembled in any order to generate 100 distinguishable nucleic acid molecules (e.g., identifiers).
[0101]
[0147] The nucleic acid sequences (e.g., components) within each layer may contain a unique (i.e., distinguishable) sequence or barcode with an intermediate common hybridization region on one end and another common hybridization region on the other end. The barcode may contain a sufficient number of nucleotides to uniquely identify every sequence within the layer. For example, there are typically four possible nucleotides at each base position within the barcode. Thus, a three base barcode may contain four nucleotides. 3= 64 nucleic acid sequences. Barcodes can be designed to be randomly generated. Alternatively, barcodes can be designed to avoid sequences that may create complications for the identifier construction chemistry or sequencing. Additionally, barcodes can be designed so that each has a minimum Hamming distance from other barcodes, thereby reducing the likelihood that mutations or reading errors at base resolution can interfere with proper identification of the barcode. See Chemical Methods Section H for rational design of DNA sequences.
[0102]
[0148] The hybridization regions at one end of a nucleic acid sequence (e.g., a component) can be different in each layer, but the hybridization regions can be the same for each member within a layer. Adjacent layers are layers that have complementary hybridization regions on the components that allow them to interact with each other. For example, any component from layer X may have complementary hybridization regions and thus be able to attach to any component from layer Y. The hybridization region on the opposite end may serve the same purpose as the hybridization region on the first end. For example, any component from layer Y may attach to any component of layer X on one end and any component of layer Z on the opposite end.
[0103]
[0149] Figures 15A and 15B show an example method, called a "product scheme," for constructing an identifier (e.g., a nucleic acid molecule) by combinatorially assembling distinguishable components (e.g., nucleic acid sequences) from each layer in a fixed order. Figure 15A shows the architecture of an identifier constructed using the product scheme. An identifier can be constructed by combining a single component from each layer in a fixed order. For M layers, each with N components, N MThere are 27 possible identifiers. Figure 15B shows an example of a combinatorial space of identifiers that can be constructed using the product method. In one example, the combinatorial space can be generated from three layers, each containing three distinct components. The components can be combined such that one component from each layer can be combined in a fixed order. The total combinatorial space of this assembly method can include 27 possible identifiers.
[0104]
[0150] 16-19 illustrate chemical methods for implementing the product method (see FIG. 6). The methods illustrated in FIGS. 16-19, along with any other method for assembling two or more distinguishable components in a fixed order, can be used, for example, to generate any one or more identifiers in an identifier library. Identifiers may be constructed using any of the implementation methods described in FIGS. 16-19 at any time during the methods or systems disclosed herein. In some cases, all or part of the combinatorial space of possible identifiers may be constructed before digital information is encoded or written, in which case the writing process may involve mechanically selecting and pooling identifiers (that encoded the information) from a pre-existing set. In other cases, identifiers may be constructed after one or more steps of the data encoding or writing process have occurred (i.e., as the information is being written).
[0105]
[0151] Enzymatic reactions can be used to assemble components from different layers or sets. Because components (e.g., nucleic acid sequences) from each layer have specific hybridization or attachment regions to components from adjacent layers, assembly can be performed in a one-pot reaction. For example, a nucleic acid sequence (e.g., component) X1 from layer X, a nucleic acid sequence Y1 from layer Y, and a nucleic acid sequence Z1 from layer Z can form an assembled nucleic acid molecule (e.g., identifier) X1Y1Z1. Furthermore, by including multiple nucleic acid sequences from each layer, multiple nucleic acid molecules (e.g., identifiers) can be assembled in a single reaction. For example, including both Y1 and Y2 in the one-pot reaction of the previous example can produce two assembled products (e.g., identifiers) X1Y1Z1 and X1Y2Z1. This reaction multiplexing can be used to accelerate the writing time of multiple physically assembled identifiers. See Chemical Methods Section H for more information on rational design of DNA sequences as it relates to assembly efficiency. Assembly of nucleic acid sequences can be performed in a time period of about 1 day, 12 hours, 10 hours, 9 hours, 8 hours, 7 hours, 6 hours, 5 hours, 4 hours, 3 hours, 2 hours, or 1 hour or less. The accuracy of the encoded data can be about 90% or more, about 95% or more, about 96% or more, about 97% or more, about 98% or more, about 99% or more, or greater than 99%.
[0106]
[0152] Identifiers may be constructed in a product-based manner using overlap extension polymerase chain reaction (OEPCR), as shown in Figure 16. Each component in each layer may comprise a double-stranded or single-stranded (as shown in the figure) nucleic acid sequence with a common hybridization region on the sequence end that may be homologous and / or complementary to the common hybridization region on the sequence end of a component from an adjacent layer. Individual identifiers are composed of components X1 through X A One component (e.g., a unique sequence) from layer X (or layer 1), Y1 to Y A a second component (e.g., a unique sequence) from layer Y (or layer 2) containing Z1 to Z BA component from layer X may have a 3' end that shares complementarity with the 3' end of a component from layer Y. Thus, single-stranded components from layers X and Y can be annealed together at their 3' ends and extended using PCR to generate a double-stranded nucleic acid molecule. The generated double-stranded nucleic acid molecule can be melted to generate a 3' end that shares complementarity with the 3' end of the component from layer Z. The component from layer Z can anneal with the generated nucleic acid molecule and extended to generate a unique identifier comprising single components from layers X, Y, and Z in a fixed order. See Chemical Methods Section A for OEPCR. DNA size selection (e.g., using gel extraction; see Chemical Methods Section E) or polymerase chain reaction (PCR) using primers flanking the outermost layers (see Chemical Methods Section D) can be performed to separate the fully assembled identifier product from other by-products that may be formed during the reaction. Sequential nucleic acid capture with two probes (one for each of the two outermost layers) can also be performed to separate the fully assembled identifier product from other by-products that may be formed during the reaction (see Chemical Methods Section F).
[0107]
[0153] Identifiers can be assembled using sticky end ligation according to a product scheme, as shown in Figure 17. Distinguishable identifiers can be assembled using three layers, each containing a double-stranded component (e.g., double-stranded DNA (dsDNA)) with a single-stranded 3' overhang. For example, components X1-X A One component from layer X (or layer 1) containing Y1-Y B A second component from layer Y (or layer 2) containing Z1-Z C and a third component from layer Z (or layer 3) comprising: To combine a component from layer X with a component from layer Y, the component in layer X can comprise a common 3' overhang, labeled a in FIG. 17, and the component in layer Y can comprise a common complementary 3' overhang, a *To combine components from layer Y with components from layer Z, the elements of layer Y can include a common 3' overhang, designated b in Figure 17, and the elements of layer Z can include a common complementary 3' overhang, b * The 3' overhang of the Layer X component can be complementary to the 3' end of the Layer Y component, and the other 3' overhang of the Layer Y component can be complementary to the 3' end of the Layer Z component, allowing hybridization and ligation of these components. Thus, a component from Layer X cannot hybridize to other components from Layer X or Layer Z, and similarly, a component from Layer Y cannot hybridize to other elements from Layer Y. Furthermore, a single component from Layer Y can be ligated to a single component from Layer X and a single component from Layer Z, ensuring the formation of a complete identifier. See Chemical Methods Section B for sticky end ligation. DNA size selection (e.g., using gel extraction; see Chemical Methods Section E) or polymerase chain reaction (PCR) using primers flanking the outermost layers (see Chemical Methods Section D) can be performed to separate the identifier product from other by-products that may be formed during the reaction. Sequential nucleic acid capture with two probes (one for each of the two outermost layers) can also be performed to separate the identifier product from other by-products that may be formed during the reaction (see Chemical Methods Section F).
[0108]
[0154] Sticky ends for sticky-end ligation can be generated by treating each layer's components with a restriction endonuclease (see Chemical Methods section C for more information on restriction enzyme reactions). In some embodiments, multiple layer components can be generated from one "parent" set of components. For example, in embodiments, a single parent set of double-stranded components can have complementary restriction sites at each end (e.g., BamHI and BglII restriction sites). Any two components can be selected for assembly and individually digested with one or the other complementary restriction enzyme (e.g., BglII or BamHI), resulting in complementary sticky ends that can be ligated to each other, resulting in an inert scar. The product nucleic acid sequence can also contain complementary restriction sites at each end (e.g., BamHI at the 5' end and BglII at the 3' end), and such nucleic acid sequences can be ligated to another component from the parent set following the same process. This process can be cyclical indefinitely (Figure 20). If the parent contains N components, then each cycle may correspond to adding an additional layer of N components to the product scheme.
[0109]
[0155] A method of using ligation to construct a sequence of nucleic acids comprising elements from Set X (e.g., dsDNA Set 1) and elements from Set Y (e.g., dsDNA Set 2) involves obtaining or constructing two or more pools of double-stranded sequences (e.g., dsDNA Set 1 and dsDNA Set 2), where the first set (e.g., dsDNA Set 1) contains a sticky end (e.g., a) and the second set (e.g., dsDNA Set 2) contains a sticky end (e.g., a) that is complementary to the sticky end of the first set. * Any DNA from the first set (e.g., dsDNA Set 1) and any subset of DNA from the second set (e.g., dsDNA Set 2) can be combined, assembled, and then ligated together to form a single double-stranded DNA having elements from the first set and elements from the second set.
[0110]
[0156] Identifiers can be assembled in a product-wise manner using site-specific recombination, as shown in Figure 18. Identifiers can be constructed by assembling components from three different layers. Layer X (or layer 1) components have attB on one side of the molecule. x The component from layer Y (or layer 2) can contain a double-stranded molecule with a recombinase site on one side and an attP x recombinase site and attB on the other side y Layer Z (or layer 3) components can comprise a double-stranded molecule with a recombinase site, and the components of layer Z (or layer 3) can comprise an attP yEach pair can contain a recombinase site. The attB and attP sites within a pair are capable of recombination in the presence of their corresponding recombinase enzyme, as indicated by their subscripts. One component from each layer can be combined so that one component from layer X associates with one component from layer Y, and one component from layer Y associates with one component from layer Z. Application of one or more recombinase enzymes can recombine the components to generate a double-stranded identifier containing the ordered components. DNA size selection (e.g., using gel extraction) or PCR using primers flanking the outermost layer can be performed to separate the identifier product from other by-products that may be formed during the reaction. Generally, multiple orthogonal pairs of attB and attP can be used, and each pair can be used to assemble components from additional layers. For large serine recombinase families, up to six orthogonal pairs of attB and attP can be generated per recombinase, and multiple orthogonal recombinases can be implemented as well. For example, 13 layers can be assembled by using 12 orthogonal pairs of attB and attP, six from each of two large serine recombinases, such as BxbI and PhiC31. The orthogonality of the attB and attP pairs ensures that the attB site from one pair does not react with the attP site from another pair. This allows components from different layers to assemble in a fixed order. Recombinase-mediated recombination reactions can be reversible or irreversible, depending on the recombinase system being implemented. For example, the large serine recombinase family catalyzes irreversible recombination reactions without the need for any high-energy cofactors, whereas the tyrosine recombinase family catalyzes reversible reactions.
[0111]
[0157] Identifiers can be constructed in a multi-layer fashion using template-directed ligation (TDL), as shown in Figure 19A. Template-directed ligation utilizes single-stranded nucleic acid sequences, called "templates" or "staples," to facilitate the ordered ligation of components to form the identifier. The templates simultaneously hybridize to components from adjacent layers, holding them adjacent to each other (3' ends relative to 5' ends) while a ligase ligates them. In the example from Figure 19A, three layers or sets of single-stranded components are combined. Sequence a * a first layer (e.g., Layer X or Layer 1) of components sharing a common sequence a at their 3' ends that is complementary to sequence b * and c * a second layer (e.g., Layer Y or Layer 2) of components sharing common sequences b and c at their 5' and 3' ends, respectively, which are complementary to sequence d * a third layer (e.g., layer Z or layer 3) of components sharing a common sequence d at their 5' ends, which may be complementary to the sequence a; and a set of two templates, or a first staple, * b * (5'→3'), and the second staple contains the sequence c * d * A set of two "staples" containing (5'→3') nucleotides. In this example, one or more components from each layer can be selected and mixed into a reaction with staples, which can facilitate ligation of one component from each layer in a defined order to form the identifier by complementary annealing. See Chemical Methods Section B for TDL. DNA size selection (e.g., using gel extraction; see Chemical Methods Section E) or polymerase chain reaction (PCR) using primers flanking the outermost layer (see Chemical Methods Section D) can be performed to separate the identifier product from other by-products that may be formed during the reaction. Sequential nucleic acid capture with two probes (one for each of the two outermost layers) can also be performed to separate the identifier product from other by-products that may be formed during the reaction (see Chemical Methods Section F).
[0112]
[0158] Figure 19B shows a histogram of copy number (abundance) for the 256 distinct nucleic acid sequences assembled in each six-layer TDL. Each edge layer (the first and last layers) contained one component, and each of the inner layers (the remaining four layers) contained four components. Each edge layer component was 28 bases long, including a 10-base hybridization region. Each inner layer component was 30 bases long, including a 10-base common hybridization region at the 5' end, a 10-base variable (barcode) region, and a 10-base common hybridization region at the 3' end. Each of the three template strands was 20 bases long. All 256 distinct sequences were assembled in a multiplexed manner, with one reaction containing all the components and templates, T4 polynucleotide kinase (to phosphorylate the components), T4 ligase, ATP, and other appropriate reaction reagents. The reactions were incubated at 37°C for 30 minutes, then at room temperature for 1 hour. Sequencing adapters were added to the reaction products by PCR, and the products were sequenced on an Illumina MiSeq instrument. The relative copy numbers for each distinct assembled sequence are shown, out of a total of 192,910 assembled sequence reads. Other embodiments of this method may use double-stranded components, where these components are first melted to form single-stranded versions that can be annealed to staples. Other embodiments or variants of this method (i.e., TDL) can be used to construct a combinatorial space of identifiers that is more complex than can be achieved with the product method.
[0113]
[0159] A variety of other chemical implementations can be used to construct identifiers according to a product scheme, including Golden Gate assembly, Gibson assembly, and ligase cycling reaction assembly.
[0114]
[0160] 20A and 20B show schematic diagrams of an example of a method, termed a "permutation scheme," for permuting components (e.g., nucleic acid sequences) to construct identifiers (e.g., nucleic acid molecules). FIG. 20A shows the architecture of an identifier constructed using the permutation scheme. Identifiers can be constructed by combining single components from each layer in a programmable order. FIG. 20B shows an example of a combinatorial space of identifiers that can be constructed using the permutation scheme. In one example, three layers, each containing one distinguishable component, can generate a combinatorial space of size 6. Components can be concatenated in any order. In general, with M layers, each with N components, the permutation scheme can generate a total of N M This allows for a combinatorial space of M! identifiers.
[0115]
[0161] Figure 20C shows an example of an embodiment of a permutation scheme using template-directed ligation (TDL, see Chemical Methods section B). Components from multiple layers are assembled between a fixed left-end component and a fixed right-end component, called edge scaffolds. These edge scaffolds are the same for all identifiers in the combinatorial space, and therefore these edge scaffolds can be added as part of the reaction master mix for implementation. Templates or staples are present at any possible junction between any two layers or scaffolds, such that the order in which components from different layers are incorporated into the identifier during the reaction depends on the template selected for the reaction. To allow for any possible permutation of the layers for M layers, M junctions are created for each possible junction (including junctions with scaffolds). 2There can be +2M distinct selectable staples. M of these templates (shaded gray) form junctions between the layers and themselves and may not be included for sorting assembly as described here. However, their inclusion can enable a larger combinatorial space using identifiers containing repetitive components, as shown in Figures 20D-G. DNA size selection (e.g., using gel extraction; see Chemical Methods section E) or polymerase chain reaction (PCR) using primers flanking the outermost layer (see Chemical Methods section D) can be performed to separate the identifier product from other by-products that may be formed during the reaction. Sequential nucleic acid capture with two probes, one for each of the two outermost layers, can also be performed to separate the identifier product from other by-products that may be formed during the reaction (see Chemical Methods section F).
[0116]
[0162] Figures 20D-G show an example of how the permutation scheme can be extended to include the specific case of identifiers with repeating components. Figure 20D shows an example of a method of the embodiment from Figure 20C that can be used to construct identifiers with permuted and repeating components. For example, an identifier may include a total of three components assembled from two distinguishable components. In this example, a component from a layer may be present multiple times in the identifier. Adjacent linkages of the same component may be represented by staples with adjacent complementary hybridization regions, e.g., a in the figure. * b *This can be achieved by using a (5'→3') staple at both the 3' and 5' ends of the same component. Generally, for M layers, there are M such staples. The incorporation of repeating components in this embodiment can generate nucleic acid sequences of more than one length (i.e., containing 1, 2, 3, 4, or more components) assembled between edge scaffolds, as shown in Figure 20E. Figure 20E shows how the example embodiment from Figure 20D can result in non-targeting nucleic acid sequences assembled between edge scaffolds in addition to the identifier. The appropriate identifier cannot be separated from the non-targeting nucleic acid sequences by PCR because they share the same primer binding sites at the edges. However, in this example, because each assembled nucleic acid sequence can be designed to have a unique length (e.g., if all components have the same length), DNA size selection (e.g., using gel extraction) can be performed to separate the targeted identifier (e.g., the second sequence from the top) from the non-targeting sequences. See Chemical Methods section E for size selection. Figure 20F shows another example in which construction of identifiers with repeating components can generate multiple nucleic acid sequences with distinct lengths but equal end sequences in the same reaction. This method can use templates that assemble components in one layer with components in another layer in an alternating pattern. Similar to the method shown in Figure 20E, size selection can be used to select identifiers of a designed length. Figure 20G shows an example in which construction of identifiers with repeating components can generate multiple nucleic acid sequences with equal end sequences and, for some nucleic acid sequences (e.g., the third and fourth, and the sixth and seventh, from the top), equal lengths. In this example, nucleic acid sequences that share equal lengths can be excluded from both individual identifiers, such that even when PCR and DNA size exclusion are performed, one cannot be constructed and the other cannot be constructed.
[0117]
[0163] 21A-21D schematically illustrate an example of a method, referred to as the "MchooseK method," for constructing an identifier (e.g., a nucleic acid molecule) having any number of assembled components (e.g., nucleic acid sequences) K out of a larger number of M possible components. FIG. 21A illustrates the architecture of an identifier constructed using the MchooseK method. Using this method, an identifier is constructed by assembling one component from each layer in any subset of all layers (e.g., selecting components from k layers out of M possible layers). FIG. 21B illustrates an example of the combinatorial space of an identifier that can be constructed using the MchooseK method. In this assembly method, the combinatorial space is N for M layers, N components per layer, and an identifier length of K components. K In one example, if there are five layers, each containing one component, then up to ten distinct identifiers can be assembled, each containing two components.
[0118]
[0164] The MchooseK method can be implemented using template-directed ligation (see Chemical Methods section B), as shown in Figure 21C. Similar to the TDL embodiment for the permutation method (Figure 20C), components in this example are assembled between edge scaffolds that may or may not be included in the reaction master mix. Components can be divided into M layers, e.g., where the left edge scaffold can be rank 1 and the right edge scaffold can be rank M+1, with M=4 layers having predefined ranks from 2 to M. The template contains the nucleic acid sequences for 3'→5' ligation of any two components having lower to higher ranks, respectively. ((M+1) 2There are (M+1) / 2 such templates. Individual identifiers for any K components from the distinguishable layers can be constructed by combining those selected components in a ligation reaction in which corresponding K+1 staples are used to join the edge scaffold and the K components in their rank order. Such a reaction setup can yield nucleic acid sequences corresponding to target identifiers between edge scaffolds. Alternatively, a reaction mix containing all templates can be combined with selected components to assemble target identifiers. This alternative method can generate a variety of nucleic acid sequences of distinguishable lengths but with the same end sequences (if all component lengths are equal), as shown in Figure 21D. Target identifiers (bottom) can be separated by size from by-product nucleic acid sequences. See Chemical Methods section E for nucleic acid size selection.
[0119]
[0165] Figures 22A and 22B schematically illustrate an example of a method, referred to as a "compartmentalization scheme," for constructing identifiers with compartmentalized components. Figure 22A shows an example of a combinatorial space of identifiers that can be constructed using the compartmentalization scheme. Individual identifiers can be constructed by assembling one component from each layer in a fixed order, with any compartment (spatial classification component) placed between any two components in different layers as needed. For example, a set of components can be organized into one compartment component and four layers, each containing one component. Components from each layer can be combined in a fixed order, and single compartment components can be assembled at various locations between layers. Identifiers in this combinatorial space can include no compartment component, a compartment between a component from the first layer and a component from the second layer, a compartment between a component from the second layer and a component from the third layer, and so on, to create a combinatorial space of eight possible identifiers. In general, with M layers, each with N components, and p compartment components, N can be constructed. K (p+1) M-1 possible identifiers can be constructed. This method can generate identifiers of various lengths.
[0120]
[0166] Figure 22B shows an example of an embodiment of a compartmentalization scheme using template-guided ligation (see Chemical Methods Section B). The template contains a nucleic acid sequence for ligating one component from each of the M layers to each other in a fixed order. For each compartment component, there is an additional pair of templates, which allow for ligation of the compartment component between components from any two adjacent layers. For example, one template of the pair (e.g., sequence g * b * (5'→3')) to allow the 3' end of layer 1 (having sequence b) to ligate to the 5' end of the compartment component (having sequence g), and the other template of the pair (e.g., sequence c * h * A template pair (having sequence h (5'→3')) allows the 3' end of a compartment component (having sequence h) to ligate to the 5' end of layer 2 (having sequence c). To insert a compartment between any two components of adjacent layers, the reaction need not include a standard template for ligating these layers together, but a template pair for ligating the compartment at that position can be selected in the reaction. In the current example, targeting of a compartment component between layer 1 and layer 2 is achieved using template c. * b * (5'→3') but template c * h * (5'→3') and template g * b * (5'→3') pairs can be used for selection for the reaction. Components can be assembled between edge scaffolds that can be included in the reaction mix (with their corresponding templates for ligation to the first and Mth layers, respectively). In general, for M layers and p compartment components, there will be a total of about M-1+2 * p *(M-1) selectable templates can be used in this method. This embodiment of the compartmentalization scheme allows reactions to generate a variety of nucleic acid sequences of distinct lengths but with the same end sequences. Target identifiers can be separated from by-product nucleic acid sequences by DNA size selection. Specifically, exactly one nucleic acid sequence product can have exactly M layer components. If the layer components are designed to be large enough compared to the compartment components, it may be possible to define a universal size selection region where identifiers can be selected (and none of the non-target by-products will be selected) regardless of the specific compartmentalization of components within the identifier, thereby allowing multiple compartmentalized identifiers from multiple reactions to be separated in the same size selection step. See Chemical Methods Section E for nucleic acid size selection.
[0121]
[0167] 23A and 23B schematically illustrate an example of a method, referred to as the "unconstrained sequence scheme" or "USS," for constructing identifiers made up of any sequence of components from several possible components. FIG. 23A illustrates an example of the combinatorial space of three-component (or four-scaffold) long identifiers that can be constructed using the unconstrained sequence scheme. The unconstrained sequence scheme constructs individual identifiers of length K components with one or more distinguishable components each taken from one or more layers, where each distinguishable component can appear in any of the K component positions in the identifier (this allows for repetition). For example, for two layers each containing one component, there are eight possible three-component long identifiers. In general, for M layers each having one component, there are M possible identifiers for components of length K. KFigure 23B shows an example of an embodiment of the unconstrained array method using template-directed ligation (see Chemical Methods section B). In this method, K+1 single-stranded, ordered scaffold DNA components (including two edge scaffolds and K-1 internal scaffolds) are present in the reaction mix. An individual identifier comprises a single component ligated between every pair of adjacent scaffolds. For example, a component ligated between scaffold A and scaffold B, a component ligated between scaffold C and scaffold D, etc. (until all K adjacent scaffold junctions are occupied by components). In the reaction, selected components from different layers are introduced to the scaffolds along with selected pairs of staples that direct them to assemble onto the appropriate scaffold. For example, staple a * L * (5'→3') and Staple A * b * The (5'→3') pair directs the ligation of layer 1 components with 5'-terminal region "a" and 3'-terminal region "b" between the L and A scaffolds. Generally, with M layers and K+1 scaffolds, 2 * M *Any USS identifier of length K can be constructed using K selectable staples. Because the staples connecting a moiety to a scaffold at its 5' end and the staples connecting the same moiety to a scaffold at its 3' end are separate, nucleic acid by-products can be formed by reacting a target identifier with an equal edge scaffold, but with fewer than K moieties (fewer than K+1 scaffolds), or with more than K moieties (more than K+1 scaffolds). Targeted identifiers can be formed using exactly K moieties (K+1 scaffolds) and therefore may be selectable by techniques such as DNA size selection if all moieties are designed to be equal length and all scaffolds are designed to be equal length. See Chemical Methods Section E for nucleic acid size selection. In certain embodiments for the unconstrained array format, where there may be one component per layer, that component may comprise exclusively a single distinct nucleic acid sequence that fulfills all three roles: (1) an identification barcode, (2) a hybridization region for staple-mediated ligation of the 5' end to the scaffold, and (3) a hybridization region for staple-mediated ligation of the 3' end to the scaffold.
[0122]
[0168] The internal scaffolds shown in Figure 23B can be designed so that they use the same hybridization sequence for both staple-mediated 5' ligation of the scaffold to one component and staple-mediated 3' ligation of the scaffold to another (not necessarily distinguishable) component. Thus, the one-scaffold, two-staple stacked hybridization event depicted in Figure 23B occurs between the scaffold and each of the staples, thus representing a statistical back-and-force hybridization event that allows both 5' and 3' component ligation. In other embodiments of the unconstrained array approach, scaffolds can be designed with two linked hybridization regions—a distinguishable 3' hybridization region for staple-mediated 3' ligation and a distinguishable 5' hybridization region for staple-mediated 5' ligation.
[0123]
[0169] Figures 24A and 24B schematically illustrate an example of a method, termed the "component elimination scheme," for constructing identifiers by deleting nucleic acid sequences (or components) from parent identifiers. Figure 24A shows an example of a combinatorial space of possible identifiers that can be constructed using the component elimination scheme. In this example, the parent identifier can include multiple components. The parent identifier can include a number of components greater than or equal to about 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, or more. Individual identifiers can be constructed by selectively deleting any number of components from the N possible components to create identifiers of size 2. N or by removing a fixed number K components from the N possible components, thus resulting in an "NchooseK" combination space of size NchooseK. In an example using a parent identifier with 3 components, the complete combination space might be 8 and the 3choose2 combination space might be 3.
[0124]
[0170] Figure 24B shows an example of an embodiment of a component deletion scheme using double-strand targeted cleavage and repair (DSTCR). A parent sequence can be a single-stranded DNA substrate containing a component flanked by nuclease-specific target sites (which can be four bases in length or fewer), in which case the parent can be incubated with one or more double-strand-specific nucleases corresponding to the target sites. Individual components can be targeted for deletion with complementary single-stranded DNA (or cleavage template) that binds to the parent component DNA (and the flanking nuclease sites), resulting in the formation of a stable double-stranded sequence on the parent that can be cleaved at both ends by the nuclease. Another single-stranded DNA (or repair template) hybridizes with the resulting separated ends of the parent (between which the component sequence was located) and brings them together for ligation, either directly or bridged by a replacement sequence such that the ligated parent sequence no longer contains the active site targeted by the nuclease. We refer to this method as "double-stranded targeted cleavage" (DSTC). Size selection can be used to select identifiers with a specific number of components deleted. See Chemical Methods Section E for nucleic acid size selection.
[0125]
[0171] Alternatively or additionally, the parent identifier can be a double-stranded or single-stranded nucleic acid substrate containing components separated by a spacer sequence so that no two components are adjacent to the same sequence. The parent identifier can be incubated with Cas9 nuclease. Individual components can be targeted for deletion with a guide ribonucleic acid (cleavage template) that binds to the edge of the component and enables Cas9-mediated cleavage at its adjacent site. A single-stranded nucleic acid (repair template) can hybridize to the resulting separated ends of the parent identifier (e.g., where the component sequence was located between these ends), thus bringing them together for ligation. Ligation can be performed directly or by bridging the ends with a replacement sequence so that the parent ligated sequence no longer contains a spacer sequence that can be targeted by Cas9. We refer to this method as "sequence-specific targeted cleavage and repair" or "SSTCR."
[0126]
[0172] Identifiers can be constructed by inserting components into a parent identifier using a derivative of a DSTCR. The parent identifier can be a single-stranded nucleic acid substrate containing nuclease-specific target sites (which can be four or fewer bases in length) each embedded within a distinct nucleic acid sequence. The parent identifier can be incubated with one or more double-stranded-specific nucleases corresponding to the target sites. Each target site of the parent identifier can be targeted for component insertion with a complementary single-stranded nucleic acid (cleavage template) that binds to the target site of the parent identifier and the distinct surrounding nucleic acid sequence, resulting in the formation of a double-stranded site. The double-stranded site can also be cleaved by a nuclease. Another single-stranded nucleic acid (repair template) hybridizes to the resulting separated ends of the parent identifier and bridges them together for ligation, such that the ligated parent sequence no longer contains the active site targeted by the nuclease. Alternatively, a derivative of an SSTCR can be used to insert components into the parent identifier. The parent identifier can be a double-stranded or single-stranded nucleic acid, and the parent can be incubated with Cas9 nuclease. Distinguishable sites on the parent identifier can be targeted for cleavage with a guide RNA (cleavage template). Single-stranded nucleic acids (repair templates) hybridize to the separate ends of the parent identifier, bridging them together for ligation by the component sequences, such that the ligated sequence of the parent identifier no longer contains the active site targeted by the nuclease. Size selection can be used to select identifiers with a specific number of components inserted.
[0127]
[0173] Figure 25 shows a schematic representation of a parent identifier with recombinase recognition sites. Different patterns of recognition sites can be recognized by different recombinases. All recognition sites for a given set of recombinases are arranged so that the nucleic acid between them can be excised when the recombinase is applied. The nucleic acid strand shown in Figure 25 can be split into two strands depending on the subset of recombinases applied to it. 5A total of N recombinases can be used to excise, shift, invert, and transpose segments of DNA to generate unique molecules, creating different nucleic acid molecules, as depicted in Figure 25. Generally, N recombinases can be used to generate 2 N possible identifiers can be constructed from the parents. In some embodiments, multiple orthogonal pairs of recognition sites from different recombinases can be arranged on the parent identifier in an overlapping manner, such that application of one recombinase influences the type of recombination event that occurs when a downstream recombinase is applied (see Roquet et al., Synthetic recombinase-based state machines in living cells, Science 353(6297):aad8559(2016), incorporated herein by reference in its entirety). Such a system may be capable of ordering N recombinases, constructing different identifiers for each N!. The recombinases may be tyrosine family recombinases, e.g., Flp and Cre, or may be recombinases of the large serine recombinase family, e.g., PhiC31, BxbI, TP901, or A118. The use of recombinases from the large serine recombinase family can be advantageous because they facilitate irreversible recombination and therefore can generate identifiers more efficiently than other recombinases.
[0128]
[0174] In some instances, a single nucleic acid sequence can be programmed to become many distinct nucleic acid sequences by applying multiple recombinases in distinct orders. Where the number of recombinases, M, can be less than 7 or can be 7 for the large serine recombinase family, applying M recombinases in different subsets in different orders can result in approximately e 1 M! distinct nucleic acid sequences can be generated. If M, the number of recombinases, can exceed 7, the number of sequences that can be generated is 3.9 MSee, for example, Roquet et al., Synthetic recombinase-based state machines in living cells, Science 353(6297):aad8559(2016), which is incorporated herein by reference in its entirety. Additional methods for generating different DNA sequences from a single consensus sequence can include targeted nucleic acid editing enzymes, such as CRISPR-Cas, TALEN, and zinc finger nucleases. Sequences generated by recombinases, targeted editing enzymes, and the like, can be used in conjunction with previous methods, such as any of the methods disclosed in any of the figures and disclosures of the present application.
[0129]
[0175] If the bitstream of information to be encoded is larger than can be encoded by any single nucleic acid molecule, the information can be divided and indexed with nucleic acid sequence barcodes. Furthermore, any subset of nucleic acid molecules of size k from a set of N nucleic acid molecules can be selected to generate log2(Nchoosek) bits of information. Barcodes can be assembled onto nucleic acid molecules in the subset of size k to encode even longer bitstreams. For example, M barcodes can be used to encode M * Log2(Nchoosek) bits of information can be generated. Given the number N of available nucleic acid molecules in a set and the number M of available barcodes, a subset of size k=k0 can be selected to minimize the total number of molecules in the pool for encoding a piece of information. A method for encoding digital information can include splitting a bitstream and encoding individual elements. For example, a bitstream containing six bits can be split into three components, each containing two bits. Each two-bit component can be barcoded to form an information cassette, which can then be grouped or pooled together to form a hyperpool of information cassettes.
[0130]
[0176] Barcodes can facilitate information indexing when the amount of digital information to be encoded exceeds the amount that can fit into a single pool. For example, by layering the approach disclosed in FIG. 12 by including tags with unique nucleic acid sequences encoded using nucleic acid indexes, longer bit strings and / or information containing multiple bytes can be encoded. An information cassette or identifier library can include nitrogenous bases or nucleic acid sequences containing unique nucleic acid sequences that provide position and bit value information, in addition to barcodes or tags that indicate the component of the bit stream to which a given sequence corresponds. An information cassette can include one or more unique nucleic acid sequences and barcodes or tags. The barcodes or tags on the information cassette can provide a reference to the information cassette and any sequences contained in the information cassette. For example, the tags or barcodes on the information cassette can indicate which portion of the bit stream or which bit component of the bit stream the unique sequence encodes information (e.g., bit value and bit position information).
[0131]
[0177] Barcodes can be used to encode information in bits into pools that exceed the size of the combinatorial space of possible identifiers. For example, a 10-bit sequence can be divided into two sets of bytes, each containing five bits. Each byte can be mapped to a set of five possible distinguishable identifiers. Initially, the identifiers generated for each byte may be the same, but they can be kept in separate pools; otherwise, a reader of the information may not be able to tell which byte a particular nucleic acid sequence belongs to. However, by barcoding or tagging each identifier with a label corresponding to the byte to which the encoded information applies (e.g., barcode 1 can be attached to a sequence in the nucleic acid pool to provide the first five bits, and barcode 2 can be attached to a sequence in the nucleic acid pool to provide the second five bits), the identifiers corresponding to those two bytes can then be combined into a pool (e.g., a "hyperpool" or one or more identifier libraries). Each identifier library of one or more combined identifier libraries can contain a distinguishable barcode that identifies a given identifier as belonging to the given identifier library. Methods for attaching a barcode to each identifier in the identifier library can include using PCR, Gibson, ligation, or any other technique that allows a given barcode (e.g., barcode 1) to be attached to a given nucleic acid sample pool (e.g., barcode 1 to nucleic acid sample pool 1 and barcode 2 to nucleic acid sample pool 2). Sequencing methods can be used to read samples from the hyperpools, and the barcodes or tags can be used to parse the sequencing information. Methods that use identifier libraries and barcodes with a set of M barcodes and N possible identifiers (combinatorial space) can encode a bitstream having a length corresponding to the product of M and N.
[0132]
[0178] In some embodiments, the identifier libraries can be stored in an array of wells. The array of wells can be defined as having n columns and q rows, with each well containing two or more identifier libraries in a hyperpool. The encoded information in each well can constitute one large contiguous item of information, n x q in size, larger than the information contained in each well. Aliquots can be taken from one or more wells in the array of wells, and the encoding can be read using sequencing, hybridization, or PCR.
[0133]
[0179] A nucleic acid sample pool, hyperpool, identifier library, group of identifier libraries, or well containing a nucleic acid sample pool or hyperpool may contain unique nucleic acid molecules corresponding to bits of information (e.g., identifiers) and multiple complementary nucleic acid sequences. The complementary nucleic acid sequences may not correspond to encoded data (e.g., not correspond to bit values). A complementary nucleic acid sample can mask or conceal the information stored in the sample pool. The complementary nucleic acid sequences may be derived from a biological source or synthetically generated. Complementary nucleic acid sequences derived from a biological source may include randomly fragmented nucleic acid sequences or rationally fragmented sequences. Biologically derived complementary nucleic acids can hide or obscure data-containing nucleic acids in a sample pool by providing natural genetic information along with synthetically encoded information, particularly when the synthetically encoded information (e.g., the combinatorial space of the identifiers) is created to resemble natural genetic information (e.g., a fragmented genome). In one example, the identifiers are derived from a biological source and the complementary nucleic acids are derived from a biological source. A sample pool may contain multiple sets of identifiers and complementary nucleic acid sequences. Each set of identifiers and complementary nucleic acid sequences may be derived from different organisms. In one example, the identifiers are derived from one or more organisms and the complementary nucleic acid sequences are derived from a single, different organism. The complementary nucleic acid sequences may be derived from one or more organisms, and the identifiers may be derived from a single organism that is different from the organism from which the complementary nucleic acids are derived. Both the identifiers and complementary nucleic acid sequences may be derived from multiple different organisms. A key may be used to distinguish between the identifiers and complementary nucleic acid sequences.
[0134]
[0180] The supplemental nucleic acid sequence can store metadata about the written information. The metadata may include additional information for determining and / or authorizing the primary source and / or intended recipient of the primary information. The metadata may include additional information about the format of the primary information, the device and method used to encode and write the primary information, and the date and time the primary information was written to the identifier. The metadata may include additional information about the format of the primary information, the device and method used to encode and write the primary information, and the date and time the primary information was written to the nucleic acid sequence. The metadata may include additional information about modifications made to the primary information after the information was written to the nucleic acid sequence. The metadata may include annotations to the primary information or one or more references to external information. Alternatively or additionally, the metadata may be stored in one or more barcodes or tags associated with the identifier.
[0135]
[0181] The identifiers in the identifier pool can have the same, similar, or different lengths from one another. The complementary nucleic acid sequences can have a length that is less than the length of the identifiers, a length that is substantially equal to the length of the identifiers, or a length that is longer than the length of the identifiers. The complementary nucleic acid sequences can have an average length that is within 1 base, 2 bases, 3 bases, 4 bases, 5 bases, 6 bases, 7 bases, 8 bases, 9 bases, 10 bases, or more of the average length of the identifiers. In one example, the complementary nucleic acid sequences are the same or substantially the same length as the identifiers. The concentration of the complementary nucleic acid sequences can be less than, substantially equal to, or higher than the concentration of the identifiers in the identifier library. The concentration of the complementary nucleic acid can be about 1%, 10%, 20%, 40%, 60%, 80%, 100%, 125%, 150%, 175%, 200%, 1000%, 1×10 of the concentration of the identifiers. 4 %, 1×10 5 %, 1×10 6 %, 1×10 7 %, 1×10 8% or less, or about 1%, 10%, 20%, 40%, 60%, 80%, 100%, 125%, 150%, 175%, 200%, 1000%, 1×10 concentration of the identifier. 4 %, 1×10 5 %, 1×10 6 %, 1×10 7 %, 1×10 8 The concentration of the complementary nucleic acid may be equal to or less than about 1%, 10%, 20%, 40%, 60%, 80%, 100% of the concentration of the identifier. , 125%, 150%, 175%, 200%, 1000%, 1×10 4 %, 1×10 5 %, 1×10 6 %, 1×10 7 %, 1×10 8 %, or more than about 1%, 10%, 20%, 40%, 60%, 80%, 100%, 125%, 150%, 175%, 200%, 1000%, 1×10 concentration of the identifier. 4 %, 1×10 5 %, 1×10 6 %, 1×10 7 %, 1×10 8 % or more. Higher concentrations may be beneficial for obfuscation or data hiding. In one example, the concentration of the capture nucleic acid sequences is substantially higher than the concentration of the identifiers in the identifier pool (e.g., 1 x 10 8 %expensive).
[0136] Methods for copying data stored in nucleic acid sequences and accessing such data
[0182] In another aspect, the present disclosure provides a method for copying information encoded in a nucleic acid sequence. The method for copying information encoded in a nucleic acid sequence may include (a) providing an identifier library and (b) constructing one or more copies of the identifier library. The identifier library may include a subset of a plurality of identifiers from a larger combinatorial space. Each individual identifier in the plurality of identifiers may correspond to an individual symbol in a symbol string. The identifier may include one or more components. The components may include a nucleic acid sequence.
[0137]
[0183] In another aspect, the present disclosure provides a method for accessing information encoded in a nucleic acid sequence. The method for accessing information encoded in a nucleic acid sequence may include (a) providing an identifier library and (b) extracting from the identifier library a portion or subset of identifiers present in the identifier library. The identifier library may include a subset of a plurality of identifiers from a larger combinatorial space. Each individual identifier of the plurality of identifiers may correspond to an individual symbol in a symbol string. The identifier may include one or more components. The components may include a nucleic acid sequence.
[0138]
[0184] Information can be written to one or more identifier libraries as described elsewhere herein. Identifiers can be constructed using any of the methods described elsewhere herein. Stored data can be copied by generating copies of individual identifiers in the identifier library or in one or more identifier libraries. Portions of identifiers may be copied, or the entire library may be copied. Copying can be accomplished by amplifying identifiers in the identifier library. When one or more identifier libraries are combined, a single identifier library may be copied, or multiple identifier libraries may be copied. If an identifier library includes a supplemental nucleic acid sequence, the supplemental nucleic acid sequence may or may not be copied.
[0139]
[0185] Identifiers in an identifier library may be constructed to include one or more common primer binding sites. The one or more binding sites may be located on the edge of each identifier or may be interwoven throughout each identifier. The primer binding sites may allow an identifier library-specific primer pair or a universal primer pair to bind to the identifier and amplify the identifier. All identifiers in an identifier library or all identifiers in one or more identifier libraries may be replicated multiple times using multiple PCR cycles. Identifiers may be copied using conventional PCR, and the identifiers may be replicated exponentially with each PCR cycle. The number of identifier copies may increase exponentially with each PCR cycle. Identifiers may be copied using linear PCR, and the identifiers may be replicated linearly with each PCR cycle. The number of identifier copies may increase linearly with each PCR cycle. Identifiers may be ligated into a circular vector prior to PCR amplification. The circular vector may include a barcode at each end of the identifier insertion site. PCR primers for amplifying the identifier can be designed to prime from the vector, so that the barcoded edges are included in the amplification product along with the identifier. During amplification, recombination between identifiers can result in copied identifiers containing uncorrelated barcodes on each edge. Uncorrelated barcodes can be detectable when reading the identifier. Identifiers containing uncorrelated barcodes can be considered false positives and can be ignored during the information decoding process. See Chemical Methods Section D.
[0140]
[0186] Information can be encoded by assigning each bit of information to a unique nucleic acid molecule. For example, three sample sets (X, Y, and Z), each with two nucleic acid sequences, can be assembled into eight unique nucleic acid molecules to encode the following eight data bits: N1=X1Y1Z1 N2=X1Y1Z2 N3=X1Y2Z1 N4=X1Y2Z2 N5=X2Y1Z1 N6=X2Y1Z2 N7=X2Y2Z1 N8=X2Y2Z2 Thus, each bit in the string can be assigned to a corresponding nucleic acid molecule (e.g., N1 can designate the first bit, N2 can designate the second bit, N3 can designate the third bit, etc.). The entire bit string can be assigned to a combination of nucleic acid molecules, where nucleic acid molecules corresponding to a bit value of "1" are included in the combination or pool. For example, in UTF-8 encoding, the letter "K" can be represented by the 8-bit string code 01001011, and this 8-bit string code can be encoded by the presence of four nucleic acid molecules (e.g., X1Y1Z2, X2Y1Z1, X2Y2Z1, and X2Y2Z2 in the example above).
[0141]
[0187] Information can be accessed by sequencing or hybridization assays. For example, primers or probes can be designed to bind to common or barcoded regions of a nucleic acid sequence. This can allow for amplification of any region of a nucleic acid molecule. The amplification product can then be read by sequencing the amplification product or by hybridization assays. In the above example of encoding the letter "K," if the first half of the data is of interest, a primer specific to the barcode region of the X1 nucleic acid sequence and a primer binding to the common region of the Z set can be used to amplify the nucleic acid molecule. This can return the sequence Y1Z2, which can encode 0100. Subsequent sequences of that data can also be accessed by further amplifying the nucleic acid molecule with a primer binding to the barcode region of the Y1 nucleic acid sequence and a primer binding to the common sequence of the Z set. This can return the Z2 nucleic acid sequence, which encodes the subsequence 01. Alternatively, data can be accessed by checking for the presence or absence of specific nucleic acid sequences without sequencing. For example, amplification using a primer specific to the Y2 barcode can generate an amplification product for the Y2 barcode but not the Y1 barcode. The presence of a Y2 amplification product can signal a bit value of "1." Alternatively, the absence of a Y2 amplification product can signal a bit value of "0."
[0142]
[0188] PCR-based methods can be used to access and copy data from identifiers or nucleic acid sample pools. Common primer binding sites adjacent to identifiers within a pool or hyperpool can be used to easily copy information-containing nucleic acids. Alternatively, other nucleic acid amplification techniques, such as isothermal amplification, can be used to easily copy data from a sample pool or hyperpool (e.g., an identifier library). See Chemical Methods Section D for nucleic acid amplification. In examples where a sample contains a hyperpool, a primer that binds in the forward direction to a specific barcode on one edge of the identifier can be used with another primer that binds in the reverse direction to a common sequence on the opposite edge of the identifier to access and obtain a specific subset of information (e.g., all nucleic acids associated with a particular barcode). Various reading methods can be used to extract information from the encoded nucleic acids, for example, microarrays (or any type of fluorescent hybridization), digital PCR, quantitative PCR (qPCR), and various sequencing platforms can also be used to read the encoded sequence and, by extension, the digitally encoded data.
[0143]
[0189] Accessing information stored in nucleic acid molecules (e.g., identifiers) can be achieved by selectively removing a portion of non-targeted identifiers from an identifier library or pool of identifiers, or, for example, by selectively removing all identifiers in an identifier library from a pool of multiple identifier libraries. As used herein, "access" and "query" can be used interchangeably. Accessing data can also be achieved by selectively capturing targeted identifiers from an identifier library or pool of identifiers. Targeted identifiers can correspond to data of interest within a longer information item. A pool of identifiers may also include supplemental nucleic acid molecules. Supplemental nucleic acid molecules may contain metadata about the encoded information and may be used to conceal or mask identifiers corresponding to the information. Supplemental nucleic acid molecules may or may not be extracted during access to targeted identifiers. Figures 26A-26C schematically outline an example method for accessing a portion of information stored in a nucleic acid sequence by accessing certain specific identifiers from a larger number of identifiers. Figure 26A shows an example method for accessing identifiers containing specified components using polymerase chain reaction, affinity-tagged probes, and degradation-targeted probes. For PCR-based access, a pool of identifiers (e.g., an identifier library) may contain identifiers with a common sequence at each end, a variable sequence at each end, or either a common sequence or a variable sequence at each end. The common sequence or variable sequence may be a primer binding site. One or more primers may bind to the common or variable regions at the edges of the identifiers. Primed identifiers can be amplified by PCR. Amplified identifiers can significantly outnumber unamplified identifiers. During reading, amplified identifiers can be identified. Identifiers from an identifier library can contain a sequence at one or both of their ends that is distinguishable from that library, thus allowing selective access to a single library from a pool or group of more than one identifier library.
[0144]
[0190] In the case of affinity tag-based access, a process sometimes referred to as nucleic acid capture, components constituting the identifiers in the pool may share complementarity with one or more probes. One or more probes may bind or hybridize to the identifiers to be accessed. The probes may include affinity tags. The affinity tags may be captured on a solid support such as a membrane, a well, a column, or beads. When beads are used as the solid support, the affinity tags may bind to the beads to form complexes comprising the beads, at least one probe, and at least one identifier. The beads may be magnetic, and together with a magnet, the beads can collect and separate the identifiers to be accessed. Prior to reading, the identifiers may be removed from the beads under denaturing conditions. Alternatively or additionally, the beads may collect non-targeted identifiers and sequester them from the remainder of the pool, which may be washed, transferred to a separate container, and read. When a column is used, the affinity tags may be bound to the column. The identifiers to be accessed may be bound to the column for capture. Subsequently, the column-bound identifiers may be eluted or denatured from the column prior to reading. Alternatively, non-targeted identifiers can be selectively targeted to a column, while targeted identifiers can flow through the column. Identifiers bound to a solid support can be removed from the solid support by exposure to conditions such as acid, base, oxidation, reduction, heat, light, metal ion catalysis, displacement, or elimination chemical reactions, or by enzymatic cleavage. In certain embodiments, the accessed identifier can be attached to the solid support through a cleavable linkage moiety. For example, the solid support can be functionalized to provide a cleavable linker for covalently binding to the targeted identifier. The linker moiety can be six atoms or longer. In some embodiments, the cleavable linker can be a TOPS (two oligonucleotides per synthesis) linker, an amino linker, a chemically cleavable linker, or a photocleavable linker. Accessing the targeted identifiers can involve simultaneously applying one or more probes to the pool of identifiers, or sequentially applying one or more probes to the pool of identifiers.For nucleic acid capture, see Chemical Methods Section F.
[0145]
[0191] In the case of degradation-based access, the components constituting the identifiers in the pool may share complementarity with one or more degradation-targeting probes. The probes can bind or hybridize to distinguishable components of the identifiers. The probes can be targeted by degradative enzymes such as endonucleases. In one example, one or more identifier libraries can be combined. A set of probes can hybridize with one of the identifier libraries. The set of probes can include RNA, which can guide a Cas9 enzyme. The Cas9 enzyme can be introduced into one or more identifier libraries. Identifiers hybridized with the probes can be degraded by the Cas9 enzyme. Identifiers to be accessed may not be degraded by the degradative enzyme. In another example, the identifiers can be single-stranded, and the identifier library can be combined with a single-strand-specific endonuclease, such as S1 nuclease, that selectively degrades identifiers that are not to be accessed. Identifiers to be accessed can be hybridized with a complementary set of identifiers to protect them from degradation by the single-strand-specific endonuclease. The identifier to be accessed may be separated from the degradation products by size selection, such as by size-selective chromatography (e.g., agarose gel electrophoresis). Alternatively or additionally, the undegraded identifier may be selectively amplified (e.g., using PCR), so that the degradation products are not amplified. Primers that hybridize to each end of the undegraded identifier, and therefore do not hybridize to each end of the degraded or cleaved identifier, can be used to amplify the undegraded identifier.
[0146]
[0192] Figure 26B shows an example of a method for performing an "OR" or "AND" operation using polymerase chain reaction to access identifiers containing multiple components. In one example, if two forward primers bind to distinct sets of identifiers on the left end, "OR" amplification of the intersection of these sets of identifiers can be achieved by using the two forward primers together in a multiplex PCR reaction with a reverse primer that binds to all of the identifiers on the right end. In another example, if one forward primer binds to a set of identifiers on the left end and one reverse primer binds to a set of identifiers on the right end, "AND" amplification of the intersection of these two sets of identifiers can be achieved by using the forward and reverse primers together as a primer pair in a PCR reaction.
[0147]
[0193] Figure 26C shows an example of a method for using affinity tags to perform an "OR" or "AND" operation to access identifiers containing multiple components. In one example, if affinity probe "P1" captures all identifiers with component "C1" and another affinity probe "P2" captures all identifiers with component "C2," then P1 and P2 can be used simultaneously to capture the set of all identifiers with C1 or C2 (corresponding to an "OR" operation). In another example, using the same components and probes, P1 and P2 can be used sequentially to capture the set of all identifiers with C1 and C2 (corresponding to an "AND" operation).
[0148] Methods for reading information stored in nucleic acid sequences
[0194] In another aspect, the present disclosure provides a method for reading information encoded in a nucleic acid sequence. The method for reading information encoded in a nucleic acid sequence may include (a) providing an identifier library, (b) identifying identifiers present in the identifier library, (c) generating a symbol string from the identifiers present in the identifier library, and (d) compiling information from the symbol string. The identifier library may include a subset of a plurality of identifiers from the combinatorial space. Each individual identifier of the subset of identifiers may correspond to an individual symbol in the symbol string. The identifier may include one or more components. The components may include nucleic acid sequences.
[0149]
[0195] Information can be written to one or more identifier libraries as described elsewhere herein. Identifiers can be constructed using any of the methods described elsewhere herein. Stored data can be copied and stored data can be accessed using any of the methods described elsewhere herein.
[0150]
[0196] The identifier may include information about the location of the coded symbol, the value of the coded symbol, or both the location and value of the coded symbol. The identifier may include information about the location of the coded symbol, and the presence or absence of the identifier in the identifier library may indicate the value of the symbol. The presence of the identifier in the identifier library may indicate a first symbol value (e.g., a first bit value) in the binary string, and the absence of the identifier in the identifier library may indicate a second symbol value (e.g., a second bit value) in the binary string. Basing the bit value on the presence or absence of the identifier in the identifier library in a binary manner may reduce the number of identifiers to be assembled and therefore reduce writing time. In one example, the presence of the identifier may indicate a bit value of "1" at the mapped position, and the absence of the identifier may indicate a bit value of "0" at the mapped position.
[0151]
[0197] Generating a symbol (e.g., a bit value) for a piece of information can include identifying the presence or absence of an identifier to which the symbol (e.g., bit) can be mapped or encoded. Determining the presence or absence of an identifier can include sequencing the identifier or using a hybridization array to detect the presence of the identifier. In one example, decoding and reading the encoded sequence can be performed using a sequencing platform. Exemplary sequencing platforms include U.S. Patent Application No. 14 / 465,685, filed August 21, 2014, entitled "METHOD OF NUCLEIC ACID AMPLIFICATION," which was published December 18, 2014 as U.S. Patent Application Publication No. 2014-0371100A1; U.S. Patent Application No. 13 / 886,234, filed May 2, 2013, entitled "METHOD OF NUCLEIC ACID AMPLIFICATION," which was published September 5, 2013 as U.S. Patent Application Publication No. 2013-0231254A1; and U.S. Patent Application No. 13 / 886,234, filed May 2, 2013, entitled "METHOD OF NUCLEIC ACID AMPLIFICATION," which was published October 8, 2009 as U.S. Patent Application Publication No. 2009-0253141A1. No. 12 / 400,593, filed March 9, 2009, entitled "SEQUENCES," each of which is incorporated herein by reference in its entirety.
[0152]
[0198] In one example, decoding of nucleic acid-encoded data can be achieved by base-by-base sequencing of nucleic acid strands, such as Illumina® Sequencing, or by utilizing sequencing techniques that indicate the presence or absence of specific nucleic acid sequences, such as capillary electrophoretic fragmentation analysis. Sequencing may also utilize the use of reversible terminators. Sequencing may also utilize the use of natural or unnatural (e.g., engineered) nucleotides or nucleotide analogs. Alternatively or additionally, decoding of nucleic acid sequences can be performed using a variety of analytical techniques, including, but not limited to, any method that generates an optical, electrochemical, or chemical signal. A variety of sequencing techniques can be used, including but not limited to polymerase chain reaction (PCR), digital PCR, Sanger sequencing, high-throughput sequencing, sequencing-by-synthesis, single molecule sequencing, sequencing-by-ligation, RNA-Seq (Illumina), next-generation sequencing, digital gene expression (Helicos), clonal single microarray (Solexa), shotgun sequencing, Maxim-Gilbert sequencing, or massively parallel sequencing.
[0153]
[0199] Various readout methods can be used to extract information from the encoded nucleic acids. In one example, microarrays (or any type of fluorescent hybridization), digital PCR, quantitative PCR (qPCR), and various sequencing platforms can also be used to read the encoded sequence and, by extension, the digitally encoded data.
[0154]
[0200] The identifier library may further include complementary nucleic acid sequences that provide metadata about the information, that conceal or mask the information, or that both provide metadata and mask the information. The complementary nucleic acids may be identified simultaneously with the identification of the identifier. Alternatively, the complementary nucleic acids may be identified before or after the identifier is identified. In one example, the complementary nucleic acids are not identified during reading of the encoded information. The complementary nucleic acid sequences may be indistinguishable from the identifier. An identifier index or key may be used to differentiate complementary nucleic acid molecules from the identifier.
[0155]
[0201] Data encoding and decoding efficiency can be improved by re-encoding an input bit string to reduce the number of nucleic acid molecules used. For example, if an encoding method receives an input string with a high occurrence of "111" subsequences that can be mapped to three nucleic acid molecules (e.g., identifiers), it can be re-encoded to a "000" subsequence that can be mapped to an empty set of nucleic acid molecules. Alternative input subsequences of "000" can also be re-encoded to "111." This re-encoding method can reduce the total amount of nucleic acid molecules used to encode the data because the number of "1"s in the dataset can be reduced. In this example, the total size of the dataset can be increased to accommodate a codebook that specifies new mapping instructions. An alternative method for improving encoding and decoding efficiency can be to re-encode an input string to reduce its variable length. For example, "111" can be re-encoded to "00," which can reduce the size of the dataset and reduce the number of "1"s in the dataset.
[0156]
[0202] By specifically designing identifiers to facilitate detection, the speed and efficiency of decoding nucleic acid-encoded data can be controlled (e.g., increased). For example, a nucleic acid sequence (e.g., an identifier) designed for ease of detection can include a nucleic acid sequence containing a majority of nucleotides that are easier to call and detect based on their optical, electrochemical, chemical, or physical properties. Engineered nucleic acid sequences can be single-stranded or double-stranded. Engineered nucleic acid sequences can also contain synthetic or non-natural nucleotides that enhance the detectable properties of the nucleic acid sequence. Engineered nucleic acid sequences can contain all natural nucleotides, all synthetic or non-natural nucleotides, or a combination of natural, synthetic, and non-natural nucleotides. Synthetic nucleotides can include nucleotide analogs, such as peptide nucleic acids, locked nucleic acids, glycol nucleic acids, and threose nucleic acids. Non-natural nucleotides can include dNaM, an artificial nucleoside containing a 3-methoxy-2-naphthyl group, and d5SICS, an artificial nucleoside containing a 6-methylisoquinoline-1-thion-2-yl group. The engineered nucleic acid sequences may be designed for a single enhanced property, such as enhanced optical properties, or the engineered nucleic acid sequences may be designed with multiple enhanced properties, such as enhanced optical and electrochemical properties or enhanced optical and chemical properties. See Chemical Methods Section H regarding DNA design.
[0157]
[0203] Engineered nucleic acid sequences may contain reactive natural, synthetic, and non-natural nucleotides that do not enhance the optical, electrochemical, chemical, or physical properties of the nucleic acid sequence. The reactive components of the nucleic acid sequence may allow for the addition of chemical moieties that confer enhanced properties to the nucleic acid sequence. Each nucleic acid sequence may contain a single chemical moiety or multiple chemical moieties. Examples of chemical moieties include, but are not limited to, fluorescent moieties, chemiluminescent moieties, acidic or basic moieties, hydrophobic or hydrophilic moieties, and moieties that alter the oxidation state or reactivity of the nucleic acid sequence.
[0158]
[0204] Sequencing platforms may be specifically designed for decoding and reading information encoded in nucleic acid sequences. Sequencing platforms may be dedicated to sequencing single-stranded nucleic acid molecules or double-stranded nucleic acid molecules. Sequencing platforms may decode nucleic acid-encoded data by reading individual bases (e.g., base-by-base sequencing) or by detecting the presence or absence of the entire nucleic acid sequence (e.g., component) incorporated into a nucleic acid molecule (e.g., an identifier). Sequencing platforms may include the use of promiscuous reagents, longer read lengths, and the use of detection of specific nucleic acid sequences by adding detectable chemical moieties. Using more promiscuous reagents during sequencing may increase read efficiency by enabling faster base calling, thereby reducing sequencing time. The use of longer read lengths may allow longer sequences of encoded nucleic acids to be decoded per read. Adding detectable chemical moiety tags may allow the detection of the presence or absence of a nucleic acid sequence by the presence or absence of the chemical moiety. For example, each nucleic acid sequence encoding a bit of information can be tagged with a chemical moiety that produces a unique optical, electrochemical, or chemical signal. The presence or absence of that unique optical, electrochemical, or chemical signal can indicate a "0" or "1" bit value. A nucleic acid sequence can contain a single chemical moiety, or it can contain multiple chemical moieties. The chemical moiety can be added to a nucleic acid sequence prior to using the nucleic acid sequence to encode data. Alternatively, or in addition, the chemical moiety can be added to a nucleic acid sequence after encoding the data but before decoding the data. The chemical moiety tag can be added directly to the nucleic acid sequence, or the nucleic acid sequence can contain a synthetic or non-natural nucleotide anchor to which the chemical moiety tag can be added.
[0159]
[0205] A unique code can be applied to minimize or detect encoding and decoding errors. Encoding and decoding errors can occur due to false negatives (e.g., nucleic acid molecules or identifiers not included in random sampling). One example of an error detection code can be a checksum sequence that counts the number of identifiers in a consecutive set of possible identifiers included in an identifier library. During reading of the identifier library, the checksum can indicate the expected number of identifiers obtained from that consecutive set, and identifiers can continue to be sampled for reading until the expected number is met. In some embodiments, a checksum sequence can be included for every R consecutive sets of identifiers, where R can be equal to or greater than 1, 2, 5, 10, 50, 100, 200, 500, or 1000 in size, or can be less than 1000, 500, 200, 100, 50, 10, 5, or 2. The smaller the value of R, the better the error detection. In some embodiments, the checksum can be a complementary nucleic acid sequence. For example, a set containing seven nucleic acid sequences (e.g., components) can be divided into two groups: nucleic acid sequences for constructing identifiers in a product manner (components X1-X3 in layer X and Y1-Y3 in layer Y) and nucleic acid sequences for complementary checksums (X4-X7 and Y4-Y7). Checksum sequences X4-X7 can indicate whether 0, 1, 2, or 3 sequences from layer X assemble with each member of layer Y. Alternatively, checksum sequences Y4-Y7 can indicate whether 0, 1, 2, or 3 sequences from layer Y assemble with each member of layer X. In this example, the original identifier library with identifiers {X1Y1, X1Y3, X2Y1, X2Y2, X2Y3} can be supplemented to include checksums to result in the following pool: {X1Y1, X1Y3, X2Y1, X2Y2, X2Y3, X1Y6, X2Y7, X3Y4, X6Y1, X5Y2, X6Y3}. Checksum sequences can also be used for error correction. For example, the absence of X1Y1 and the presence of X1Y6 and X6Y1 in the above dataset can allow for the inference that the X1Y1 nucleic acid molecule is missing from the dataset.The checksum sequence can indicate whether the identifier is missing from the sampled or accessed portion of the identifier library. If the checksum sequence is missing, an accessing method such as PCR or affinity-tagged probe hybridization can amplify and / or isolate it. In some embodiments, the checksum may not be a complementary nucleic acid sequence. In that case, the checksum can be directly encoded into the information so that it is represented by the identifier.
[0160]
[0206] Data encoding and decoding noise can be reduced by constructing identifiers as palindromes, for example, by using palindromic pairs of components rather than single components in a product manner. Pairs of components from different layers can then be assembled together in a palindromic manner (e.g., YXY rather than XY for components X and Y). This palindromic method can be extended to a larger number of layers (e.g., ZYXYZ rather than XYZ), and may allow for the detection of erroneous cross-reactivity between identifiers.
[0161]
[0207] Adding excess (e.g., large excess) complementary nucleic acid sequences to the identifier can prevent recovery of the encoded identifier by sequencing. Prior to decoding the information, the identifier may be enriched by the complementary nucleic acid sequences. For example, the identifier may be enriched by a nucleic acid amplification reaction using primers specific to the identifier end. Alternatively or additionally, the information may be decoded without enriching the sample pool by sequencing using specific primers (e.g., sequencing-by-synthesis). In both decoding methods, it may be difficult to enrich or decode the information without the decoding key or without knowing something about the composition of the identifier. Alternative access methods, such as the use of affinity tag-based probes, may also be utilized.
[0162] System for encoding binary array data
[0208] Systems for encoding digital information into nucleic acids (e.g., DNA) can include systems, methods, and devices for converting files and data (e.g., raw data, compressed zip files, integer data, and other forms of data) into bytes and encoding the bytes into nucleic acids, typically segments or sequences of DNA, or combinations thereof.
[0163]
[0209] In one aspect, the present disclosure provides a system for encoding binary sequence data using nucleic acids. The system for encoding binary sequence data using nucleic acids may include a device and one or more computer processors. The device may be configured to construct an identifier library. The one or more computer processors may be individually or collectively programmed to (i) translate information into a symbol string, (ii) map the symbol string to a plurality of identifiers, and (iii) construct an identifier library including at least a subset of the plurality of identifiers. Each identifier of the plurality of identifiers may correspond to an individual symbol of the symbol string. Each identifier of the plurality of identifiers may include one or more components. Each component of the one or more components may include a nucleic acid sequence.
[0164]
[0210] In another aspect, the present disclosure provides a system for reading binary sequence data using nucleic acids. The system for reading binary sequence data using nucleic acids may include a database and one or more computer processors. The database may store an identifier library encoding information. The one or more computer processors may be individually or collectively programmed to (i) identify identifiers in the identifier library, (ii) generate a plurality of symbols from the identifiers identified in (i), and (iii) compile information from the plurality of symbols. The identifier library may include a subset of the plurality of identifiers. Each individual identifier in the plurality of identifiers may correspond to an individual symbol in a symbol string. The identifier may include one or more components. The components may include nucleic acid sequences.
[0165]
[0211] A non-limiting embodiment of a method of using the system for encoding digital data can include receiving digital information in the form of a byte stream, parsing the byte stream into individual bytes, mapping bit positions within the bytes using a nucleic acid index (or identifier rank), and encoding sequences corresponding to either a bit value of 1 or a bit value of 0 into an identifier. Obtaining the digital data can include sequencing a nucleic acid sample or pool containing sequences of nucleic acids (e.g., identifiers) that map to one or more bits, referencing the identifier rank to determine whether the identifier is present in the nucleic acid pool, and decoding the position and bit value information for each sequence into bytes containing the sequence of digital information.
[0166]
[0212] A system for encoding, writing, copying, accessing, reading, and decoding information encoded in or written to a nucleic acid molecule may be a single integrated unit or multiple units configured to perform one or more of the above-mentioned operations. A system for encoding and writing information to a nucleic acid molecule (e.g., an identifier) may include a device and one or more computer processors. The one or more computer processors may be programmed to parse the information into a string of symbols (e.g., a string of bits). The computer processor may generate a rank of the identifiers. The computer processor may categorize the symbols into two or more categories. One category may include symbols represented by the presence of a corresponding identifier in the identifier library, and the other category may include symbols represented by the absence of a corresponding identifier in the identifier library. The computer processor may direct the device to assemble an identifier corresponding to a symbol represented by the presence of the identifier in the identifier library.
[0167]
[0213] The device may include multiple regions, sections, or compartments. Reagents and components for assembling the identifier may be stored in one or more regions, sections, or compartments of the device. Layers may be stored in separate regions of a section of the device. Layers may contain one or more unique components. Components within one layer may be unique and not overlap with components in another layer. Regions or sections may include containers, and compartments may include wells. Each layer may be stored in a separate container or compartment. Each reagent or nucleic acid sequence may be stored in a separate container or compartment. Alternatively or additionally, reagents may be combined to form a master mix for identifier construction. The device may transfer reagents, components, and templates from one section of the device to be combined with each other. The device may provide conditions for completing the assembly reaction. For example, the device may provide heating, agitation, and detection of reaction progress. The constructed identifier may be subjected to one or more subsequent reactions to add barcodes, common sequences, variable sequences, or tags to one or more ends of the identifier. The identifiers can then be directed to the regions or compartments to generate an identifier library. One or more identifier libraries can be stored in each region, section, or individual compartment of the device. The device can transfer fluids (e.g., reagents, components, templates) using pressure, vacuum, or suction.
[0168]
[0214] The identifier library can be stored on the device or transferred to a separate database. The database can contain one or more identifier libraries. The database can provide conditions for long-term storage of the identifier library (e.g., conditions to reduce degradation of the identifiers). The identifier library can be stored in powder, liquid, or solid form. Aqueous solutions of the identifiers can be lyophilized for more stable storage (see Chemical Methods Section G for more information on lyophilization). Alternatively, the identifiers can be stored in the absence of oxygen (e.g., anaerobic storage conditions). The database can provide UV photoprotection, reduced temperature (e.g., refrigeration or freezing), and protection from degradative chemicals and enzymes. Prior to transfer to the database, the identifier library can be lyophilized or frozen. The identifier library can contain ethylenediaminetetraacetic acid (EDTA) to inactivate nucleases and / or buffers to maintain the stability of the nucleic acid molecules.
[0169]
[0215] The database may be coupled to, include, or be separate from a device that writes, copies, accesses, or reads information to the identifiers. A portion of the identifier library can be removed from the database before copying, accessing, or reading. The device that copies information from the database can be the same device as the device that writes the information or a different device. The device that copies information can extract an aliquot of the identifier library from the device and combine the aliquot with reagents and components to amplify some or all of the identifier library. The device can control the temperature, pressure, and agitation of the amplification reaction. The device can include compartments, and one or more amplification reactions can occur in the compartment containing the identifier library. The device can copy more than one pool of identifiers simultaneously.
[0170]
[0216] The copied identifiers may be transferred from the copy device to the access device. The access device may be the same device as the copy device. The access device may include separate regions, sections, or compartments. The access device may have one or more columns, bead reservoirs, or magnetic regions for separating the identifiers bound to the affinity tags (see Chemical Methods Section F for nucleic acid capture). Alternatively, or in addition, the access device may have one or more size selection units. The size selection unit may include agarose gel electrophoresis or any other method for size-selecting nucleic acid molecules (see Chemical Methods Section E for more information on nucleic acid size selection). Copying and extraction may be performed in the same region of the device or in different regions of the device (see Chemical Methods Section D for nucleic acid amplification).
[0171]
[0217] The accessed data can be read in the same device, or the accessed data can be transferred to another device. The reading device can include a detection unit for detecting and identifying the identifier. The detection unit can be part of a sequencer, hybridization array, or other unit for identifying the presence or absence of the identifier. The sequencing platform can be specifically designed for decoding and reading information encoded in nucleic acid sequences. The sequencing platform can be dedicated to sequencing single-stranded or double-stranded nucleic acid molecules. The sequencing platform can decode nucleic acid-encoded data by reading individual bases (e.g., base-by-base sequencing) or by detecting the presence or absence of an entire nucleic acid sequence (e.g., a component) incorporated within the nucleic acid molecule (e.g., an identifier). Alternatively, the sequencing platform can be a system such as Illumina® sequencing or capillary electrophoretic fragmentation analysis. Alternatively, or in addition, decoding of the nucleic acid sequence can be performed using a variety of analytical techniques implemented by the device, including, but not limited to, any method that produces an optical, electrochemical, or chemical signal.
[0172]
[0218] Storing information in nucleic acid molecules can have various applications, including, but not limited to, long-term information storage, confidential information storage, and medical information storage. In one example, a person's medical information (e.g., medical history and medical records) can be stored in a nucleic acid molecule and kept by the person. The information can be stored externally (e.g., in a wearable device) or internally (e.g., in a subcutaneous capsule). When a patient is brought to a clinic or hospital, a sample can be obtained from the device or capsule, and the information can be decoded using a nucleic acid sequencer. Storing personal medical records in nucleic acid molecules can provide an alternative to computer- and cloud-based storage systems. Storing personal medical records in nucleic acid molecules can reduce the incidence or prevalence of medical record hacking. The nucleic acid molecules used in capsule-based medical record storage can be derived from the human genome sequence. Using the human genome sequence can reduce the immunogenicity of the nucleic acid sequence in the event of capsule damage and leakage.
[0173] Computer Systems
[0219] The present disclosure provides computer systems programmed to implement the methods of the present disclosure. Figure 28 shows a computer system 1901 programmed or otherwise configured to encode digital information into a nucleic acid sequence and / or read (e.g., decode) information derived from a nucleic acid sequence. The computer system 1901 can adjust various aspects of the encoding and decoding procedures of the present disclosure, such as, for example, bit value and bit position information for a given bit or byte from an encoded bitstream or bytestream.
[0174]
[0220] The computer system 1901 includes a central processing unit (CPU, also referred to herein as a "processor" and a "computer processor") 1905, which may be a single-core processor or a multi-core processor, or multiple processors for parallel processing. The computer system 1901 also includes memory or memory locations 1910 (e.g., random access memory, read-only memory, flash memory), electronic storage 1915 (e.g., a hard disk), a communication interface 1920 (e.g., a network adapter) for communicating with one or more other systems, and peripherals 1925, such as cache, other memory, data storage, and / or electronic display adapters. The memory 1910, storage 1915, interface 1920, and peripherals 1925 communicate with the CPU 1905 through a communication bus (solid lines) such as a motherboard. The storage 1915 may be a data storage unit (or data repository) for storing data. The computer system 1901 may be operably coupled to a computer network ("network") 1930 using the communication interface 1920. Network 1930 may be the Internet, an Internet and / or extranet, or an intranet and / or extranet in communication with the Internet. Network 1930 may, in some cases, be a telecommunications and / or data network. Network 1930 may include one or more computer servers, thereby enabling distributed computing such as cloud computing. Network 1930 may, in some cases, utilize computer system 1901 to implement a peer-to-peer network, thereby enabling devices coupled to computer system 1901 to act as clients or servers.
[0175]
[0221] The CPU 1905 is capable of executing sequences of machine-readable instructions, which may be embodied in a program or software. The instructions may be stored in a memory location, such as the memory 1910. The instructions may be directed to the CPU 1905, which may then cause the CPU 1905 to be programmed or otherwise configured to implement the methods of the present disclosure. Examples of operations performed by the CPU 1905 may include fetch, decode, execute, and writeback.
[0176]
[0222] The CPU 1905 may be part of a circuit, such as an integrated circuit. One or more other components of the system 1901 may be included in the circuit. In some cases, the circuit is an application specific integrated circuit (ASIC).
[0177]
[0223] The storage device 1915 may store files, such as drivers, libraries, and saved programs. The storage device 1915 may store user data, such as user preferences and user programs. The computer system 1901 may include one or more additional data storage units that, in some cases, are external to the computer system 1901, such as located on a remote server that communicates with the computer system 1901 over an intranet or the Internet.
[0178]
[0224] Computer system 1901 is capable of communicating with one or more remote computer systems over network 1930. For example, computer system 1901 is capable of communicating with a user's remote computer system or other devices and / or mechanisms (e.g., a sequencer or other system for chemically determining the order of nitrogenous bases in a nucleic acid sequence) that the user can use in the process of analyzing data encoded or decoded in a nucleic acid sequence. Examples of remote computer systems include personal computers (e.g., portable PCs), slate or tablet PCs (e.g., Apple® iPad®, Samsung® Galaxy Tab), telephones, smartphones (e.g., Apple® iPhone®, Android-enabled devices, Blackberry®), or personal digital assistants. A user can access computer system 1901 via network 1930.
[0179]
[0225] The methods described herein may be implemented by machine-executable (e.g., computer processor) code stored in an electronic storage location of the computer system 1901, such as, for example, memory 1910 or electronic storage 1915. The machine-executable or machine-readable code may be provided in the form of software. During use, the code may be executed by the processor 1905. In some cases, the code may be retrieved from storage 1915 and stored in memory 1910 for immediate access by the processor 1905. In some circumstances, the electronic storage 1915 may be omitted, and the machine-executable instructions may be stored in memory 1910.
[0180]
[0226] The code may be pre-compiled and configured for use with a machine having a processor adapted to execute the code, or it may be compiled at run time. The code may be provided in a programming language that can be selected to allow the code to be executed in a pre-compiled or as-compiled fashion.
[0181]
[0227] Aspects of the systems and methods presented herein, such as computer system 1901, can be embodied in programming. Various aspects of the technology can be considered "products" or "articles of manufacture," generally in the form of machine- (or processor-) executable code and / or associated data carried or embodied on some type of machine-readable medium. The machine-executable code can be stored in electronic storage, such as memory (e.g., read-only memory, random-access memory, flash memory) or a hard disk. A "storage" type medium can include any or all of a computer's tangible memory, processor, etc., or its associated modules, such as various semiconductor memories, tape drives, disk drives, etc., that can provide non-transitory storage at any time for software programming. All or portions of the software may, from time to time, be communicated over the Internet or various other telecommunications networks. Such communication, for example, enables the software to be loaded from one computer or processor to another, e.g., from a management server or host computer to an application server's computer platform. Thus, other types of media that may carry software elements include light waves, radio waves, and electromagnetic waves, such as those used across physical interfaces between local devices through wired and optical landline networks and through various air links. The physical elements that carry such waves, such as wired or wireless links, optical links, etc., may also be considered media bearing software. As used herein, unless limited to non-transitory tangible "storage" media, terms such as computer or machine "readable medium" refer to any medium that participates in providing instructions to a processor for execution.
[0182]
[0228] Thus, machine-readable media, such as computer-executable code, may take many forms, including but not limited to tangible storage media, carrier wave media, or physical transmission media. Non-volatile storage media include, for example, optical or magnetic disks, such as storage devices in any computer, such as those that can be used to implement databases, etc., as shown in the figures. Volatile storage media include dynamic memory, such as the main memory of such a computer platform. Tangible transmission media include coaxial cables; copper wire, including the electrical wires that comprise the bus bars within a computer system, and fiber optics. Carrier-wave transmission media may take the form of electric or electromagnetic signals, or acoustic or light waves, such as those generated during radio frequency (RF) and infrared (IR) data communications. Thus, common forms of computer readable media include, for example, floppy disks, flexible disks, hard disks, magnetic tape, any other magnetic media, CD-ROMs, DVDs or DVD-ROMs, any other optical media, punched card paper tape, any other physical storage media with patterns of holes, RAM, ROM, PROMs and EPROMs, FLASH-EPROMs, any other memory chips or cartridges, carrier waves carrying data or instructions, cables or links which transport such carrier waves, or any other medium from which a computer can read programming code and / or data. Many of these forms of computer readable media may be involved in carrying one or more sequences of one or more instructions to a processor for execution.
[0183]
[0229] The computer system 1901 may include or communicate with an electronic display 1935 including a user interface (UI) 1940 to provide sequence output data including, for example, chromatographs, sequences, and bits, bytes, or bitstreams encoded or read by a machine or computer system encoding or decoding nucleic acids, raw data, files, and compressed or uncompressed zip files, encoded or read by a machine or computer system that is encoding or decoding the raw data, files, and compressed or uncompressed zip files. Examples of UIs include, without limitation, graphical user interfaces (GUIs) and web-based user interfaces. The methods and systems of the present disclosure may be implemented via one or more algorithms. The algorithms may be implemented via software when executed by the central processing unit 1905. The algorithms may be used, for example, with the DNA index and the raw data or the data compressed or uncompressed into zip files, to determine a customized method for coding the digital information into the raw data or the data compressed or uncompressed into zip files prior to encoding the digital information.
[0184] Chemical Methods Section A. Overlap extension PCR (OEPCR) assembly
[0230] In OEPCR, components are assembled in a reaction containing a polymerase and dNTPs (deoxynucleotide triphosphates, including dATP, dTTP, dCTP, dGTP, or variants or analogs thereof). Components can be single-stranded or double-stranded nucleic acids. Assembled components adjacent to each other can have complementary 3' ends, complementary 5' ends, or homology between the 5' end of one component and the 3' end of the adjacent component. These terminal regions are referred to as "hybridization regions" and are intended to facilitate the formation of hybridized junctions between components in OEPCR, where the 3' end of one input component (or its complement) hybridizes to the 3' end of its intended adjacent component (or its complement). An assembled double-stranded product can then be formed by polymerase extension. This product can then be assembled into more components through subsequent hybridization and extension. FIG. 16 shows an example schematic of OEPCR for assembling three nucleic acids.
[0185]
[0231] In some embodiments, OEPCR can involve cycling between three temperatures: a melting temperature, an annealing temperature, and an extension temperature. The melting temperature is intended to convert double-stranded nucleic acids into single-stranded nucleic acids and eliminate the formation of secondary structures or hybridization within or between components. Typically, the melting temperature is high, e.g., greater than 95 degrees Celsius. In some embodiments, the melting temperature can be at least 96, 97, 98, 99, 100, 101, 102, 103, 104, or 105 degrees Celsius. In other embodiments, the melting temperature can be up to 95, 94, 93, 92, 91, or 90 degrees Celsius. Higher melting temperatures improve dissociation of nucleic acids and their secondary structures, but can also cause side effects, such as degradation of the nucleic acids or polymerase. The melting temperature may be applied to the reaction for at least 1 second, 2 seconds, 3 seconds, 4 seconds, 5 seconds, or longer, for example, 30 seconds, 1 minute, 2 minutes, or 3 minutes.
[0186]
[0232] The annealing temperature is intended to facilitate the formation of hybridization between complementary 3' ends of intended adjacent components (or their complements). In some embodiments, the annealing temperature may correspond to the calculated melting temperature of the intended hybridized nucleic acid formation. In other embodiments, the annealing temperature may be within 10 degrees Celsius or higher of the melting temperature. In some embodiments, the annealing temperature may be at least 25, 30, 50, 55, 60, 65, or 70 degrees Celsius. The melting temperature may depend on the sequence of the intended hybridization region between the components. Longer hybridization regions may have higher melting temperatures, and hybridization regions with a higher percent content of guanine or cytosine nucleotides may have higher melting temperatures. Thus, it may be possible to design components for an OEPCR reaction that are intended to assemble optimally at a specific annealing temperature. The annealing temperature may be applied to the reaction for at least 1 second, 5 seconds, 10 seconds, 15 seconds, 20 seconds, 25 seconds, or 30 seconds, or longer.
[0187]
[0233] The extension temperature is intended to initiate and facilitate nucleic acid chain extension of the hybridized 3' end, catalyzed by one or more polymerase enzymes. In some embodiments, the extension temperature can be set to a temperature at which the polymerase functions optimally in terms of nucleic acid binding strength, extension speed, extension stability, or fidelity. In some embodiments, the extension temperature can be at least 30, 40, 50, 60, or 70 degrees Celsius, or higher. The annealing temperature can be applied to the reaction for at least 1 second, 5 seconds, 10 seconds, 15 seconds, 20 seconds, 25 seconds, 30 seconds, 40 seconds, 50 seconds, or 60 seconds, or longer. The recommended extension time can be approximately 15 to 45 seconds per kilobase of expected extension.
[0188]
[0234] In some embodiments of OEPCR, the annealing temperature and the extension temperature can be the same. Thus, a two-step temperature cycle can be used instead of a three-step temperature cycle. Examples of combined annealing and extension temperatures include 60, 65, or 72 degrees Celsius.
[0189]
[0235] In some embodiments, OEPCR may be performed in one temperature cycle. Such embodiments may involve the intended assembly of only two components. In other embodiments, OEPCR may be performed in multiple temperature cycles. Any given nucleic acid in OEPCR can assemble with at most one other nucleic acid in one cycle. This is because assembly (or extension or extension) can only occur at the 3' end of the nucleic acid, and each nucleic acid can have only one 3' end. Thus, assembly of multiple components may require multiple temperature cycles. For example, assembly of four components may involve three temperature cycles. Assembly of six components may involve five temperature cycles. Assembly of ten components may involve nine temperature cycles. In some embodiments, assembly efficiency can be increased by using more temperature cycles than the minimum required. For example, using four temperature cycles to assemble two components may result in more product than using only one temperature cycle. This is because component hybridization and extension is a statistical event that occurs on a small fraction of the total number of components in each cycle, and therefore the total fraction of assembled components can increase with increasing cycles.
[0190]
[0236] In addition to temperature cycling considerations, the design of nucleic acid sequences in OEPCR can affect the efficiency of their assembly with each other. Nucleic acids with long hybridization regions can hybridize more efficiently at a given annealing temperature than nucleic acids with short hybridization regions. This is because longer hybridized products contain a greater number of stable base pairs, and therefore the overall hybridized product can be more stable than shorter hybridized products. The hybridization region can have a length of at least 1 base, 2 bases, 3 bases, 4 bases, 5 bases, 6 bases, 7 bases, 8 bases, 9 bases, 10 bases, or more.
[0191]
[0237] A hybridization region with a high guanine or cytosine content may hybridize more efficiently at a given temperature than a hybridization region with a low guanine or cytosine content because guanine and cytosine form more stable base pairs than adenine and thymine. A hybridization region can have any guanine or cytosine content (also known as GC content) between 0% and 100%.
[0192]
[0238] In addition to the length and GC content of the hybridization region, there are many more aspects of nucleic acid sequence design that can affect the efficiency of OEPCR. For example, the formation of undesired secondary structures within a component can interfere with its ability to form a hybridization product with its intended neighboring component. These secondary structures can include hairpin loops. The types of possible secondary structures for nucleic acids and their stability (e.g., melting temperature) can be predicted based on the sequence. Design space search algorithms can be used to determine nucleic acid sequences that meet appropriate length and GC content criteria for efficient OEPCR, while avoiding sequences with potentially inhibitory secondary structures. Design space search algorithms can include genetic algorithms, heuristic search algorithms, meta-heuristic search strategies such as tabu search, branch-and-bound search algorithms, dynamic programming-based algorithms, constrained combinatorial optimization algorithms, steepest descent-based algorithms, randomized search algorithms, or combinations thereof.
[0193]
[0239] Similarly, the formation of homodimers (nucleic acid molecules that hybridize with nucleic acid molecules of the same sequence) and unwanted heterodimers (nucleic acid sequences that hybridize with other nucleic acid sequences in addition to their intended assembly partners) can interfere with OEPCR. Similar to secondary structures within nucleic acids, the formation of homodimers and heterodimers can be predicted and accounted for during nucleic acid design using computational methods and design space search algorithms.
[0194]
[0240] Longer nucleic acid sequences or higher GC content can result in increased formation of undesired secondary structures, homodimers, and heterodimers in OEPCR. Therefore, in some embodiments, using shorter nucleic acid sequences or lower GC content can lead to higher assembly efficiency. These design principles can counteract design strategies that use long hybridization regions or high GC content for more efficient assembly. Thus, in some embodiments, OEPCR can be optimized by using long hybridization regions with high GC content and short non-hybridization regions with low GC content. The overall length of the nucleic acid can be at least 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 bases, or more. In some embodiments, there may be an optimal length and optimal GC content of the nucleic acid hybridization region at which assembly efficiency is optimized.
[0195]
[0241] A larger number of distinct nucleic acids in an OEPCR reaction can interfere with the expected assembly efficiency, as a larger number of distinct nucleic acid sequences can result in a higher probability of undesired intermolecular interactions, particularly heterodimeric formation. Thus, in some embodiments of OEPCR that assemble a large number of components, the nucleic acid sequence constraints for efficient assembly can be more stringent.
[0196]
[0242] Primers for amplifying the predicted final assembled product can be included in the OEPCR reaction, which can then be run with more temperature cycles to improve the yield of assembled product not just by creating more assemblies between the constituent components, but also by exponentially amplifying the complete assembled product in the manner of conventional PCR (see Chemical Methods Section D).
[0197]
[0243] Additives can be included in the OEPCR reaction to improve assembly efficiency, such as the addition of betaine, dimethyl sulfoxide (DMSO), non-ionic surfactants, formamide, magnesium, bovine serum albumin (BSA), or combinations thereof. The additive content (weight / volume) can be at least 0%, 1%, 5%, 10%, 20%, or more.
[0198]
[0244] A variety of polymerases can be used for OEPCR. The polymerase can be naturally occurring or synthetic. An example of a polymerase is Φ29 polymerase or its derivatives. In some cases, a transcriptase or ligase (i.e., an enzyme that catalyzes the formation of bonds) is used in conjunction with or instead of a polymerase to construct new nucleic acid sequences. Examples of polymerases include DNA polymerase, RNA polymerase, thermostable polymerase, wild-type polymerase, modified polymerase, E. coli DNA polymerase I, T7 DNA polymerase, bacteriophage T4 DNA polymerase Φ29 (phi29) DNA polymerase, Taq polymerase, Tth polymerase, Tli polymerase, Pfu polymerase, Pwo polymerase, VENT polymerase, DEEPVENT polymerase, Ex-Taq polymerase, LA-Taw polymerase, Sso polymerase, Poc polymerase, Pab polymerase, Mth polymerase, ES4 polymerase, Tru polymerase, Tac polymerase, Tne polymerase, Tma polymerase, Tca polymerase, Tih polymerase, Tfi polymerase, Platinum Examples of polymerases include Taq polymerase, Tbr polymerase, Phusion polymerase, KAPA polymerase, Q5 polymerase, Tfl polymerase, Pfutubo polymerase, Pyrobest polymerase, KOD polymerase, Bst polymerase, Sac polymerase, and Klenow fragment polymerase with 3' to 5' exonuclease activity, as well as their variants, modified products, and derivatives. Different polymerases may be stable and function optimally at different temperatures. Furthermore, different polymerases have different properties. For example, some polymerases, such as Phusion polymerase, may exhibit 3' to 5' exonuclease activity, which may contribute to higher fidelity during nucleic acid elongation. Some polymerases may replace leading sequences during elongation, while others may degrade them or terminate elongation. Some polymerases, such as Taq, incorporate an adenine base at the 3' end of a nucleic acid sequence.This process is called A-tail addition and can be inhibitory to OEPCR because the addition of an adenine base can disrupt the designed 3' complementarity between intended flanking components.
[0199]
[0245] OEPCR may also be referred to as polymerase cycling assembly (or PCA).
[0200] B. Ligation Assembly
[0246] In ligation assembly, separate nucleic acids are assembled in a reaction containing one or more ligase enzymes and additional cofactors, such as adenosine triphosphate (ATP), dithiothreitol (DTT), or magnesium ions (Mg 2+ During ligation, the 3' end of one nucleic acid strand is covalently linked to the 5' end of another nucleic acid strand, thus forming an assembled nucleic acid. The components of the ligation reaction can be blunt-ended double-stranded DNA (dsDNA), single-stranded DNA (ssDNA), or partially hybridized single-stranded DNA. Strategies for bringing nucleic acid ends together increase the frequency of viable substrates for ligase enzymes and can therefore be used to improve the efficiency of ligase reactions. While blunt-ended dsDNA molecules tend to form hydrophobic stacks on which ligase enzymes can act, a more successful strategy for bringing nucleic acids together can be to use nucleic acid components with either 5' or 3' single-stranded overhangs that are complementary to the overhangs of the components they are intended to assemble. In the latter example, more stable nucleic acid duplexes can be formed due to base-base hybridization.
[0201]
[0247] When a double-stranded nucleic acid has an overhang at one end, the other strand at that end may be referred to as a "depression." Together, the depression and overhang form a "sticky end," also known as a "cohesive end." A sticky end may be either a 3' overhang and a 5' depression, or a 5' overhang and a 3' depression. The sticky ends between two intended adjacent components may be designed to be complementary, such that the overhangs of both sticky ends hybridize, with each overhang directly adjacent to the beginning of the depression of the other component. This creates a "nick" (a break in double-stranded DNA) that can be "sealed" (covalently linked through a phosphodiester bond) by the action of a ligase. See Figure 17 for a schematic example of sticky end ligation for assembling three nucleic acids. Nicks in either one strand, the other strand, or both strands can be sealed. Thermodynamically, the upper and lower strands of a molecule forming a sticky end can move between associated and dissociated states, and thus the sticky end may be a transient formation. However, once a nick along one strand of a sticky-end duplex between two components is sealed, the covalent linkage remains even if a member of the opposite strand dissociates. The linked strand then becomes a template to which the intended adjacent member of the opposite strand can bind, re-forming a nick that can be sealed.
[0202]
[0248] Sticky ends can be created by digesting dsDNA with one or more endonucleases. Endonucleases (which may be called restriction enzymes) can target specific sites (which may be called restriction sites) at either or both ends of a dsDNA molecule and create staggered cuts (sometimes called digestion), thus leaving sticky ends. See Chemical Methods Section C for information on restriction enzyme digestion. Digestion can leave palindromic overhangs (overhangs with a sequence that is the reverse complement of itself). In this case, two components digested with the same endonuclease can form complementary sticky ends along which they can be assembled using a ligase. Digestion and ligation can be performed together in the same reaction if the endonuclease and ligase are compatible. The reaction can be performed at a uniform temperature, such as 4, 10, 16, 25, or 37 degrees Celsius. Alternatively, the reaction can be cycled between temperatures, for example, between 16 and 37 degrees Celsius. Cycling between multiple temperatures allows digestion and ligation to each proceed at their respective optimum temperatures during different parts of the cycle.
[0203]
[0249] It may be beneficial to perform digestion and ligation in separate reactions, for example, when the desired ligase and desired endonuclease function optimally under different conditions, or when the ligation product forms a new restriction site for the endonuclease. In these instances, it may be better to perform restriction enzyme digestion followed by ligation separately, and perhaps even beneficial to remove the restriction enzyme before ligation. Nucleic acids can be separated from the enzyme by phenol-chloroform extraction, ethanol precipitation, magnetic bead capture, and / or silica membrane adsorption, washing, and elution. Multiple endonucleases can be used in the same reaction, but care should be taken to ensure that the endonucleases do not interfere with each other and function under similar reaction conditions. Two endonucleases can be used, with one endonuclease creating orthogonal (non-complementary) sticky ends at both ends of the dsDNA component.
[0204]
[0250] Endonuclease digestion leaves behind a phosphorylated 5' end at the sticky end. Ligase can only function on phosphorylated 5' ends, not on non-phosphorylated 5' ends. As such, there may be no need for an intermediate 5' phosphorylation step between digestion and ligation. Digested dsDNA components with palindromic overhangs at the sticky ends may ligate to themselves. To prevent self-ligation, it may be beneficial to dephosphorylate the dsDNA components before ligation.
[0205]
[0251] Multiple endonucleases can target different restriction sites but leave compatible overhangs (overhangs that are reverse complements of each other). Ligation of sticky-ends created with two such endonucleases can result in an assembled product that does not contain the restriction site of either endonuclease at the ligation site. Such endonucleases form the basis of assembly methods such as BioBrick assembly, which can programmably assemble multiple components using only two endonucleases by performing recursive digestion-ligation cycles. Figure 20 shows an example of a digestion-ligation cycle using the endonucleases BamHI and BglII with compatible overhangs.
[0206]
[0252] In some embodiments, the endonuclease used to create sticky ends can be a Type IIS restriction enzyme. These enzymes excise a fixed number of bases from their restriction site in a specific direction, thus allowing for customization of the sequence of the overhang generated by these enzymes. The overhang sequence does not need to be palindromic. The same Type IIS restriction enzyme can be used to create multiple different sticky ends in the same reaction or multiple reactions. Furthermore, one or more Type IIS restriction enzymes can be used to create components with compatible overhangs in the same reaction or multiple reactions. The ligation site between two sticky ends generated by a Type IIS restriction enzyme can be designed so that a new restriction site is not thereby formed. Furthermore, a Type IIS restriction enzyme site can be positioned in dsDNA such that the restriction enzyme cleaves its own restriction site as it generates the sticky-ended component. Thus, the ligation product between multiple components generated by a Type IIS restriction enzyme may not contain any restriction sites.
[0207]
[0253] A Type IIS restriction enzyme may be mixed with a ligase in a reaction to perform digestion and ligation of components together. The temperature of the reaction may be cycled between two or more values to promote optimal digestion and ligation. For example, digestion may be optimally performed at 37°C, and ligation may be optimally performed at 16°C. More generally, the reaction may be cycled between temperature values of at least 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, or 65°C or higher. Combined digestion and ligation reactions may be used to assemble at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 components, or more. Examples of assembly reactions that utilize Type IIS restriction enzymes to create sticky ends include Golden Gate Assembly (also known as Golden Gate Cloning) or Modular Cloning (also known as MoClo).
[0208]
[0254] In some ligation embodiments, exonucleases may be used to create components with sticky ends. 3' exonucleases are used to chew back 3' ends from dsDNA, thus creating 5' overhangs. Similarly, 5' exonucleases are used to chew back 5' ends from dsDNA, thus creating 3' overhangs. Different exonucleases may have different properties. For example, exonucleases may differ in the direction of their nuclease activity (5' to 3' or 3' to 5'), whether they act on ssDNA, whether they act on phosphorylated or non-phosphorylated 5' ends, whether they can initiate at a nick, or whether they can initiate their activity in a 5' recess, a 3' recess, a 5' overhang, or a 3' overhang. Different types of exonucleases include lambda exonuclease, RecJ, and the like. f , Exonuclease III, Exonuclease I, Exonuclease T, Exonuclease V, Exonuclease VIII, Exonuclease VII, Nuclease BAL_31, T5 Exonuclease, and T7 Exonuclease.
[0209]
[0255] An exonuclease can be used in a reaction together with a ligase to assemble multiple components. The reaction can be performed at a fixed temperature or cycled between temperatures ideal for each ligase or exonuclease. A polymerase can be included in the assembly reaction along with the ligase and 5' to 3' exonuclease. Components in such a reaction can be designed so that components intended to assemble adjacent to each other share homologous sequences at their edges. For example, component X to be assembled with component Y can have a 3' edge sequence in the form 5'-z-3', and component Y can have a 5' edge sequence in the form 5'-z-3', where z is any nucleic acid sequence. Homologous edge sequences in this form can be referred to as "Gibson overlaps." Chewback of the 5' ends of dsDNA components with Gibson overlaps by a 5' exonuclease creates compatible 3' overhangs that hybridize with each other. The hybridized 3' end can then be extended by the action of a polymerase to the end of the template component or to the point where the extended 3' overhang of one component fills the 5' recess of the adjacent component, thereby forming a nick that can be sealed by a ligase. Such assembly reactions using a polymerase, ligase, and exonuclease together are often referred to as "Gibson assembly." Gibson assembly can be performed using T5 exonuclease, Phusion polymerase, and Taq ligase and incubating the reaction at 50 degrees Celsius. In the above example, the use of Taq, a thermophilic ligase, allows the reaction to proceed at 50 degrees Celsius, a temperature suitable for all three types of enzymes in the reaction.
[0210]
[0256] The term "Gibson assembly" generally refers to any assembly reaction involving a polymerase, a ligase, and an exonuclease. Gibson assembly can be used to assemble at least two, three, four, five, six, seven, eight, nine, ten, or more components. Gibson assembly can be performed as a single-step isothermal reaction or as a multi-step reaction involving incubation at one or more temperatures. For example, Gibson assembly can be performed at temperatures of at least 30°C, 40°C, 50°C, 60°C, or 70°C, or lower. Gibson assembly incubation times can be at least 1 minute, 5 minutes, 10 minutes, 20 minutes, 40 minutes, or 80 minutes.
[0211]
[0257] Gibson assembly reactions are optimally performed when the Gibson overlap between intended adjacent components is of a specific length and has sequence features, such as sequences that avoid undesired hybridization events, such as hairpins, homodimers, or undesired heterodimers. Generally, a Gibson overlap of at least 20 bases is recommended. However, the Gibson overlap can be at least 1, 2, 3, 5, 10, 20, 30, 40, 50, 60, 100, or more bases in length. The GC content of the Gibson overlap can be anywhere between 0% and 100%.
[0212]
[0258] Although Gibson assembly is commonly described using a 5' exonuclease, the reaction can also be performed using a 3' exonuclease. The 3' exonuclease chews back the 3' end of a dsDNA component, which is counteracted by a polymerase extending the 3' end. This dynamic process can continue until the 5' overhangs (created by the exonuclease) of two components (that share a Gibson overlap) hybridize and the polymerase extends the 3' end of one component sufficiently to reach the 5' end of its adjacent component, thus leaving a nick that can be sealed by a ligase.
[0213]
[0259] In some ligation embodiments, sticky-ended components can be synthetically, as opposed to enzymatically, created by mixing together two single-stranded nucleic acids, or oligos, that do not share perfect complementarity. For example, two oligos, oligo X and oligo Y, can be designed to hybridize perfectly only along a contiguous stretch of complementary bases that forms a substrand of a larger stretch of bases that makes up the entirety of either or both of the oligos. This stretch of complementary bases is referred to as an "index region." When the index region occupies the entirety of oligo X and only the 5' end of oligo Y, the oligos combine to form a component with a blunt end on one side and a sticky end on the other side with a 3' overhang from oligo Y (Figure 30A). When the index region occupies the entirety of oligo X and only the 3' end of oligo Y, the oligos combine to form a component with a blunt end on one side and a sticky end on the other side with a 5' overhang from oligo Y (Figure 30B). When the index region occupies the entire oligo X but not either end of oligo Y (meaning the index region is embedded in the center of oligo Y), the oligos together form a component with a 3' overhang from oligo Y on one side and a 5' overhang from oligo Y on the other side (Figure 30C). When the index region occupies only the 5' end of oligo X and only the 5' end of oligo Y, the oligos together form a component with a 3' overhang from oligo Y on one side and a 3' overhang from oligo X on the other side (Figure 30D). When the index region occupies only the 3' end of oligo X and only the 3' end of oligo Y, the oligos together form a component with a 5' overhang from oligo Y on one side and a 5' overhang from oligo X on the other side (Figure 30E). In the above example, the sequence of the overhangs is defined by the oligo sequence outside the index region. These overhanging sequences may be referred to as hybridization regions, as this is the region to which the components hybridize for ligation.
[0214]
[0260] The index and hybridization regions of oligos in sticky end ligation can be designed to facilitate proper assembly of the components. Components with long overhangs can hybridize to each other more efficiently at a given annealing temperature compared to components with short overhangs. Overhangs can be at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, or more bases in length.
[0215]
[0261] Components with overhangs containing a high guanine or cytosine content may hybridize to their complementary components more efficiently at a given temperature than components with overhangs containing a low guanine or cytosine content. This is because guanine and cytosine form more stable base pairs than adenine and thymine. Overhangs can have a guanine or cytosine content (also known as GC content) anywhere between 0% and 100%.
[0216]
[0262] Similar to overhanging sequences, the GC content and length of an oligo's index region can also affect ligation efficiency. This is because sticky-end components can assemble more efficiently if the top and bottom strands of each component are stably linked. Therefore, index regions can be designed with higher GC content, longer sequences, and other features that promote higher melting temperatures. However, with regard to both index regions and overhanging sequences, there are many more aspects of oligo design that can affect the efficiency of ligation assembly. For example, the formation of undesired secondary structures within a component can hinder its ability to form assembled products with its intended neighboring components. This can occur due to secondary structures within the index region, the overhanging sequence, or both. These secondary structures can include hairpin loops. The types of possible secondary structures of oligos and their stability (e.g., melting temperature) can be predicted based on the sequence. Design space search algorithms can be used to determine oligo sequences that meet the appropriate length and GC content criteria for forming effective components, while avoiding sequences with potentially inhibitory secondary structures. The design space search algorithm may include a genetic algorithm, a heuristic search algorithm, a meta-heuristic search strategy such as tabu search, a branch and bound search algorithm, an algorithm based on dynamic programming, a constrained combinatorial optimization algorithm, an algorithm based on steepest descent, a randomized search algorithm, or a combination thereof.
[0217]
[0263] Similarly, the formation of homodimers (oligos that hybridize with oligos of the same sequence) and undesired heterodimers (oligos that hybridize with other oligos in addition to their intended assembly partners) can prevent ligation. Similar to secondary structure within components, homodimer and heterodimer formation can be predicted and accounted for using computational methods and design space search algorithms during oligo design.
[0218]
[0264] Longer oligo sequences or higher GC content can result in increased formation of undesired secondary structures, homodimers, and heterodimers in the ligation reaction. Therefore, in some embodiments, using shorter oligos or lower GC content can lead to higher assembly efficiency. These design principles can counteract design strategies that use long oligos or high GC content for more efficient assembly. Thus, there may be an optimal length and GC content for each component oligo that optimizes ligation assembly efficiency. The overall length of the oligos used for ligation can be at least 10 bases, 20 bases, 30 bases, 40 bases, 50 bases, 60 bases, 70 bases, 80 bases, 90 bases, or 100 bases, or more. The overall GC content of the oligos used for ligation can be anywhere between 0% and 100%.
[0219]
[0265] In addition to sticky-end ligation, ligation can also be performed using a staple (or template or bridge) strand between single-stranded nucleic acids. This method may be referred to as staple-strand ligation (SSL), template-directed ligation (TDL), or bridge-strand ligation. See Figure 19A for a schematic example of TDL for assembling three nucleic acids. In TDL, two single-stranded nucleic acids are hybridized adjacently on a template, thus forming a nick that can be sealed by a ligase. The same nucleic acid design considerations as for sticky-end ligation also apply to TDL. Stronger hybridization between templates and their intended complementary nucleic acid sequences can lead to increased ligation efficiency. Therefore, sequence features that improve hybridization stability (or melting temperature) on both sides of the template can improve ligation efficiency. These features may include longer sequence length and higher GC content. The length of the nucleic acid in the TDL, including the template, can be at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 bases, or more. The GC content of the nucleic acid, including the template, can be anywhere between 0% and 100%.
[0220]
[0266] In TDL, as with sticky end ligation, care can be taken to design component and template sequences that avoid undesired secondary structures by using nucleic acid structure prediction software that employs sequence space search algorithms. Because the components in TDL can be single-stranded instead of double-stranded, the incidence of undesired secondary structures (compared to sticky end ligation) can be higher due to exposed bases.
[0221]
[0267] TDL can also be performed using blunt-ended dsDNA components. In such reactions, the staple strands may first need to replace or partially replace their complete single-stranded complements in order for them to properly bridge two single-stranded nucleic acids. To facilitate TDL reactions using dsDNA components, the dsDNA can first be melted by incubation at high temperatures. The reaction can then be cooled, thus allowing the staple strands to anneal to their appropriate nucleic acid complements. This process can be made even more efficient by using a relatively high concentration of template compared to the dsDNA components, thereby allowing the template to outcompete the appropriate full-length ssDNA complement for binding. Once the two ssDNA strands are assembled by their template and ligase, the assembled nucleic acid can serve as a template for the inverse full-length ssDNA complement. Therefore, ligation of blunt-ended dsDNA using TDL can be improved through multiple rounds of melting (incubation at higher temperatures) and annealing (incubation at lower temperatures). This process may be referred to as ligase cycling reaction, or LCR. The melting and annealing temperatures depend on the nucleic acid sequence. The melting and annealing temperatures may be at least 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 degrees Celsius. The number of temperature cycles may be at least 1, 5, 10, 15, 20, 15, 30, or more.
[0222]
[0268] All ligations can be performed in fixed-temperature or multi-temperature reactions. Ligation temperatures can be at least 0, 4, 10, 20, 30, 40, 50, or 60 degrees Celsius, or higher. The optimal temperature for ligase activity can vary depending on the type of ligase. Furthermore, the rate at which components align or hybridize in a reaction can vary depending on their nucleic acid sequences. Higher incubation temperatures can promote faster diffusion and thus increase the frequency at which components align or hybridize temporarily. However, elevated temperatures can also result in the disruption of base-pair hydrogen bonds and, therefore, reduced stability of the aligning or hybridizing component duplexes. The optimal ligation temperature can depend on the number of nucleic acids to be assembled, the sequences of those nucleic acids, the type of ligase, and other factors, such as reaction additives. For example, two sticky-end components with four-base complementary overhangs may assemble faster using T4 ligase at 4 degrees Celsius than using T4 ligase at 25 degrees Celsius. However, two sticky-end components with 25-base complementary overhangs may assemble faster using T4 ligase at 25 degrees Celsius than using T4 ligase at 4 degrees Celsius, and likely faster than ligating four-base overhangs at either temperature. In some ligation embodiments, it may be beneficial to heat and slowly cool the components for annealing before adding the ligase.
[0223]
[0269] Ligation can be used to assemble at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more nucleic acids. Ligation incubation times can be up to 30 seconds, 1 minute, 2 minutes, 5 minutes, 10 minutes, 20 minutes, 30 minutes, 1 hour, or longer. Longer incubation times can improve ligation efficiency.
[0224]
[0270] Ligation may require nucleic acids with 5' phosphorylated ends. Nucleic acid components without 5' phosphorylated ends can be phosphorylated by reaction with a polynucleotide kinase such as T4 polynucleotide kinase (or T4 PNK). Other cofactors, such as ATP, magnesium ions, or DTT, may be present in the reaction. The polynucleotide kinase reaction can be performed at 37°C for 30 minutes. The polynucleotide kinase reaction temperature can be at least 4, 10, 20, 30, 40, 50, or 60°C. The incubation time for the polynucleotide kinase reaction can be up to 1 minute, 5 minutes, 10 minutes, 20 minutes, 30 minutes, 60 minutes, or longer. Alternatively, nucleic acid components can be synthetically designed and manufactured (as opposed to enzymatically) with modified 5' phosphorylation. Only nucleic acids that are assembled at their 5' ends may require phosphorylation. For example, templates in TDLs do not need to be phosphorylated because they are not to be assembled.
[0225]
[0271] To improve ligation efficiency, additives can be included in the ligation reaction. For example, dimethyl sulfoxide (DMSO), polyethylene glycol (PEG), 1,2-propanediol (1,2-Pr), glycerol, Tween®-20, or a combination thereof can be added. PEG 6000 can be a particularly effective ligation enhancer. PEG 6000 can increase ligation efficiency by acting as a crowding agent. For example, PEG 6000 can form aggregated clumps that occupy space in the ligase reaction solution, bringing the ligase and components closer together. The additive content (weight / volume) can be at least 0%, 1%, 5%, 10%, 20%, or more.
[0226]
[0272] Various ligases can be used for ligation. Ligases can be naturally occurring or synthetic. Examples of ligases include T4 DNA ligase, T7 DNA ligase, T3 DNA ligase, Taq DNA ligase, 9o Examples of suitable ligases include N™ DNA ligase, E. coli DNA ligase, and Splint® DNA ligase. Different ligases may be stable and function optimally at different temperatures. For example, Taq DNA ligase is thermostable, while T4 DNA ligase is not. Furthermore, different ligases have different properties. For example, T4 DNA ligase can ligate blunt-ended dsDNA, while T7 DNA ligase cannot ligate blunt-ended dsDNA.
[0227]
[0273] Ligation can be used to attach sequencing adapters to a library of nucleic acids. For example, ligation can be performed using a common sticky end or staple at the end of each member of the nucleic acid library. Sequencing adapters can be asymmetrically ligated when the sticky end or staple at one end of the nucleic acid is distinct from that at the other end. For example, a forward sequencing adapter can be ligated to one end of a member of the nucleic acid library, and a reverse sequencing adapter can be ligated to the other end of the member of the nucleic acid library. Alternatively, blunt-ended ligation can be used to attach adapters to a library of blunt-ended double-stranded nucleic acids. Forked adapters can be used to asymmetrically attach adapters to a nucleic acid library with equivalent blunt or sticky ends at each end (e.g., A-tails, etc.).
[0228]
[0274] Ligation can be inhibited by heat inactivation (eg, incubation at 65 degrees Celsius for at least 20 minutes), addition of denaturing agents, or addition of chelating agents such as EDTA.
[0229] C. Restriction enzyme digestion
[0275] Restriction enzyme digestion is a reaction in which restriction endonucleases (or restriction enzymes) recognize their cognate restriction sites on nucleic acids and then cleave (or digest) the nucleic acid containing the restriction site. Type I, II, III, or IV restriction enzymes can be used for restriction enzyme digestion. Type II restriction enzymes may be the most efficient restriction enzymes for nucleic acid digestion. Type II restriction enzymes can recognize palindromic restriction sites and cleave the nucleic acid within the recognition site. Examples of such restriction enzymes (and their restriction sites) include AatII (GACGTC), AfeI (AGCGCT), ApaI (GGGCCC), DpnI (GATC), EcoRI (GAATTC), NgeI (GCTAGC), and many more. Some restriction enzymes, such as DpnI and AfeI, can cleave their restriction sites in the middle, thus leaving a blunt-ended dsDNA product. Other restriction enzymes, such as EcoRI and AatII, cut their restriction sites off-center, thus leaving a dsDNA product with sticky (or staggered) ends. Some restriction enzymes can target discontinuous restriction sites. For example, the restriction enzyme AlwNI recognizes the restriction site CAGNNNCTG, where N can be either A, T, C, or G. Restriction sites can be at least 2, 4, 6, 8, 10, or more bases in length.
[0230]
[0276] Some type II restriction enzymes cleave nucleic acids outside their restriction sites. These enzymes may be subclassified as type IIS or type IIG restriction enzymes. These enzymes may recognize non-palindromic restriction sites. An example of such an enzyme is BbsI, which recognizes GAAAC and makes staggered cuts 2 bases (on the same strand) and 6 bases (on the opposite strand) further downstream. Another example is BsaI, which recognizes GGTCTC and makes staggered cuts 1 base (on the same strand) and 5 bases (on the opposite strand) further downstream. These restriction enzymes may be used in Golden Gate assembly or modular cloning (MoClo). Some restriction enzymes, such as BcgI (a type IIG restriction enzyme), can make staggered cuts at both ends of their recognition site. Restriction enzymes can cleave nucleic acids at least 1 base, 5 bases, 10 bases, 15 bases, 20 bases, or more away from their recognition site. Because these restriction enzymes can make staggered cuts outside their recognition sites, the sequences of the resulting nucleic acid overhangs can be arbitrarily designed. This is in contrast to restriction enzymes, which create staggered cuts within their recognition sites, where the sequence of the resulting nucleic acid overhang binds to the sequence of the restriction site. The nucleic acid overhangs created by restriction enzyme digestion can be at least 1, 2, 3, 4, 5, 6, 7, 8, or more bases in length. When a nucleic acid is cleaved by a restriction enzyme, the resulting 5' end contains a phosphate.
[0231]
[0277] One or more nucleic acid sequences can be included in a restriction enzyme digestion reaction. Similarly, one or more restriction enzymes can be used together in a restriction enzyme digestion reaction. The restriction enzyme digestion can include additives and cofactors, including potassium ions, magnesium ions, sodium ions, BSA, S-adenosyl-L-methionine (SAM), or combinations thereof. The restriction enzyme digestion reaction can be incubated at 37 degrees Celsius for 1 hour. The restriction enzyme digestion reaction can be incubated at a temperature of at least 0, 10, 20, 30, 40, 50, or 60 degrees Celsius. The optimal digestion temperature can depend on the enzyme. The restriction enzyme digestion reaction can be incubated for up to 1 minute, 10 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes, or longer. Longer incubation times can result in increased digestion.
[0232] D. Nucleic Acid Amplification
[0278] Nucleic acid amplification can be performed using polymerase chain reaction (PCR). In PCR, a starting pool of nucleic acids (referred to as a template pool or template) can be combined with a polymerase, primers (short nucleic acid probes), nucleotide triphosphates (e.g., dATP, dTTP, dCTP, dGTP, and analogs or variants thereof), and additional cofactors and additives such as betaine, DMSO, and magnesium ions. The template can be a single-stranded or double-stranded nucleic acid. Primers can be short nucleic acid sequences synthetically constructed to be complementary to and hybridize with target sequences in the template pool. A primer can bind to each identifier nucleic acid sequence containing the target sequence in the template pool to select only those identifier nucleic acid sequences containing the target sequence. Typically, two primers are present in a PCR reaction: one complementary to a primer binding site on the top strand of the target template, and the other complementary to a primer binding site on the bottom strand of the target template downstream of the first binding site. The 5' to 3' orientation of the primers binding to their targets must face each other to successfully replicate and exponentially amplify the nucleic acid sequence between them. "PCR" typically refers specifically to this form of reaction, but can also be used more generally to refer to any nucleic acid amplification reaction.
[0233]
[0279] In some embodiments, PCR may involve cycling between three temperatures: a melting temperature, an annealing temperature, and an extension temperature. The melting temperature is intended to convert double-stranded nucleic acids into single-stranded nucleic acids and eliminate the formation of hybridization products and secondary structures. Typically, the melting temperature is high, e.g., greater than 95°C. In some embodiments, the melting temperature may be at least 96, 97, 98, 99, 100, 101, 102, 103, 104, or 105°C. In other embodiments, the melting temperature may be up to 95, 94, 93, 92, 91, or 90°C. A higher melting temperature improves the dissociation of nucleic acids and their secondary structures, but may also cause side effects, such as degradation of the nucleic acids or polymerase. The melting temperature may be applied to the reaction for at least 1 second, 2 seconds, 3 seconds, 4 seconds, 5 seconds, or longer, e.g., 30 seconds, 1 minute, 2 minutes, or 3 minutes. A longer initial melting temperature step may be recommended for PCR with complex or long templates.
[0234]
[0280] The annealing temperature is intended to facilitate the formation of hybridization between the primers and their target templates. In some embodiments, the annealing temperature may correspond to the calculated melting temperature of the primers. In other embodiments, the annealing temperature may be within 10 degrees Celsius or more of the melting temperature. In some embodiments, the annealing temperature may be at least 25, 30, 50, 55, 60, 65, or 70 degrees Celsius. The melting temperature may depend on the sequence of the primer. Longer primers may have higher melting temperatures, and primers with a higher percentage of guanine or cytosine nucleotides may have higher melting temperatures. Therefore, it may be possible to design primers that are designed to assemble optimally at a specific annealing temperature. The annealing temperature may be applied to the reaction for at least 1 second, 5 seconds, 10 seconds, 15 seconds, 20 seconds, 25 seconds, or 30 seconds, or longer. To help ensure annealing, primer concentrations or saturating amounts may be used. Primer concentrations can be 500 nanomolar (nM). Primer concentrations can be up to 1 nM, 10 nM, 100 nM, 1000 nM, or higher.
[0235]
[0281] The extension temperature is intended to initiate and facilitate nucleic acid chain extension of the 3' end of the primer, catalyzed by one or more polymerase enzymes. In some embodiments, the extension temperature can be set to a temperature at which the polymerase functions optimally in terms of nucleic acid binding strength, extension speed, extension stability, or fidelity. In some embodiments, the extension temperature can be at least 30, 40, 50, 60, or 70 degrees Celsius, or higher. The annealing temperature can be applied to the reaction for at least 1 second, 5 seconds, 10 seconds, 15 seconds, 20 seconds, 25 seconds, 30 seconds, 40 seconds, 50 seconds, or 60 seconds, or longer. The recommended extension time can be approximately 15 to 45 seconds per kilobase of expected extension.
[0236]
[0282] In some embodiments of PCR, the annealing temperature and the extension temperature can be the same. Thus, a two-step temperature cycle can be used instead of a three-step temperature cycle. Examples of combined annealing and extension temperatures include 60, 65, or 72 degrees Celsius.
[0237]
[0283] In some embodiments, PCR can be performed in one temperature cycle. Such embodiments can involve converting targeted single-stranded template nucleic acids into double-stranded nucleic acids. In other embodiments, PCR can be performed in multiple temperature cycles. If PCR is efficient, it is expected that the number of target nucleic acid molecules will double with each cycle, thereby resulting in an exponential increase in the number of targeted nucleic acid templates from the original template pool. PCR efficiency can vary. Therefore, the actual percentage of targeted nucleic acids replicated in each round may be more or less than 100%. Undesirable artifacts, such as mutated and recombined nucleic acids, can be introduced with each PCR cycle. To reduce this potential harm, high-fidelity, high-processivity polymerases can be used. Furthermore, a limited number of PCR cycles can be used. PCR can involve up to 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, or more cycles.
[0238]
[0284] In some embodiments, multiple distinct target nucleic acid sequences can be amplified together in a single PCR. If each target sequence has a common primer binding site, all nucleic acid sequences can be amplified using the same primer set. Alternatively, the PCR can include multiple primers, each intended to target a distinct nucleic acid. Such a PCR can be referred to as multiplex PCR. The PCR can involve up to one, two, three, four, five, six, seven, eight, nine, ten, or more distinct primers. In PCR with multiple distinct nucleic acid targets, each PCR cycle can change the relative distribution of the targeted nucleic acids. For example, a uniform distribution can become skewed or non-uniform. To mitigate this potential harm, an optimal polymerase (e.g., with high fidelity and sequence robustness) and optimal PCR conditions can be used. Factors such as annealing and extension temperature and time can be optimized. Furthermore, a limited number of PCR cycles can be used.
[0239]
[0285] In some embodiments of PCR, a primer with a base mismatch to its targeting primer binding site in the template can be used to mutate the target sequence. In some embodiments of PCR, a primer with an extra sequence (known as an overhang) at the 5' end can be used to attach a sequence to its targeted nucleic acid. For example, a primer containing a sequencing adapter at the 5' end can be used to prepare and / or amplify a nucleic acid library for sequencing. For sufficient enrichment for a particular sequencing technique, a primer targeting the sequencing adapter can be used to amplify a nucleic acid library.
[0240]
[0286] In some embodiments, linear PCR (or asymmetric PCR) is used, in which primers target only one strand of the template (rather than both strands). In linear PCR, the nucleic acid replicated from each cycle is not complementary to the primer, and therefore the primer does not bind to that nucleic acid. Thus, the primer replicates only the original target template in each cycle, resulting in linear (as opposed to exponential) amplification. Amplification from linear PCR may not be as fast as conventional (exponential) PCR, but the maximum yield may be greater. Theoretically, primer concentration in linear PCR is not a limiting factor in increasing cycles and yield, as it is in conventional PCR. Linear-After-The-Exponential-PCR (or LATE-PCR) is a modified version of linear PCR that may enable particularly high yields.
[0241]
[0287] In some embodiments of nucleic acid amplification, the melting, annealing, and extension processes can occur at a single temperature. Such PCR can be referred to as isothermal PCR. Isothermal PCR can utilize temperature-independent methods to dissociate or displace sufficiently complementary nucleic acid strands from each other to favor primer binding. Strategies include loop-mediated isothermal amplification, strand displacement amplification, helicase-dependent amplification, and nicking enzyme amplification reactions. Isothermal nucleic acid amplification can occur at temperatures up to 20, 30, 40, 50, 60, or 70 degrees Celsius or higher.
[0242]
[0288] In some embodiments, PCR may further include a fluorescent probe or dye for quantifying the amount of nucleic acid in a sample. For example, the dye may intercalate into double-stranded nucleic acid. An example of such a dye is SYBR Green. The fluorescent probe may be a nucleic acid sequence with a fluorescent unit attached. The fluorescent unit may be released when the probe hybridizes to the target nucleic acid and is subsequently modified from the elongating polymerase unit. An example of such a probe is a TaqMan probe. Such a probe may be used in conjunction with PCR and optical measurement tools (for excitation and detection) to quantify the concentration of nucleic acid in a sample. This process may be referred to as quantitative PCR (qPCR) or real-time PCR (rtPCR).
[0243]
[0289] In some embodiments, PCR can be performed on a single molecular template rather than on a pool of multiple template molecules (a process that may be referred to as single-molecule PCR). For example, emulsion-PCR (ePCR) can be used to encapsulate a single nucleic acid molecule within an aqueous droplet in an oil emulsion. The droplets can also contain PCR reagents, and the droplets can be maintained in a temperature-controlled environment that allows for the necessary temperature cycling for PCR. In this way, multiple self-contained PCR reactions can be performed simultaneously with high throughput. Surfactants can be used to improve the stability of the oil emulsion. Pressure can be used through microfluidic channels to control the movement of the droplets. Microfluidic devices can be used to create droplets, split droplets, coalesce droplets, inject materials into droplets, and incubate droplets. The size of the aqueous droplets in the oil emulsion can be at least 1 picoliter (pL), 10 pL, 100 pL, 1 nanoliter (nL), 10 nL, 100 nL, or larger.
[0244]
[0290] In some embodiments, single molecule PCR can be carried out on a solid support. Examples include Illumina solid-phase amplification or its variants. A template pool is exposed to a solid support, where the solid support can immobilize the template with specific spatial resolution. Then, bridge amplification is carried out in the spatial vicinity of each template, thereby amplifying single molecules on the support in a high-throughput manner.
[0245]
[0291] High-throughput single-molecule PCR can be useful for amplifying a pool of distinguishable nucleic acids that may interfere with each other. For example, if multiple distinguishable nucleic acids share a common sequence region, recombination between the nucleic acids along this common region may occur during the PCR reaction, resulting in a new, recombined nucleic acid. In single-molecule PCR, distinguishable nucleic acid sequences are compartmentalized with each other and therefore cannot interact, preventing this potential amplification error. Single-molecule PCR can be particularly useful for preparing nucleic acids for sequencing. Single-molecule PCR can also be useful for absolute quantification of several targets in a template pool. For example, digital PCR (or dPCR) uses the frequency of distinguishable single-molecule PCR amplification signals to estimate the number of starting nucleic acid molecules in a sample.
[0246]
[0292] In some embodiments of PCR, primers directed to primer binding sites common to all nucleic acids can be used to non-discriminately amplify a group of nucleic acids. For example, primers directed to primer binding sites flanking all nucleic acids in a pool. These common sites can be used for general amplification to create or assemble a synthetic nucleic acid library. However, in some embodiments, PCR can be used to selectively amplify a subset of targeted nucleic acids from a pool, for example, by using primers with primer binding sites present only in a subset of the targeted nucleic acids. Synthetic nucleic acid libraries can be created or assembled such that all nucleic acids belonging to a potential sublibrary of interest share common primer binding sites at their edges (common within the sublibrary but distinct from other sublibraries) to selectively amplify the sublibrary from a more general library. In some embodiments, PCR can be combined with a nucleic acid assembly reaction (e.g., ligation or OEPCR) to selectively amplify fully assembled or potentially fully assembled nucleic acids from partially assembled or misassembled (or unintended or undesired) by-products. For example, assembly can involve assembling nucleic acids with a primer binding site on each edge sequence such that only the fully assembled nucleic acid product contains the two necessary primer binding sites for amplification. In the above example, a partially assembled product might contain neither or only one of the edge sequences with primer binding sites and therefore would not be amplified. Similarly, a misassembled (or unintended or undesired) product might contain neither or only one of the edge sequences, or contain both edge sequences but in the wrong orientation or separated by the wrong amount of bases. Thus, the misassembled product would not be amplified or would be amplified to create a product of the wrong length.In the latter case, amplified misassembled products of the incorrect length can be separated from amplified fully assembled products of the correct length by nucleic acid size selection methods such as DNA electrophoresis in an agarose gel followed by gel extraction (see Chemical Methods Section E).
[0247]
[0293] To improve the efficiency of nucleic acid amplification, additives may be included in PCR, such as betaine, dimethyl sulfoxide (DMSO), non-ionic surfactants, formamide, magnesium, bovine serum albumin (BSA), or combinations thereof. The additive content (weight / volume) may be at least 0%, 1%, 5%, 10%, 20%, or more.
[0248]
[0294] A variety of polymerases can be used for PCR. The polymerase may be naturally occurring or synthetic. An example of a polymerase is Φ29 polymerase or its derivatives. In some cases, a transcriptase or a ligase (i.e., an enzyme that catalyzes the formation of bonds) is used in conjunction with or as a substitute for a polymerase to construct new nucleic acid sequences. Examples of polymerases include DNA polymerase, RNA polymerase, thermostable polymerase, wild-type polymerase, modified polymerase, E. coli DNA polymerase I, T7 DNA polymerase, bacteriophage T4 DNA polymerase Φ29 (phi29) DNA polymerase, Taq polymerase, Tth polymerase, Tli polymerase, Pfu polymerase, Pwo polymerase, VENT polymerase, DEEPVENT polymerase, Ex-Taq polymerase, LA-Taw polymerase, Sso polymerase, Poc polymerase, Pab polymerase, Mth polymerase, ES4 polymerase, Tru polymerase, Tac polymerase, Tne polymerase, Tma polymerase, Tca polymerase, Tih polymerase, Tfi polymerase, Platinum Examples of polymerases include Taq polymerase, Tbr polymerase, Phusion polymerase, KAPA polymerase, Q5 polymerase, Tfl polymerase, Pfutubo polymerase, Pyrobest polymerase, KOD polymerase, Bst polymerase, Sac polymerase, and Klenow fragment polymerase with 3' to 5' exonuclease activity, as well as variants, modified products, and derivatives thereof. Different polymerases may be stable and function optimally at different temperatures. Furthermore, different polymerases have different properties. For example, some polymerases, such as Phusion polymerase, may exhibit 3' to 5' exonuclease activity, which may contribute to higher fidelity during nucleic acid elongation. Some polymerases may replace leading sequences during elongation, while others may degrade them or terminate elongation. Some polymerases, such as Taq, incorporate an adenine base at the 3' end of a nucleic acid sequence.Additionally, some polymerases may have higher fidelity and processivity than others and may be more suitable for PCR applications such as sequencing preparation where it is important to have minimal mutations for amplified nucleic acid yield and where it is important to maintain a uniform distribution throughout the amplification for distinct nucleic acid distribution.
[0249] E. Size Selection
[0295] Size selection techniques can be used to select nucleic acids of specific sizes from a sample. In some embodiments, size selection can be performed using gel electrophoresis or chromatography. A liquid sample of nucleic acids can be loaded onto one terminal of a stationary phase or gel (or matrix). A voltage difference can be applied across the gel, with the negative terminal of the gel being the terminal onto which the nucleic acid sample is loaded and the positive terminal of the gel being the opposite terminal. Because nucleic acids have a negatively charged phosphate backbone, they migrate across the gel to the positive terminal. The size of the nucleic acid determines the relative migration speed of the nucleic acid through the gel. Thus, nucleic acids of different sizes are resolved as they migrate across the gel. The voltage difference can be 100V or 120V. The voltage difference can be up to 50V, 100V, 150V, 200V, 250V, or greater. A larger voltage difference can increase the speed of nucleic acid migration and size resolution. However, a larger voltage difference can also cause damage to the nucleic acid or the gel. A larger voltage difference may be recommended to resolve larger sized nucleic acids. Typical migration time can be between 15 minutes and 60 minutes. Migration time can be up to 10 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes, or longer. As with higher voltage, longer migration time can lead to better nucleic acid resolution, but can also lead to increased nucleic acid damage. For decomposing larger-sized nucleic acids, longer migration time may be recommended. For example, a voltage difference of 120V and a migration time of 30 minutes may be sufficient to decompose a 200-base nucleic acid from a 250-base nucleic acid.
[0250]
[0296] The nature of the gel, or matrix, can affect the size selection process. Gels generally contain polymeric materials such as agarose or polyacrylamide dispersed in a conductive buffer such as TAE (Tris-acetate-EDTA) or TBE (Tris-borate-EDTA). The content (weight / volume) of material (e.g., agarose or acrylamide) in the gel can be up to 5%, 1%, 2%, 3%, 5%, 10%, 15%, 20%, 25%, or more. Higher contents can slow migration speeds. Higher contents may be preferred for resolving smaller nucleic acids. Agarose gels may be better for resolving double-stranded DNA (dsDNA). Polyacrylamide gels may be better for resolving single-stranded DNA (ssDNA). The preferred gel composition may depend on the nucleic acid type and size, compatibility of additives (e.g., dyes, stains, denaturing solutions, or loading buffers), and the anticipated downstream application (e.g., gel extraction followed by ligation, PCR, or sequencing). Agarose gels may be simpler than polyacrylamide gels for gel extraction. TAE is not as good a conductor as TBE, but may be better for gel extraction as well, since borate (an enzyme inhibitor) carryover contamination in the extraction process can inhibit downstream enzymatic reactions.
[0251]
[0297] The gel may further contain a denaturing solution such as SDS (sodium dodecyl sulfate) or urea. SDS may be used, for example, to denature proteins or to separate nucleic acids from potentially bound proteins. Urea may be used to denature the secondary structure of DNA. For example, urea can convert dsDNA to ssDNA, or urea can convert folded ssDNA (e.g., hairpins) to unfolded ssDNA. Urea-polyacrylamide gels (which further contain TBE) can be used to precisely resolve ssDNA.
[0252]
[0298] Samples can be incorporated into gels in different formats. In some embodiments, gels can include wells into which samples can be manually loaded. A single gel can have multiple wells for running multiple nucleic acid samples. In other embodiments, gels can be attached to microfluidic channels into which nucleic acid samples are automatically loaded. Each gel can be downstream of several microfluidic channels, or the gel itself can occupy a separate microfluidic channel. The dimensions of the gel can affect the sensitivity of nucleic acid detection (or visualization). For example, thin gels or gels inside microfluidic channels (such as those in bioanalyzers or tape stations) can improve the sensitivity of nucleic acid detection. The nucleic acid detection step can be important for selecting and extracting nucleic acid fragments of the correct size.
[0253]
[0299] A ladder can be loaded onto the gel for nucleic acid size reference. The ladder can contain markers of various sizes that can be used to compare nucleic acid samples. Different ladders can have different size ranges and resolutions. For example, a 50-base ladder can have markers at 50 bases, 100 bases, 150 bases, 200 bases, 250 bases, 300 bases, 350 bases, 400 bases, 450 bases, 500 bases, 550 bases, and 600 bases. The ladder can be useful for detecting and selecting nucleic acids within the size range of 50 to 600 bases. The ladder can also be used as a standard to estimate the concentration of nucleic acids of various sizes in a sample.
[0254]
[0300] The nucleic acid sample and ladder may be mixed with a loading buffer to facilitate the gel electrophoresis (or chromatography) process. The loading buffer may contain dyes and markers to aid in tracking the migration of nucleic acids. The loading buffer may further contain a reagent (e.g., glycerol, etc.) that is denser than the running buffer (e.g., TAE or TBE) to ensure that the nucleic acid sample sinks to the bottom of the sample loading well (which may be immersed in the running buffer). The loading buffer may further contain a denaturant such as SDS or urea. The loading buffer may further contain a reagent to improve the stability of the nucleic acid. For example, the loading buffer may contain EDTA to protect the nucleic acid from nucleases.
[0255]
[0301] In some embodiments, the gel may contain dyes that bind to nucleic acids and can be used to optically detect nucleic acids of different sizes. The dyes may be specific for dsDNA, ssDNA, or both. Different dyes can be compatible with different gel materials. Some dyes require excitation from a light source (or electromagnetic radiation) for visualization. The light source may be UV (ultraviolet) or blue light. In some embodiments, the dyes may be added to the gel before electrophoresis. In other embodiments, the dyes may be added to the gel after electrophoresis. Examples of dyes include ethidium bromide (EtBr), SYBR Safe, SYBR Gold, silver stain, or methylene blue. A reliable method for visualizing dsDNA of specific sizes may be, for example, using an agarose-TAE gel with SYBR Safe or EtBr stain. A reliable method for visualizing ssDNA of specific sizes may be, for example, using a urea-polyacrylamide TBE gel with methylene blue or silver stain.
[0256]
[0302] In some embodiments, the movement of nucleic acids through the gel can be driven by other methods in addition to electrophoresis, for example, gravity, centrifugation, vacuum, or pressure can be used to drive nucleic acids through the gel and thereby resolve them according to size.
[0257]
[0303] Nucleic acids of a specific size can be extracted from the gel using a blade or razor, and the gel band containing the nucleic acid can be excised. Appropriate optical detection techniques and DNA ladders can be used to ensure that excision is performed accurately on the specific band and that excision successfully eliminates nucleic acids that may belong to bands of different, undesired sizes. The gel band can be incubated with a buffer to dissolve the gel band, thus releasing the nucleic acid into the buffer solution. Heating or physical agitation can be used to speed up the dissolution. Alternatively, the gel band can be incubated in the buffer long enough to allow diffusion of the DNA into the buffer solution without the need for gel dissolution. The buffer can then be separated from the remaining solid-phase gel, for example, by aspiration or centrifugation. The nucleic acid can then be purified from the solution using standard purification or buffer exchange techniques, such as phenol-chloroform extraction, ethanol precipitation, magnetic bead capture, and / or silica membrane adsorption, washing, and elution. Nucleic acids can also be concentrated in this step.
[0258]
[0304] As an alternative to gel excision, nucleic acids of a specific size can be separated from the gel by allowing them to flow out of the gel. The migrating nucleic acids can pass through a basin (or well) embedded in the gel or at the end of the gel. The migration process can be timed or optically monitored, and thus, once a population of nucleic acids of a specific size has entered the basin, the sample can be collected from the basin. Collection can be performed, for example, by aspiration. The nucleic acids can then be purified from the collected solution using standard purification or buffer exchange techniques, such as phenol-chloroform extraction, ethanol precipitation, magnetic bead capture, and / or silica membrane adsorption, washing, and elution. Nucleic acids can also be concentrated in this step.
[0259]
[0305] Other methods for nucleic acid size selection can include mass spectrometry or membrane-based filtration. In some embodiments of membrane-based filtration, nucleic acids are passed through a membrane (e.g., a silica membrane) that can preferentially bind either dsDNA, ssDNA, or both. The membrane can be designed to preferentially capture nucleic acids of at least a specific size. For example, the membrane can be designed to filter out nucleic acids that are less than 20 bases, less than 30 bases, less than 40 bases, less than 50 bases, less than 70 bases, less than 90 bases, or more than that. The membrane-based size selection techniques may not be as stringent as gel electrophoresis or chromatography.
[0260] F. Nucleic acid capture
[0306] Affinity-tagged nucleic acids can be used as sequence-specific probes for nucleic acid capture. The probe can be designed to be complementary to a target sequence in a pool of nucleic acids. The probe can then be incubated with the nucleic acid pool and hybridized to the target. The incubation temperature can be below the melting temperature of the probe to facilitate hybridization. The incubation temperature can be up to 5, 10, 15, 20, 25, or more degrees Celsius below the melting temperature of the probe. The hybridized target can be captured on a solid support that specifically binds to the affinity tag. The solid support can be a membrane, well, column, or bead. Multiple rounds of washing can remove all unhybridized nucleic acids from the target. Washing can be performed at a temperature below the melting temperature of the probe to facilitate stable immobilization of the target sequence during washing. The washing temperature can be up to 5 degrees Celsius below, 10 degrees Celsius below, 15 degrees Celsius below, 20 degrees Celsius below, 25 degrees Celsius below, or more than that below the melting temperature of the probe. A final elution step can recover the nucleic acid target from the solid support and from the affinity-tagged probe. The elution step can be performed at a temperature above the melting temperature of the probe to facilitate release of the nucleic acid target into the elution buffer. The elution temperature can be up to 5 degrees Celsius above, 10 degrees Celsius above, 15 degrees Celsius above, 20 degrees Celsius above, 25 degrees Celsius above, or more than that above the melting temperature of the probe.
[0261]
[0307] In certain embodiments, oligonucleotides bound to a solid support can be removed from the solid support by exposure to conditions such as acid, base, oxidation, reduction, heat, light, metal ion catalysis, displacement, or elimination chemical reactions, or by enzymatic cleavage. In certain embodiments, oligonucleotides can be attached to the solid support through a cleavable linkage moiety. For example, the solid support can be functionalized to provide a cleavable linker for covalently binding to a targeted oligonucleotide. In some embodiments, the linker moiety can be six or more atoms long. In some embodiments, the cleavable linker can be a TOPS (two oligonucleotides per synthesis) linker, an amino linker, or a photocleavable linker.
[0262]
[0308] In some embodiments, biotin can be used as an affinity tag immobilized by streptavidin on a solid support. Biotinylated oligos can be designed and manufactured for use as nucleic acid capture probes. The 5' or 3' end of an oligo can be biotinylated. Internal thymine residues in an oligo can be biotinylated. Increasing the amount of biotin on an oligo can result in stronger capture on a streptavidin support. Biotin at the 3' end of an oligo can block oligo extension during PCR. The biotin tag can be a variant of standard biotin. For example, biotin variants can be biotin-TEG (triethylene glycol), double biotin, PC-biotin, desthiobiotin-TEG, and azide-biotin. Double biotin can increase biotin-streptavidin affinity. Biotin-TEG is attached to biotin groups on a nucleic acid separated by a TEG linker. This prevents biotin from interfering with the function of the nucleic acid probe, for example, hybridization with its target. A nucleic acid biotin linker can also be attached to the probe. The nucleic acid linker can include a nucleic acid sequence that is not intended to hybridize with the target.
[0263]
[0309] Biotinylated nucleic acid probes can be designed with consideration for how well they hybridize to their targets. Nucleic acid probes designed with a high melting temperature can hybridize more strongly to their targets. Longer nucleic acid probes and probes with a higher GC content can hybridize more strongly due to the increased melting temperature. Nucleic acid probes can have a length of at least 5, 10, 15, 20, 30, 40, 50, or 100 bases, or more. Nucleic acid probes can have a GC content anywhere between 0% and 100%. Care can be taken to ensure that the melting temperature of the probe does not exceed the temperature tolerance of the streptavidin carrier. Nucleic acid probes can be designed to avoid inhibitory secondary structures, such as hairpins, homodimers, and heterodimers with off-target nucleic acids. There can be a trade-off between probe melting temperature and off-target binding length. There can be an optimal probe length and GC content that results in a high melting temperature and low off-target binding. Synthetic nucleic acid libraries can be designed such that the nucleic acids contain efficient probe binding sites.
[0264]
[0310] The solid-phase streptavidin substrate can be magnetic beads. The magnetic beads can be immobilized using a magnetic strip or plate. The magnetic strip or plate is contacted with a container to immobilize the magnetic beads in the container. Conversely, the magnetic strip or plate can be removed from the container to release the magnetic beads from the container wall into solution. The properties of different beads can affect their application. The beads can have various sizes. For example, the beads can be anywhere from 1 micrometer (μm) to 3 micrometers (μm) in diameter. The beads can have diameters up to 1 micrometer, 2 micrometers, 3 micrometers, 4 micrometers, 5 micrometers, 10 micrometers, 15 micrometers, 20 micrometers, or more. The bead surface can be hydrophobic or hydrophilic. The beads can be coated with a blocking protein, such as BSA. Before use, the beads can be washed or pretreated with an additive, such as a blocking solution, to prevent nonspecific binding of the beads to nucleic acids.
[0265]
[0311] The biotinylated probe can be bound to magnetic streptavidin beads and then incubated with a nucleic acid sample pool. This process can be called direct capture. Alternatively, the biotinylated probe can be incubated with a nucleic acid sample pool and then magnetic streptavidin beads can be added. This process can be called indirect capture. The indirect capture method can improve the target yield. The shorter the nucleic acid probe, the less time it takes to bind to the magnetic beads.
[0266]
[0312] Optimal incubation of nucleic acid probes with nucleic acid samples may be performed at temperatures 1-10 degrees Celsius or greater below the melting temperature of the probe. Incubation temperatures may be up to 5, 10, 20, 30, 40, 50, 60, 70, 80, or higher. The recommended incubation time may be 1 hour. Incubation times may be up to 1, 5, 10, 20, 30, 60, 90, 120, or longer. Longer incubation times may lead to better capture efficiency. An additional 10 minutes of incubation may be performed after the addition of streptavidin beads to allow biotin-streptavidin binding. This additional time may be up to 1, 5, 10, 20, 30, 60, 90, 120, or longer. The incubation may be carried out in a buffered solution with additives such as sodium ions.
[0267]
[0313] If the nucleic acid pool is single-stranded (as opposed to double-stranded), hybridization of the probe to its target can be improved. Preparing a ssDNA pool from a dsDNA pool may generally require performing linear PCR using a single primer that binds to the edge of all nucleic acid sequences in the pool. If the nucleic acid pool is synthetically generated or assembled, this common primer binding site can be included in the synthetic design. The product of linear PCR will be ssDNA. More starting ssDNA templates for nucleic acid capture can be generated with more cycles of linear PCR. See Chemical Methods Section D for PCR.
[0268]
[0314] After the nucleic acid probe hybridizes to the target and binds to the magnetic streptavidin beads, the beads can be immobilized with a magnet and subjected to several rounds of washing. Three to five washes may be sufficient to remove non-target nucleic acids, although more or fewer wash rounds may be used. Each additional wash may further reduce non-target nucleic acids, but may also reduce the yield of target nucleic acid. To facilitate proper hybridization of the target nucleic acid and probe during the wash steps, low incubation temperatures can be used. Temperatures as low as 60, 50, 40, 30, 20, 10, or 5 degrees Celsius or lower may be used. The wash buffer may comprise a Tris-buffered solution with sodium ions.
[0269]
[0315] Optimal elution of hybridized targets from magnetic bead-bound probes can be performed at a temperature equal to or higher than the melting temperature of the probe. The higher the temperature, the easier it is for the target to dissociate from the probe. The elution temperature can be up to 30, 40, 50, 60, 70, 80, or 90 degrees Celsius, or higher. The elution incubation time can be up to 1, 2, 5, 10, 30, 60, or longer. A typical incubation time can be approximately 5 minutes, although longer incubation times can improve yields. The elution buffer can be water or a Tris-buffered solution with an additive such as EDTA.
[0270]
[0316] The nucleic acid capture of a target sequence that contains at least one or more of a set of distinguishable sites can be carried out in one reaction using a plurality of separate probes for each of these sites.The nucleic acid capture of a target sequence that includes all members of a set of distinguishable sites can be carried out in a series of capture reactions, one reaction for each separate site using a probe for that specific site.Although the yield of target after a series of capture reactions may be low, the captured target can then be amplified by PCR.When a nucleic acid library is synthetically designed, the target can be designed to have a common primer binding site for PCR.
[0271]
[0317] Synthetic nucleic acid libraries can be created or assembled with common probe binding sites for general nucleic acid capture. These common sites can be used to selectively capture fully assembled or potentially fully assembled nucleic acids from an assembly reaction, thereby filtering out partially assembled or misassembled (or unintended or undesired) by-products. For example, assembly can involve assembling nucleic acids with probe binding sites at each edge sequence such that only fully assembled nucleic acid products contain the requisite two probe binding sites necessary to pass through a series of two capture reactions using each probe. In the above example, partially assembled products may contain none or only one of the probe sites and therefore would not ultimately be captured. Similarly, misassembled (or unintended or undesired) products may contain none or only one of the edge sequences. Thus, such misassembled products may not ultimately be captured. To increase stringency, each component of the assembly can include a common probe binding site. Subsequent series of nucleic acid capture reactions using probes for each component can separate only the fully assembled product (containing each component) from any by-products of the assembly reaction. Subsequent PCR can improve target enrichment, and subsequent size selection can improve target stringency.
[0272]
[0318] In some embodiments, nucleic acid capture can be used to selectively capture a subset of targeted nucleic acids from a pool, for example, by using probes with binding sites that are present only in the targeted subset of nucleic acids. Synthetic nucleic acid libraries can be created or assembled such that all of the nucleic acids belonging to a potential sub-library of interest share a common probe binding site (common within the sub-library but distinct from other sub-libraries) to selectively capture the sub-library from a more general library.
[0273] G. Freeze-drying
[0319] Lyophilization is a dehydration process. Both nucleic acids and enzymes can be freeze-dried. Freeze-dried materials may have a longer shelf life. Additives such as chemical stabilizers may be used to maintain a functional product (e.g., an active enzyme) throughout the freeze-drying process. Disaccharides such as sucrose and trehalose may be used as chemical stabilizers.
[0274] H.DNA design
[0320] The sequences (e.g., components) of nucleic acids for constructing a synthetic library (e.g., an identifier library) can be designed to avoid the complexities of synthesis, sequencing, and assembly. Furthermore, the sequences can be designed to reduce the cost of constructing the synthetic library and to improve the longevity over which the synthetic library can be stored.
[0275]
[0321] Nucleic acids can be designed to avoid long homopolymer stretches (or repeated base sequences), which can be difficult to synthesize. Nucleic acids can be designed to avoid homopolymer lengths of more than 2, more than 3, more than 4, more than 5, more than 6, more than 7, or longer. Additionally, nucleic acids can be designed to avoid the formation of secondary structures, such as hairpin loops, which can inhibit their synthesis process. For example, prediction software can be used to generate nucleic acid sequences that do not form stable secondary structures. Nucleic acids for constructing synthetic libraries can be designed to be short. Longer nucleic acids can be more difficult and expensive to synthesize. Longer nucleic acids also increase the opportunity for mutations during synthesis. Nucleic acids (e.g., components) can be up to 5, 10, 15, 20, 25, 30, 40, 50, 60, or more bases.
[0276]
[0322] Nucleic acids that will be components of an assembly reaction can be designed to facilitate the assembly reaction. See Chemical Methods sections A and B for detailed information on nucleic acid sequence considerations for OEPCR and ligation-based assembly reactions, respectively. Efficient assembly reactions generally involve hybridization between adjacent components. Sequences can be designed to promote these on-target hybridization events while avoiding potential off-target hybridization. Nucleic acid base modifications, such as locked nucleic acids (LNAs), can be used to enhance on-target hybridization. These modified nucleic acids can be used, for example, as staples in stapled strand ligation or as sticky ends in attached strand ligation. Other modified bases that can be used to construct synthetic nucleic acid libraries (or identifier libraries) include 2,6-diaminopurine, 5-bromo-dU, deoxyuridine, inverted dT, inverted dideoxy-T, dideoxy-C, 5-methyl-dC, deoxyinosine, Super T, Super G, or 5-nitroindole. Nucleic acids can contain one or more of the same or different modified bases. Some of these modified bases are natural base analogs (e.g., 5-methyl dC and 2,6-diaminopurine) that have higher melting temperatures and thus may be useful for facilitating specific hybridization events in assembly reactions. Some of these modified bases are universal bases (e.g., 5-nitroindole) that can bind to all natural bases and thus may be useful for facilitating hybridization with nucleic acids that may have variable sequences within the desired binding site. In addition to their beneficial role in assembly reactions, these modified bases can be useful in primers (e.g., for PCR) and probes (e.g., for nucleic acid capture) because they facilitate specific binding to their target nucleic acids within a pool of primer and probe nucleic acids. See Chemical Methods sections D and F for additional nucleic acid design considerations for nucleic acid amplification (or PCR) and nucleic acid capture, respectively.
[0277]
[0323] Nucleic acids can be designed to facilitate sequencing. For example, nucleic acids can be designed to avoid typical sequencing complications such as secondary structures, stretches of homopolymers, repetitive sequences, and sequences with too high or too low GC content. Certain sequencers or sequencing methods can be error-prone. Nucleic acid sequences (or components) constituting a synthetic library (e.g., an identifier library) can be designed with a specific Hamming distance from each other. In this way, even if a high rate of base resolution errors occurs in sequencing, error-containing sequence stretches can still be mapped back to their most likely nucleic acid (or component). Nucleic acid sequences can be designed with a Hamming distance of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more base variations. Alternative distance metrics to Hamming distance can also be used to define the minimum required distance between designed nucleic acids.
[0278]
[0324] Some sequencing methods and instruments require the input nucleic acid to contain specific sequences, such as adapter sequences or primer binding sites. These sequences may be referred to as "method-specific sequences." A typical preliminary workflow for the above-described sequencing instruments and methods involves assembling method-specific sequences into a nucleic acid library. However, if it is known in advance that a synthetic nucleic acid library (e.g., an identifier library) will be sequenced by a specific instrument or method, these method-specific sequences may be designed into the nucleic acids (e.g., components) comprising the library (e.g., an identifier library). For example, sequencing adapters may be assembled onto members of a synthetic nucleic acid library in the same reaction step as the members themselves are assembled from individual nucleic acid components.
[0279]
[0325] Nucleic acid can be designed to avoid sequences that can easily cause DNA damage.For example, it can avoid sequences that contain sites for site-specific nucleases.As another example, UVB (ultraviolet-B) light can cause adjacent thymines to form pyrimidine dimers, which then inhibits sequencing and PCR.Therefore, if the synthetic nucleic acid library is intended to be stored in an environment that is exposed to UVB, it can be beneficial to design its nucleic acid sequence to avoid adjacent thymines (i.e., TT).
[0280]
[0326] All information contained in the Chemical Methods section is intended to support and enable the techniques, methods, protocols, systems, and processes described above.
[0281] Methods for Assembling Identifiers from Components Using Azide-Alkyne Modification
[0327] Chemical and / or biological ligation methods may be used to ligate two or more nucleic acid components together to create the identifier, and in some embodiments, there may be advantages associated with chemical ligation methods such as "click chemistry" versus biological methods such as enzymatic ligation.
[0282]
[0328] Click chemistry, or copper-catalyzed azide-alkyne cycloaddition (CuAAC), is a variant of the Huisgen 1,3-dipolar cycloaddition reaction. In the reaction, an alkyne group and an azide group react to form a triazole phosphodiester mimic. Current methods use Cu(I) ions to increase the specificity, rate, and yield of this reaction. The reaction can be fast with some alkynes, with completion times of approximately one minute reported. Reaction times can be 30, 60, 90, 120, 150, 180 seconds, or longer. The reaction can also be robust, tolerating a wide pH range.
[0283]
[0329] Chemical ligation using click chemistry can occur between two single-stranded nucleic acid components using a template (or staple or splint) oligonucleotide. Alternatively, chemical ligation can occur between double-stranded nucleic acid components if a common complementary overhang (or sticky end) is present. Chemical ligation by click chemistry can be used to construct identifiers according to the product method (Figure 15), permutation method (Figure 20), MchooseK method (Figure 21), compartment method (Figure 22), or unconstrained sequence method (Figure 23) described above.
[0284]
[0330] Ligation of components using click chemistry requires that one component have at least one alkyne group and the other component have at least one azide group. Either modification can be located at the 5' or 3' end of one nucleic acid component, as long as complementary modifications are located on adjacent components such that the 3' end of one component ligates to the 5' end of the other.
[0285]
[0331] Several different types of alkyne-azide bonds can be used in click chemistry. Alkyne-azide bonds, which are compatible with molecular biology methods such as PCR, may be particularly suitable for generating identifiers. If a particular pool of identifiers contains one or more alkyne-azide bonds, the identifiers can be copied to their natural form (with phosphodiester bonds between the bases) using PCR.
[0286] Method for constructing identifiers from multi-component components
[0332] The component containing the identifier can be divided into two or more parts with different functions. For example, each component can have two parts: one long part intended to hybridize to a nucleic acid probe for data access and another short part intended for sequencing readout. The two parts can be separated and intended to be assembled into the identifier at each edge so that the final identifier product has two functionally different regions. One region on one side is for chemical access and one region on the other side is for sequencing.
[0287]
[0333] Figure 31 provides a schematic of one example of this concept in sticky-end ligation assembly of identifiers, where components from each layer come together according to a product scheme. The first layer is the core of the identifier assembly process with linked two-part components, and subsequent layers contain separate two-part components that are assembled into the identifier from both edges. The symbols above the sticky ends represent their sequences. Sticky ends with different symbols are orthogonal. An asterisk next to a symbol represents the reverse complement. For example, "a" and "a" * " are reverse complements of each other and will therefore hybridize to form the product during ligation.
[0288] How to build identifiers using the base editor
[0334] A base editor can be used to programmatically mutate bases located at specific loci within a parent identifier to construct new identifiers. In one embodiment, the base editor can be a dCas9 protein fused to a cytidine deaminase that converts cytosine (C) to uracil (U). The parent identifier can be designed to have several orthogonal targets for binding of guide RNAs (gRNAs). A target locus can contain one or more cytosines within the active range of the dCas9 deaminase bound at that locus. The active range can be one, two, three, four, five, six, or more bases within the locus. Subsequently, incubating the parent identifier with dCas9 deaminase and a subset of gRNAs for specific loci can result in one or more cytosine-to-uracil mutations at each of those target loci. Furthermore, DNA polymerase recognizes uracil as thymine, and therefore, performing PCR on the mutated identifiers can similarly result in complementary mutations (guanine to adenine). A parental discriminator with N orthogonal target loci can be generated by applying different subsets of dCas9-deaminases and N gRNAs, each targeting a distinct locus in the parent. N Each gRNA sequence can be programmably converted into a set of distinct daughter identifier sequences. Thus, the combinatorial space of possible identifiers constructed in this manner can store N bits of information for N gRNA inputs.
[0289]
[0335] In some embodiments, any given target locus of the parent sequence can contain targeting cytosines on both the upper and lower strands to facilitate increased mutation efficiency. Moreover, to ensure efficient gRNA targeting, each locus must be adjacent to a PAM site. However, the PAM sequence can vary depending on the use of different engineered Cas9 variants.
[0290]
[0336] The dCas9-deaminase fusion may include a linker sequence between the two fusion proteins. The optimal linker length may be 16 amino acids for efficient targeted mutation. The linker length may be at least 0, 1, 5, 10, 15, 20, 25, or more amino acids. One of several cytidine deaminases may be used. Examples of cytidine deaminases include APOBEC1, AID, CDA1, or APOBEC3G. An active Cas9 nickase may be used instead of dCas9, in which case it may also be necessary to include a DNA repair enzyme in the identifier assembly reaction.
[0291]
[0337] In another embodiment, in which a base editor is used to construct an identifier, an adenine deaminase fused to dCas9 (as opposed to or in addition to a cytidine deaminase fused to dCas9) can be used to mutate adenine to inosine at a defined locus of the parent identifier accessible by the gRNA. Inosine is interpreted as guanine by DNA polymerase. Thus, PCR of the base-edited locus can result in a complementary thymine to cytosine mutation on the opposite strand.
[0292] How to delete information stored in DNA
[0338] The ability to reliably delete (or erase) data stored using nucleic acids can be beneficial for security, privacy, and regulatory reasons. Data erasure can involve breaking covalent bonds within the nucleic acids, irreversibly modifying the nucleic acids to destroy their ability to be sequenced, irreversibly encapsulating or adsorbing them, or adding more nucleic acids or other materials to render the original collection of nucleic acids unreadable or unreadable. These methods can be performed selectively or non-selectively. The selection process can be separate from the deletion process. For example, starting with an identifier library, sequence-specific probes can be used to pull down a subset of identifiers for deletion. As another example, purification of selected identifiers by size or mass-to-charge ratio can be performed in conjunction with other selective or non-selective deletion methods.
[0293]
[0339] Selective methods for deleting nucleic acids from libraries include the use of sequence-specific probes to pull down a subset of nucleic acids for deletion, the use of CRISPR-based methods to cleave selected nucleic acids containing one or more target sequences, and the use of purification techniques to select nucleic acids by size or mass-to-charge ratio.
[0294]
[0340] Non-selective methods for deleting information-encoding nucleic acids from libraries include sonication, autoclaving, bleaching, treatment with base, acid, ethidium bromide or other DNA modifying agents, irradiation (e.g., with ultraviolet light), combustion, and non-specific nuclease digestion (in vitr...
Claims
1. 1. A method of preparing a library of nucleic acid molecules for use in a blockchain, comprising: storing digital information representing a key to a blockchain transaction in a key to a nucleic acid molecule, thereby obtaining and storing said library of nucleic acid molecules; sequencing at least a portion of said library of nucleic acid molecules, thereby obtaining a sequencing read; converting the sequencing read into a string representing the key; applying the string of symbols to access an electronic data file that is part of a blockchain transaction; and The method includes:
2. The method of claim 1 , wherein the key is a private key.
3. The method of claim 1 , wherein the key is a public key.
4. The method of any one of claims 1 to 3, wherein converting comprises mapping the sequencing readout to the string using a decoding map.
5. The method of claim 4 , wherein the decoding map is or includes a non-fungible token (NFT).
6. The method according to any one of claims 1 to 5, wherein the blockchain transaction is a cryptocurrency transaction.
7. The method of any one of claims 1 to 6, comprising copying at least a portion of said library of nucleic acid molecules.
8. The method of any one of claims 1 to 7, comprising carrying out at least one chemical calculation step.
9. The method of claim 8 , wherein the calculation comprises at least one Boolean logic gate operation.
10. 1. A method for tagging an object for tracking or authentication, comprising: storing digital information representing ownership of non-fungible tokens (NFTs) in a blockchain in a nucleic acid molecule, thereby obtaining a library of nucleic acid molecules; associating the objects with tags that constitute the library, thereby obtaining tagged objects for tracking and authentication; The method includes:
11. The method of claim 10 , wherein the digital information represents a public key to an NFT.
12. The method of claim 10 or 11, wherein the library of nucleic acid molecules is encapsulated in droplets.
13. The method of any one of claims 10 to 12, wherein said library of nucleic acid molecules is contained in a vial.
14. The method of claim 10 or 11, wherein the library of nucleic acid molecules is lyophilized.
15. The method according to any one of claims 10 to 14, wherein the library of nucleic acid molecules is applied to a surface of the object.
16. The method according to any one of claims 10 to 15, wherein the library of nucleic acid molecules is applied to the object using biological spores.
17. The method according to any one of claims 10 to 15, wherein said library of nucleic acid molecules is applied to said object by microinjection printing.
18. A method according to any one of claims 10 to 17, wherein the digital information comprises a description of the object.
19. The method according to any one of claims 10 to 18, wherein the library comprises several copies of a DNA strand, and the digital information is represented by the several copies of the DNA strand.
20. The method according to any one of claims 10 to 19, wherein the digital information is represented by the length or weight of the DNA strands in the library.
21. The method according to any one of claims 10 to 20, wherein the object is a physical object.
22. The method according to any one of claims 10 to 20, wherein the object is a virtual object.
23. 1. A method of preparing a library of nucleic acid molecules for use in a blockchain, comprising: requesting, by a first processor of a computer network, a transaction of an item on a blockchain; generating, by a second processor of the computer network, a transaction data block, the transaction data block including at least one data item selected from sender information, recipient information, transaction amount, and request date; broadcasting said block of transaction data to a plurality of processors of said computer network having a plurality of associated nodes; verifying the transaction by the processor associated with the plurality of nodes; adding, by one or more processors of the computer network, the transaction data block to the blockchain, thereby obtaining an updated blockchain; storing digital information representing the updated blockchain digital information in a nucleic acid molecule, thereby obtaining the library of nucleic acid molecules representing the updated blockchain digital information; completing said transaction; and The method includes:
24. 24. The method of claim 23, wherein the library of nucleic acid molecules is copied and distributed to one or more nodes.
25. 25. The method of claim 23 or 24, wherein the library of nucleic acid molecules is sequenced to obtain sequence information.
26. 26. The method of claim 25, wherein the array information is copied and distributed to one or more nodes.
27. 1. A method of preparing a library of nucleic acid molecules for use in a blockchain, comprising: requesting, by a first processor of the computer network, a transaction for an item of a blockchain encoded on a plurality of nucleic acid molecules; generating, by a second processor of the computer network, a transaction data block, the transaction data block including at least one data item selected from sender information, recipient information, transaction amount, and request date; storing digital information representing said transaction data blocks in nucleic acid molecules, thereby obtaining said library of nucleic acid molecules representing said transaction data blocks; The method includes:
28. transferring said library of nucleic acid molecules to a central register; verifying said transaction by said central register; adding, by the central register, the library of nucleic acid molecules to the blockchain, thereby obtaining an updated blockchain encoded with a plurality of nucleic acid molecules; completing said transaction; and 28. The method of claim 27, comprising:
29. requesting, by a first processor of the computer network, a transaction for an item of a blockchain encoded on a plurality of nucleic acid molecules; generating, by a second processor of the computer network, a transaction data block, the transaction data block including at least one data item selected from sender information, recipient information, transaction amount, and request date; storing digital information representing said transaction data blocks in nucleic acid molecules, thereby obtaining said library of nucleic acid molecules representing said transaction data blocks; copying said library of nucleic acid molecules, thereby obtaining a plurality of copies of said library; transferring the copy to a plurality of nodes, each node including a plurality of nucleic acid molecules encoding the blockchain; verifying the transaction by the node; adding, by each node, a copy of the library to a plurality of nucleic acid molecules encoding the blockchain, thereby obtaining an updated blockchain; completing said transaction; and 30. The method of claim 28, comprising:
30. requesting, by a first processor of the computer network, a transaction for an item of a blockchain encoded with sequence information representing a plurality of nucleic acid molecules; generating, by a second processor of the computer network, a transaction data block, the transaction data block including at least one data item selected from sender information, recipient information, transaction amount, and request date; storing digital information representing said transaction data blocks in nucleic acid molecules, thereby obtaining said library of nucleic acid molecules representing said transaction data blocks; sequencing said library of nucleic acid molecules, thereby obtaining library sequence information; broadcasting said library sequence information to a plurality of processors of said computer network having a plurality of associated nodes; verifying the transaction by the processor associated with the plurality of nodes; adding, by one or more processors of the computer network, the sequence information to the blockchain, thereby obtaining an updated blockchain; and completing said transaction; and 30. The method of claim 28, comprising:
31. Storing digital information in nucleic acid molecules (a) receiving the digital information as a string of symbols, each symbol in the string having a symbol value and a symbol position within the string; (b) forming a first identifier nucleic acid molecule, (1) selecting, from a set of distinguishable component nucleic acid molecules separated into M distinct tiers, one component nucleic acid molecule from each of said M tiers; (2) depositing the M selected component nucleic acid molecules into compartments; (3) physically assembling the M selected component nucleic acid molecules in (2) such that the component nucleic acid molecules from a first and second tier correspond to the first and second terminal molecules of the identifier nucleic acid molecule, and the component nucleic acid molecule in a third tier corresponds to a third molecule of the identifier nucleic acid molecule, defining a physical order of the M tiers in the first identifier nucleic acid molecule, thereby forming the first identifier nucleic acid molecule having first and second terminal molecules and the third molecule located between the first terminal molecule and the second terminal molecule; forming, (c) forming a plurality of additional identifier nucleic acid molecules, each of the additional identifier nucleic acid molecules having (1) a first and a second terminal molecule and a third molecule located between the first terminal molecule and the second terminal molecule, and (2) corresponding to each symbol position, and at least one of the first terminal molecule, the second terminal molecule, and the third molecule of at least one additional identifier nucleic acid molecule is identical to a target molecule of the first identifier nucleic acid molecule in (b), such that a probe is capable of selecting at least two identifier nucleic acid molecules corresponding to each symbol having consecutive symbol positions within the symbol string; (d) collecting the identifier nucleic acid molecules in (b) and (c) in a pool having a powder, liquid, or solid form; The method according to any one of claims 1 to 30, comprising:
32. 32. The method of claim 31 , wherein at least one of the first and second terminal molecules of the at least one additional identifier nucleic acid molecule is identical to a target molecule of the first identifier nucleic acid molecule in (b).
33. 33. The method of claim 31 or 32, wherein physically assembling the M selected component nucleic acid molecules comprises ligating the component nucleic acid molecules.
34. 34. The method of any one of claims 31 to 33, wherein the component nucleic acid molecules from each layer comprise at least one sticky end that is complementary to at least one sticky end of a component nucleic acid molecule from another layer, allowing sticky end ligation to form the identifier nucleic acid molecules in (b) and (c).
35. 35. The method of any one of claims 31 to 34, wherein the first molecule of the at least one additional identifier nucleic acid molecule in (c) is identical to the first terminal molecule of the identifier nucleic acid molecule in (b) and the second terminal molecule of the at least one additional identifier nucleic acid molecule in (c) is identical to the second terminal molecule of the identifier nucleic acid molecule in (b).
36. 36. The method of any one of claims 31 to 35, further comprising using said probes to hybridize to said target molecule of at least some of the identifier nucleic acid molecules in said first identifier nucleic acid molecule and said plurality of additional identifier nucleic acid molecules and to select an identifier nucleic acid molecule corresponding to each symbol having consecutive symbol positions.
37. 37. The method of any one of claims 31 to 36, further comprising applying a single PCR reaction, thereby amplifying at least two identifier nucleic acid molecules corresponding to each symbol having consecutive symbol positions.
38. 38. The method of claim 37, wherein the at least two identifier nucleic acid molecules corresponding to each symbol having consecutive symbol positions can be further amplified by another PCR reaction targeting a specific component nucleic acid molecule in the third one of the identifier nucleic acid molecules.
39. 39. The method of any one of claims 31 to 38, wherein the component nucleic acid molecules in each layer are structured with first and second terminal regions, the first terminal region of each component nucleic acid molecule from one of the M layers being structured to bind to the second terminal region of any component nucleic acid molecule from another of the M layers.
40. 40. The method of any one of claims 31 to 39, wherein M is 3 or more.
41. The method of any one of claims 31 to 40, wherein each symbol position in the string has a corresponding different identifier nucleic acid molecule.
42. 42. The method of any one of claims 31-41, wherein the identifier nucleic acid molecules in (b) and (c) represent a subset of a combinatorial space of possible identifier nucleic acid molecules, each comprising one component nucleic acid molecule from each of the M strata.
43. 43. The method of claim 42, wherein the presence or absence of an identifier nucleic acid molecule in the pool in (d) represents the symbol value at each of the corresponding symbol positions in the symbol string.
44. A method according to any one of claims 31 to 43, wherein the symbols having consecutive symbol positions encode similar digital information.
45. 45. The method of any one of claims 31 to 44, wherein the distribution of numbers of component nucleic acid molecules in each of the M layers is non-uniform.
46. 46. The method of claim 45, wherein if the third tier comprises more component nucleic acid molecules than either the first tier or the second tier, the PCR query used to access the pool in (d) generates a larger pool of accessed identifier nucleic acid molecules than if the third tier comprises fewer component nucleic acid molecules than either the first tier or the second tier.
47. 47. The method of claim 46, wherein when the third tier contains fewer component nucleic acid molecules than either the first tier or the second tier, the PCR query used to access the pool in (d) produces a smaller pool of accessed identifier nucleic acid molecules than when the third tier contains more component nucleic acid molecules than either the first tier or the second tier, the smaller pool of accessed identifier nucleic acid components corresponding to finer resolution access to the symbols in the symbol string.
48. 48. The method of any one of claims 31-47, wherein the first stratum has the highest priority, the second stratum has the second highest highest priority, and the remaining M-2 stratum have corresponding component nucleic acid molecules between the first terminal molecule and the second terminal molecule.
49. 49. The method of claim 48, wherein the pool in (d) can be used to access all identifier nucleic acid molecules in the pool that have a particular component nucleic acid molecule at the first and second terminal molecules in a single PCR reaction.
50. Storing digital information in nucleic acid molecules (a) receiving the digital information as a string of symbols, each symbol in the string having a symbol value and a symbol position within the string, the digital information including image data represented by a collection of vectors; (b) depositing M selected component nucleic acid molecules selected from a set of M distinct layered distinguishable component nucleic acid molecules into a compartment and physically assembling said M selected component nucleic acid molecules to form a first identifier nucleic acid molecule; (c) forming a plurality of identifier nucleic acid molecules, each of the plurality of identifier nucleic acid molecules corresponding to each symbol position; (d) collecting the identifier nucleic acid molecules in (b) and (c) in a pool having a powder, liquid, or solid form; The method according to any one of claims 1 to 30, comprising:
51. 51. The method of claim 50, wherein at least some of the M layers correspond to different characteristics of the image data.
52. 52. The method of claim 51, wherein the different features include an x-coordinate, a y-coordinate, and an intensity value or a range of intensity values.
53. A method according to any one of claims 50 to 52, wherein storing the image data in a nucleic acid molecule allows any neighbouring pixel to be queried for its colour value using a random access scheme.
54. 54. The method of any one of claims 50 to 53, wherein storing the image data in a nucleic acid molecule allows the image data to be decoded at a fraction of the original resolution of the image data.
55. Storing digital information in nucleic acid molecules (a) receiving the digital information as a string of symbols, each symbol in the string having a symbol value and a symbol position within the string, the digital information including image data represented by a collection of vectors; (b) depositing M selected component nucleic acid molecules selected from a set of M distinct layered distinguishable component nucleic acid molecules into a compartment and physically assembling said M selected component nucleic acid molecules to form a first identifier nucleic acid molecule; (c) forming a plurality of identifier nucleic acid molecules, each of the plurality of identifier nucleic acid molecules having (1) a first and a second terminal molecule and a third molecule located between the first terminal molecule and the second terminal molecule, and (2) corresponding to each symbol position, wherein at least one of the first terminal molecule, the second terminal molecule, and the third molecule of at least one additional identifier nucleic acid molecule is identical to a target molecule of the first identifier nucleic acid molecule in (b), such that a single probe selects at least two identifier nucleic acid molecules corresponding to each symbol having an associated symbol position within the symbol string; (d) collecting the identifier nucleic acid molecules in (b) and (c) in a pool having a powder, liquid, or solid form; The method according to any one of claims 1 to 30, comprising:
56. 56. The method of claim 55, wherein storing the image data in a nucleic acid molecule allows the image data to be decoded at a fraction of its original resolution, and the decoding of the image data at said fraction is used to search for particular visual features in an archive of surveillance images or a video archive to identify frames of interest.
57. Storing digital information in nucleic acid molecules (a) receiving the digital information as a string of symbols, each symbol in the string having a symbol value and a symbol position within the string; (b) depositing M selected component nucleic acid molecules selected from a set of M distinct layered distinguishable component nucleic acid molecules into a compartment and physically assembling said M selected component nucleic acid molecules using click chemistry to form a first identifier nucleic acid molecule; (c) forming a plurality of identifier nucleic acid molecules, each of the plurality of identifier nucleic acid molecules corresponding to each symbol position; (d) collecting the identifier nucleic acid molecules in (b) and (c) in a pool having a powder, liquid, or solid form; The method according to any one of claims 1 to 30, comprising:
58. Storing digital information in nucleic acid molecules (a) receiving the digital information as a string of symbols, each symbol in the string having a symbol value and a symbol position within the string; (b) depositing M selected component nucleic acid molecules selected from a set of M distinct layered distinguishable component nucleic acid molecules into a compartment and physically assembling said M selected component nucleic acid molecules to form a first identifier nucleic acid molecule; (c) forming a plurality of identifier nucleic acid molecules, each of the plurality of identifier nucleic acid molecules corresponding to each symbol position; (d) collecting the identifier nucleic acid molecules in (b) and (c) in a pool having a powder, liquid, or solid form; and (e) deleting at least some of the data collected in the pool. The method according to any one of claims 1 to 30, comprising:
59. 59. The method of claim 58, further comprising using sequence specific probes to pull down selected identifier nucleic acid molecules from the pool in (d) to selectively remove data.
60. 60. The method of claim 59, wherein the selection identifier nucleic acid molecule is selectively deleted using a CRISPR-based method.
61. 61. The method of any one of claims 58 to 60, further comprising obfuscating the identifier nucleic acid molecules in the pool in (d) to non-selectively remove data.
62. 62. The method of any one of claims 58-61, further comprising degrading the identifier nucleic acid molecules from the pool in (d) to non-selectively delete data using sonication, autoclaving, bleaching, treatment with base, acid, ethidium bromide, or other DNA modifying agents, irradiation, combustion, and non-specific nuclease digestion.
63. Storing digital information in nucleic acid molecules (a) receiving the digital information as a string of symbols, each symbol in the string having a symbol value and a symbol position within the string; (b) dividing the string into one or more blocks of a fixed length or less; (c) depositing M selected component nucleic acid molecules selected from a set of M distinct layered distinguishable component nucleic acid molecules into the compartment and physically assembling said M selected component nucleic acid molecules to form a first identifier nucleic acid molecule; (d) forming a plurality of identifier nucleic acid molecules, each of the plurality of identifier nucleic acid molecules corresponding to each symbol position; (e) collecting the identifier nucleic acid molecules in (c) and (d) in a pool having a powder, liquid, or solid form; The method according to any one of claims 1 to 30, comprising:
64. 64. The method of claim 63, further comprising determining the size of each block based on the string, processing requirements, or intended use of the digital information.
65. 65. The method of claim 63 or 64, further comprising computing a hash of each block.
66. A method according to any one of claims 63 to 65, further comprising applying one or more error detection and correction techniques to each block, and calculating one or more error protection bytes.
67. 67. The method of any one of claims 63 to 66, further comprising mapping said one or more blocks to a set of codewords that optimize chemical conditions during encoding or decoding.
68. 68. The method of claim 67, wherein the set of code words has a fixed weight such that a fixed number of identifier nucleic acid molecules are assembled in each reaction compartment in a writer system at approximately equal concentrations within each reaction compartment and across multiple reaction compartments.
69. Storing digital information in nucleic acid molecules (a) receiving the digital information as a string of symbols, each symbol in the string having a symbol value and a symbol position within the string; (b) depositing M selected component nucleic acid molecules selected from a set of M distinct layered distinguishable component nucleic acid molecules into a compartment and physically assembling said M selected component nucleic acid molecules to form a first identifier nucleic acid molecule; (c) forming a plurality of identifier nucleic acid molecules, each of the plurality of identifier nucleic acid molecules corresponding to each symbol position; (d) collecting the identifier nucleic acid molecules in (b) and (c) in a pool having a powder, liquid, or solid form; (e) using the identifier nucleic acid molecules in (d) to perform a calculation on the string involving a Boolean logic operation, including AND, OR, NOT, or NAND, thereby generating a new pool of nucleic acid molecules; The method according to any one of claims 1 to 30, comprising:
70. 70. The method of claim 69, wherein the calculation is performed on the pool of identifier nucleic acid molecules in (d) to obtain any of the symbols in the string, without decoding any of the identifier nucleic acid molecules.
71. 71. The method of claim 69 or 70, wherein performing the calculations comprises a series of chemical operations including hybridization and cleavage.
72. 72. The method of any one of claims 69 to 71, wherein the string in (a) is denoted a and comprises sub-bitstream s, and the plurality of identifier nucleic acid molecules in the pool in (d) are double-stranded and denoted dsA, the method further comprising obtaining another pool of another plurality of identifier nucleic acid molecules representing another string, denoted b, comprising sub-bitstream t, denoted dsB, and wherein the calculation is performed for sub-bitstreams s and t by performing a series of steps on dsA and dsB.
73. The sequence of steps for dsA and dsB includes performing an initialization step, the initialization step comprising: (9) converting the double-stranded identifier nucleic acid molecule in dsA to a positive single-stranded form designated A; (10) The double-stranded identifier nucleic acid molecule in dsA is A * and converting the nucleotide sequence to a negative single-stranded form designated A * is the inverse complement of A, (11) converting the double-stranded identifier nucleic acid molecule in dsB to a positive single-stranded form designated B; (12) The double-stranded identifier nucleic acid molecule in dsB is B * and converting the nucleotide sequence to a negative single-stranded form designated B. * is the inverse complement of B, (13) selecting dsP as an identifier nucleic acid molecule in dsA corresponding to s; (14) selecting P as an identifier nucleic acid molecule in A corresponding to s; (15) selecting dsQ as an identifier nucleic acid molecule in dsB corresponding to t; (16) B corresponding to t * Q as an identifier nucleic acid molecule in * Selecting 73. The method of claim 72, comprising:
74. (9) updating A or dsA to delete the identifier nucleic acid molecule corresponding to s; (10) B to delete the identifier nucleic acid molecule corresponding to t. * or updating dsB; 74. The method of claim 73, further comprising:
75. The calculation is an AND operation, and the sequence of steps for dsA and dsB is: (1) A and B * performing said AND operation between a and b by combining a, b, hybridizing complementary nucleic acid molecules, and selecting fully complementary double-stranded nucleic acid molecules as said new pool of nucleic acid molecules; or (2) P and Q * performing said AND operation between s and t by combining s, hybridizing complementary nucleic acid molecules, and selecting completely complementary nucleic acid molecules as said new pool of nucleic acid molecules; The method of any one of claims 72 to 74, further comprising:
76. 76. The method of claim 75, wherein selecting the perfectly complementary nucleic acid molecule comprises using chromatography, gel electrophoresis, a single-strand specific endonuclease, a single-strand specific exonuclease, or a combination thereof.
77. The calculation is an OR operation, and the sequence of steps for dsA and dsB is: (c) performing the OR operation between a and b by combining dsA and dsB to produce the new pool of nucleic acid molecules; or (d) performing said OR operation between s and t by combining dsP and dsQ to produce said new pool of nucleic acid molecules. The method of any one of claims 72 to 74, further comprising:
78. 78. The method of any one of claims 74 to 77, further comprising updating A or dsA to include said new pool of nucleic acid molecules.
79. Storing digital information in nucleic acid molecules (a) receiving the digital information as a string of symbols, each symbol in the string having a symbol value and a symbol position within the string; (b) depositing M selected component nucleic acid molecules selected from a set of M distinct layered distinguishable component nucleic acid molecules into a compartment and physically assembling said M selected component nucleic acid molecules to form a first identifier nucleic acid molecule; (c) forming a plurality of identifier nucleic acid molecules; (d) partitioning the identifier nucleic acid molecules in (b) and (c) into distinct bins, each bin corresponding to a different symbol value; The method according to any one of claims 1 to 30, comprising:
80. 80. The method of claim 79, wherein the bins of a first type of symbol include identifier nucleic acid molecules that correspond to symbol positions having the first type of symbol.
81. Storing digital information in nucleic acid molecules (a) receiving the digital information as a string of symbols, each symbol in the string having a symbol value and a symbol position within the string; (b) depositing M selected components from a set of M distinct layers of distinguishable components into a compartment and physically assembling the M selected components to form a first identifier nucleic acid molecule; (c) forming a plurality of identifier nucleic acid molecules, each of the plurality of identifier nucleic acid molecules corresponding to each symbol position; (d) collecting the identifier nucleic acid molecules in (b) and (c) in a pool having a powder, liquid, or solid form; The method according to any one of claims 1 to 30, comprising:
82. 82. The method of claim 81 , wherein each of the M selected components comprises a plurality of moieties, each moiety comprising a nucleic acid molecule, and each moiety is linked to the same identifier by one or more chemical methods.
83. 83. The method of claim 82, wherein each of the multiple portions serves a separate functional purpose for different data storage operations.
84. 84. The method of claim 83, wherein the functional objectives include ease of sequencing by nucleic acid hybridization and ease of access.
85. Storing digital information in nucleic acid molecules (a) receiving the digital information as a string of symbols, each symbol in the string having a symbol value and a symbol position within the string; (b) applying a base editor to programmably mutate one or more bases in the parent identifier to form a first identifier nucleic acid molecule; (c) forming a plurality of identifier nucleic acid molecules, each identifier nucleic acid molecule corresponding to each symbol position; (d) collecting the identifier nucleic acid molecules in (b) and (c) in a pool having a powder, liquid, or solid form; The method according to any one of claims 1 to 30, comprising:
86. 86. The method of Claim 85, wherein the base editor comprises a dCas9 deaminase.
87. Storing digital information in nucleic acid molecules (a) receiving the digital information as a string of symbols, each symbol in the string having a symbol value and a symbol position within the string; (b) depositing M selected component nucleic acid molecules selected from a set of M distinct layered distinguishable component nucleic acid molecules into a compartment and physically assembling said M selected component nucleic acid molecules to form a first identifier nucleic acid molecule; (c) forming a plurality of identifier nucleic acid molecules, each of the plurality of identifier nucleic acid molecules corresponding to each symbol position; (d) collecting the identifier nucleic acid molecules in (b) and (c) in a pool having a powder, liquid, or solid form; The method according to any one of claims 1 to 30, comprising:
88. 90. An application of the method of claim 87, said application comprising encryption of information, authentication of an entity, or use as a source of entropy in applications involving randomization.
89. 90. An application of the method of claim 81 or 87, wherein identifier nucleic acid molecules from one or more disjoint identifier libraries are used to uniquely identify an entity or physical location.
90. A method according to any one of claims 30 to 89, comprising encoding digital information into sections of several random DNA species.
91. 91. The method of any one of claims 30 to 90, comprising generating random data by randomly sampling and sequencing DNA species from a large combinatorial pool of possible DNA species.
92. 92. The method of any one of claims 30 to 91, comprising generating and storing random data by randomly sampling and sequencing a subset of DNA species from a large combinatorial pool of possible DNA species.
93. 93. The method of claim 92, wherein said subset of DNA species is amplified to create multiple copies of each species.
94. 94. The method of claim 92 or 93, wherein error checking and correction nucleic acid molecules are added to said subset of DNA species to enable robust future readout.
95. 93. The method of claim 92, wherein said subsets of DNA species are barcoded with unique molecules and combined in a pool of barcoded subsets of DNA species.
96. 96. The method of claim 95, wherein a particular subset of DNA species in said pool of barcoded subsets of DNA species is accessible using input nucleic acid probes for PCR or nucleic acid capture.
97. A method for securing and authenticating a physical or virtual object using a system that includes: (1) a DNA key composed of a subset of DNA species from a defined set; and (2) a DNA reader that accepts the key and looks for a matching key to unlock an artifact locally or return a hashed token to access the artifact elsewhere.
98. Storing digital information in nucleic acid molecules (a) receiving the digital information as a string of symbols, each symbol in the string having a symbol value and a symbol position within the string; (b) forming a first identifier nucleic acid molecule, (1) selecting, from a set of distinguishable component nucleic acid molecules separated into M distinct tiers, one component nucleic acid molecule from each of said M tiers; (2) depositing the M selected component nucleic acid molecules into compartments; (3) physically assembling the M selected component nucleic acid molecules in (2) to form the first identifier nucleic acid molecule containing a designated component that includes at least one target molecule, and enabling access of the first identifier nucleic acid molecule containing the designated component; forming, (c) physically assembling a plurality of additional identifier nucleic acid molecules, each of the plurality of additional identifier nucleic acid molecules having the designated components, the designated components including the at least one target molecule of the first identifier nucleic acid molecule in (b), such that a probe is capable of selecting at least two identifier nucleic acid molecules corresponding to each symbol having consecutive symbol positions within the symbol string; (d) collecting the identifier nucleic acid molecules in (b) and (c) in a pool having a powder, liquid, or solid form; The method according to any one of claims 1 to 30, comprising:
